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Abstract 
Background: Blood donors are required to exceed a minimum haemoglobin level 
before they donate; those who fail are temporarily deferred from blood donation. In 
this way, donor health, and that of the recipient (patient), is assured and a drain on 
blood collection resource is avoided. Knowing what factors contribute to donors failing 
to reach these levels and whether provision of iron supplements decrease deferral 
rates would prove beneficial to blood collection agencies. 
Methods: Two systematic reviews of available literature were conducted after 
searching on-line databases. The first looked at observational studies of demographic 
data, donation history and haematological and biological factors that might be 
associated with deferral from blood donation. The second review studied only 
randomised controlled trials and was carried out using the protocols and facilities of 
the Cochrane Collaboration to assess the efficacy and safety of iron supplementation 
to reduce iron deficiency and/or anaemia.  
Results: Fifty-five studies met the inclusion criteria for the first review, thirty studies 
were included in the second. Key findings are: 
1. Females show a significantly greater risk (11-fold) of donor low haemoglobin 
deferral as compared to males. 
2. Higher deferral rates were also associated with increasing age, higher 
ambient temperature, lower body mass, shorter donation interval or being of 
certain ethnicity. 
3. Donor deferral is reduced by taking iron supplements but the evidence is 
moderate. 
4. Those taking iron supplementation are subject to more frequent adverse 
events.  
Conclusions: These peer-reviewed and published works help define criteria that 
should be considered in large scale studies of donor deferral, especially any which 
attempt to address failure to meet low haemoglobin thresholds. Additionally, although 
donors may benefit from iron supplementation, the risk of side effects means it is 
unlikely to be a universal treatment. Together these reviews may help determine 
suitable donation intervals which decrease risk of donor iron-deficiency.
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Chapter 1 – Introduction  
 
This chapter introduces National Health Service Blood and Transplant (NHSBT) and 
describes their role in the supply of blood and blood products, their relationship with 
blood donors and the effect of donation on donor health. It will outline iron regulation 
and metabolism, what happens when the body experiences an iron deficiency and 
how iron supplementation is used to treat that deficiency. 
Secondly, I will discuss the importance of evidence-based medicine (EBM), how 
systematic reviews contribute to EBM. Particular emphasis will be made of the 
Cochrane Review process. 
Finally, I will give an overview of how NHSBT is committed to improve blood supply 
through a programme of research to produce an evidence base for new modes of 
practice. In this way I can demonstrate the origins of this project in the context of 
where it fits within the aims of the NHSBT and how it will help inform future practise. 
These will be discussed with regards to its importance to the blood donor and how it 
relates to future studies of donor health.  
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1.1 Blood donors, iron and iron supplementation 
1.1.1 National Health Service Blood and Transplant (NHSBT) and blood donors 
NHSBT is a Special Health Authority formed in 2005. It operates primarily within 
England and North Wales but  has additional responsibilities for organ donation and 
transplantation across the United Kingdom.  It comprises of the National Blood 
Service (NBS – concerned with blood supply) and Stem Cell, Tissue and Organ 
Donation and Transplantation (NHSBT, n.d.-d).  
Through the provision of a safe and reliable supply of blood components, solid 
organs, stem cells, tissues and related services to both the NHS and other UK health 
services, its stated core purpose is to 'save and improve lives'.  
In England, NHSBT is responsible for maintaining the supply of blood and blood 
products to approximately 350 hospitals within the NBS catchment area in England 
(NHSBT, n.d.-a). Blood is collected from volunteer donors and processed into 
constituent components (red blood cells - RBC, plasma and platelets) on an almost 
industrial scale. The collection process may be manual, producing multiple 
components from one whole blood (WB) donation, or by machine (apheresis) to 
produce a greater volume of a single component. RBCs are the most frequently 
transfused blood component, with NHSBT collecting over two million blood donations 
from 1.4 million donors in 2011-12, and supplying 1.7 million units of RBC for 
transfusion (NHSBT, n.d.-a). During that period NHSBT also supplied some 250,000 
platelet donations, 87% of them being produced by 13,000 plateletpheresis donors 
(Gheveart, 2013). 
Having adequate supplies to meet the needs of health services with respect to donor 
collection is becoming increasingly difficult. In part this is due to changes in attitude 
within society to the act of donation, especially in young people ("Chloe", 2012) and, 
in part, because of over-reliance on more useful blood groups (O Rh D Negative 
donors comprise only 7% of the population but are used in 11% of transfusions, 
especially as a “Universal Donor” for emergency issue, and so are frequently in short 
supply (Better  Blood Transfusion Team, 2012)).  
Furthermore, it may be difficult to obtain compatible blood for multi-transfused 
patients developing multiple or widely reactive antibodies, for example patients with 
thalassaemia or myelodysplasia, or for patients with rare blood groups. These 
problems are compounded by the potentially devastating impact of emerging 
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infectious diseases transmissible by transfusion as shown by the clinical and 
economic impact of variant Creutzfeldt-Jakob disease (vCJD) on the supply of blood 
components in the UK in the past decade (Turner & Ludlam, 2009). This current trend 
of declining rates of blood donation, combined with an increase in the requirement for 
blood components, is likely to continue in coming years (Seifried et al., 2011). 
In order to ensure the quality of the blood supply to the patient and the continued 
health of the donor, members of the population undergo rigorous health screening 
prior to donation, part of which is exceeding a minimum blood haemoglobin (Hb) 
level. Blood donors may fail this Hb test, which means they are unable to donate on 
that occasion and are “deferred” to a future donation date, or even permanently 
excluded. Studies have shown that those deferred may well become reluctant to try 
again (Custer, Chinn, Hirschler, Busch, & Murphy, 2007). Ensuring donors have a 
good experience is very important and identified as such in the NHSBT Annual 
Review for 2012-13 (NHSBT, n.d.-b). What factors lead to a blood donor failing the 
Hb test and whether the NHSBT can, by giving the donor access to iron 
supplementation, improve retention of donors and thereby improve blood supply, is 
poorly understood. 
Iron deficiency remains a significant cause of morbidity in both the general population 
and blood donors (Baart, de Kort, Moons, & Vergouwe, 2011). Up to 5% of new donors 
(and a similar percentage of regular donors) cannot be accepted because of low Hb 
levels, leading to deferral. Little is understood as to why some individuals are unable to 
donate repeatedly, how measures of iron stores are affected by blood donation or why 
some donors are more susceptible to iron deficiency than others. 
In England, each donation of whole blood (470 mL/unit plus 30 mL samples) contains 
approximately 250 mg of iron (Page, Coppock, & Harrison, 2010); with the maximum 
permissible frequency of donation being 3 - 4 times a year (Joint United Kingdom (UK) 
Blood Transfusion and Tissue Transplantation Services Professional Advisory 
Committee (JPAC), 2013). A "double-dose" of red cells (two red cell units collected by 
machine in a process termed apheresis) may be collected every 26 weeks (Joint United 
Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional 
Advisory Committee (JPAC), 2013). Platelet donation by apheresis results in a lower 
loss of blood per donation (~100 mL) but the increased frequency of donation (up to 24 
times per year) is equivalent to 4 - 5 whole blood donations (Page et al., 2010). If this 
iron is not replaced then donors may deplete their iron stores and become iron deficient 
or develop frank iron-deficiency anaemia (Simon, Hunt, & Garry, 1984). Blood services 
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have a duty of care, both for blood donors and patients. Not only do they need to 
ensure an adequate blood supply to service the needs of the patient, they also need to 
ensure the donor is fit to donate. For the donor there is a need to avoid both the harmful 
effects of donation and their deferral due to their Hb falling below the current UK 
Guideline level of 125 g/L for females or 135 g/L for males (Joint United Kingdom (UK) 
Blood Transfusion and Tissue Transplantation Services Professional Advisory 
Committee (JPAC), 2013). Indeed, these minimum levels are themselves by no means 
universally adopted by the World's Blood Transfusion Services and have only recently 
been increased by the NHSBT in response to EU legislation. After donation, Hb levels 
fall too far to permit repeat donation on schedule in up to 10% of donors each year 
(Baart et al., 2011).  
Although donor management practices are aimed at donor safety, they can have an 
adverse effect on future donor behavior (Custer et al., 2007). Deferral is associated with 
non-return of donors, with up to 75% of deferred donors not attending in the following 
year (Bianco et al., 2002). Ever more restrictive donor selection criteria and 
demographic changes have reduced the numbers of first time donors and the 
recruitment and care of donors has become a vital issue for Transfusion Services. 
Therefore it is necessary not only to minimise deferral but also reduce the risk of 
provoking iron deficiency or anaemia to optimise the number of donors and donations. 
It is well known that Hb levels and measures of iron stores fall in regular blood donors, 
particularly in pre-menopausal women (Alvarez-Ossorio, Kirchner, Kluter, & Schlenke, 
2000; C. A. Finch, Cook, Labbe, & Culala, 1977; Milman, 1996; Skikne, Lynch, Borek, 
& Cook, 1984; Worwood & Darke, 1993). Other factors have been associated with 
increased rate of deferral. Hoekstra, Veldhuizen, van Noord, and de Kort (2007) 
reported a seasonal fluctuation in Hb levels leading to increased deferral during the 
summer months. Age and race/ethnicity have both been shown to have an effect on Hb 
in whole blood donors and plateletpheresis donors (Alvarez-Ossorio et al., 2000; 
Jeremiah & Koate, 2009; Shaz, James, Hillyer, Schreiber, & Hillyer, 2010; Tondon, 
Pandey, & Chaudhry, 2008). Additionally, Mast et al. (2010) found, in men, body weight 
to be inversely proportional to Hb level and attaining a higher education level decreased 
the risk of deferral due to low Hb. 
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1.1.2 Iron 
The human body contains 3 - 4g of iron, mainly associated with oxygen-binding 
proteins such as haemoglobin (blood) and myoglobin (muscle), but also with transport 
or storage proteins. It acts as a co-enzyme in the transfer of electrons by 
cytochromes, peroxidases, ribonucleotide reductases and catalases. Iron is stored 
bound to protein in two forms within the body – an insoluble complex known as 
haemosiderin and a soluble form found in all cells, known as ferritin. Transport of iron 
is by the blood plasma glycoprotein, transferrin. 
Iron balance (homeostasis) is regulated by intestinal absorption, but there is no 
mechanism for physiological excretion; losses result only from bleeding and 
exfoliation of skin and mucosal cells. Approximately 1 - 2 milligrams of iron are both 
gained daily in the diet and lost by excretion (see Figure 1.1). As with most metabolic 
processes, the level of iron is critical: too high a level (iron overload) can lead to 
cirrhosis, diabetes, cardiomyopathy, arthritis and testicular failure; too low a level (iron 
deficiency) to anaemia (IDA), irritability, weakness, pica and restless legs syndrome.  
The amount of iron absorbed compared to the amount actually ingested is typically 
low and dependent on a number of factors. The efficiency with which iron is absorbed 
varies depending on the source. In general, the best absorbed forms of iron come 
from animal products. Iron from animal (heme) and some plant (non-heme) sources is 
absorbed more efficiently (15% to 35% of intake), whereas between 10% and 20% of 
iron in iron salt form (as found in most supplements) is absorbed.  
Absorption of dietary iron varies according to the body's need for iron, typically iron is 
absorbed at only 1 - 2mg/day (equivalent to a dietary intake of ~15 mg/day). More 
absorption occurs in the iron-deficient individual. For example: an adolescent requires 
2 – 3 mg/day, as does a fertile woman whereas a pregnant woman needs 3 – 4 
mg/day. A maximum level of 4 mg iron a day is capable of being absorbed (Provan, 
2009). However, the amount of iron absorbed decreases with increasing doses. For 
this reason, and to avoid the toxic effects of iron poisoning (plasma iron levels of 
greater than 350-500 μg/dL) it is recommended supplements are taken in smaller, 
equally spaced, doses (Office of Dietary Supplements, 2014).  
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Iron Gain 
in food  
~15 mg/day 
Plasma 
transferrin 
(3 mg) 
Erythropoiesis 
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Red blood 
cells 
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absorption 
(~1-2 mg Fe/day) 
Muscle myoglobin 
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Iron Loss 
Desquamation 
Sloughed mucosal cells 
Menstruation (+other blood loss) 
(~1-2 mg Fe/day) 
Fe recycling by macrophages in 
liver and spleen (30 mg Fe/day) 
Reticulo-
Endothelial 
system 
(600 mg) 
Liver 
parenchyma 
(1000 mg) 
Figure 1-1: Iron distribution in the body.  
Adapted from Andrews (1999) and Roberts (2012).  
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As a healthy gastro-intestinal tract (GIT) is important for efficient absorption then 
factors that affect the GIT (gastritis, gastric surgery, coeliac disease) may affect the 
body’s ability to assimilate iron. Rates of absorption can be affected by the diet. 
Orange juice (and vitamin C in general), pickles (vinegar-containing), soy sauce and 
alcohol are all known to enhance iron absorption whereas tea, coffee, oregano and 
milk are inhibitors. Foods with high levels of iron include pulses, clams, meat, liver, 
tofu and oatmeal. Vegetarians have higher levels of IDA compared with non-
vegetarians as the body does not absorb the type of iron found in plants as well as it 
absorbs the iron from meat (International Nutritional Anemia Consultative Group 
(INACG), 1998).  
As previously stated, donating a unit of red cells removes ~250 mg of iron from the 
body’s store and it has been suggested a regular blood donor needs to absorb 3 – 4 
mg/day to replenish lost RBC iron stores (C. Finch, 1994; Page et al., 2010). 
 
1.1.3 Iron deficiency 
Iron deficiency has been described as occurring in three progressive phases: 
1. Initially, stored iron in the bone marrow diminishes due to insufficient supply. 
Usually this stage is asymptomatic, has no apparent effect on erythropoiesis, 
and escapes detection i.e. the donor would pass an Hb screening test. 
2. The second stage, of iron deficiency, is when continued depletion leads to 
substantially reduced storage levels and Hb production begins to be affected. 
The donor may, or may not, pass the screening test at this time. 
3. Finally, full IDA develops at a point when iron stores are insufficient to 
maintain Hb production. This advanced stage is reflected in low Hb values and 
it is only at this time that the donor would fail the low Hb threshold 
(Lesperance, Wu, & Bernstein, 2002; Wu, Lesperance, & Bernstein, 2002).  
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1.1.3.1  Anaemia 
The term “anaemia” derives from the Ancient Greek meaning “lack of blood”. 
Although most commonly defined as having too few, or smaller, red blood cells, 
measurement of anaemia is most often in terms of reduced Hb levels. Less 
frequently, it refers to a decreased oxygen-binding capacity of Hb due to reduced 
number of molecules or deformity within those molecules. Therefore, an automated 
full blood count (FBC) would reveal the red cell count (RCC), the size of those red 
cells via the mean cell/corpuscular volume (MCV) and the level of Hb within those 
cells (Mean Cell/Corpuscular Haemoglobin Concentration – MCHC). Decreased 
oxygen-binding can only be revealed by additional tests (usually biochemical in 
nature) and the underlying reason for the abnormality might require genetic testing.  
Anaemia diagnosis can be broadly split into two approaches – morphological and 
kinetic. The first differentiates on the basis red cell size (MCV) and colour (MCHC); 
cells being termed microcytic (MCV <80fL), normocytic (MCV = 80 – 100 fL) or 
macrocytic (MCV >100 fL); hypochromic (MHCH <315 g/L), normochromic (MHCH = 
315 – 330 g/L), or hyperchromic (MHCH >330 g/L) - see Fig 1.2 below. The kinetic 
approach to diagnosis involves the enumeration of reticulocytes, showing the degree 
of new red cell production by the bone marrow. The latter approach is more common 
in the US (Munker, 2007; Silver, 2010). 
1.1.3.1.1 Microcytic anaemia 
This is primarily the result of the failure of, or inadequate, Hb synthesis. There can be 
defects in heme synthesis (e.g. IDA), globin synthesis (alpha- and beta-thalassaemia, 
HbE and HbC syndromes) or sideroblast production (hereditary or acquired 
sideroblastic anaemia). Populations with a high incidence of these disease states 
would be more likely to fail the low Hb thresholds set for those where no such 
predisposition exists.  
IDA is the most common type of anaemia and results from insufficient dietary intake 
or absorption of iron to meet the needs of the individual (Hoffbrand, Moss, & Pettit, 
2006). However, IDA has many causes and common in the developed world is 
through bleeding or blood loss, especially from the GIT, menstrual bleeding and 
frequent blood donation. World-wide the most frequent cause of IDA is parasitic 
infection. Not only is the anaemia in IDA microcytic, but it is also hypochromic (having 
reduced colour – MCHC - due to containing less Hb). 
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Figure 1-2: Morphologic classification of anaemia, showing the common red cell form in 
iron-deficiency anaemia (circled) (The McGill Physiology Virtual Lab, n.d.). 
 
Macrocytic and normocytic anaemia 
Megaloblastic anaemia, a deficiency in vitamin B12 and/or folate, is the most frequent 
cause of macrocytic anaemia resulting in decreased red cell production. Vitamin B12 
deficiency is both macrocytic and normochromic. Hypothyroidism, alcoholism and 
certain drugs (methotrexate and zidovudine) cause anaemia described as non-
megaloblastic anaemia.  
Normocytic anaemia – where RBC are of normal size but the Hb level within that cell 
is decreased – occurs in cases of acute blood loss, chronic disease, aplastic anaemia 
and haemolytic anaemia. 
Chapter 1 – Introduction 
10 
 
Although the individual blood donor may suffer with one or more of these, neither 
macrocytic or normocytic anaemia results from donation (as far as we know). 
However, they may affect a population with poor nutrition (megaloblastic) or a higher 
level of alcoholism (non-megaloblastic) or of parasitism (microcytic) (Hoffbrand et al., 
2006; Munker, 2007). 
1.1.3.2 Physical symptoms of Anaemia 
As mentioned earlier, there are a number of physical manifestations of anaemia. In 
addition to commonly understood complaints such as lethargy, tiredness, dyspnoea 
on activity and cognitive impairment these include: 
Pica – a tendency to eat non-nutritive, non-food, substances (such as soil, hair or 
sand) over an extended period of time (usually around four weeks). It is thought to be 
a “specific hunger” – a need to eat substances containing something missing from the 
normal diet – in this instance iron. 
Restless Legs Syndrome (RLS) is characterised by an urgent need to move the body 
to try and relieve a seemingly unrelenting and uncomfortable or odd sensation, most 
often in the legs. Activity helps relieve the condition and continued movement 
provides ongoing relief. Although the exact mechanism is unknown studies have 
shown differences in iron-related markers (ferritin levels, etc.) comparing groups of 
RLS sufferers with controls. The dopamine system within the brain has been 
postulated as being involved (Clemens, Rye, & Hochman, 2006).  
1.1.4  Measures and measurement of iron, iron deficiency and anaemia 
Table 1.1 gives a brief outline of a number of haematological and biochemical 
parameters used within the systematic reviews detailed in Chapters 2 and 3 to 
measure the effects of blood donation on iron homeostasis. It should also be made 
apparent that the measurement of these parameters is dependent on the blood 
donation setting. What methods are available to a “mobile” session (i.e. one where a 
blood donation team travels to a facility where they set up a temporary collection site) 
differ to those found at a ”static” (fixed) site. Indeed, static sites themselves differ, in 
that they may be permanently situated in a hospital or blood transfusion centre or be 
in a blood collection unit on a remote site. 
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Table 1.1: Haematological and biochemical tests for iron status 
Test Mean (±2SD) or Range Units Description 
Male  Female 
Haemoglobin (Hb)* 150 (±20) 
9.31 (±1.24) 
135 (±15) 
8.37 (±0.93) 
g/L 
mmol/L 
Hb is the principle component of the RBC’s dry weight (around 97%) and has an oxygen-binding 
capacity 70 times that of dissolved oxygen in the blood.  Genetic variation in Hb forms can lead to 
different oxygen binding capabilities (“functional” anaemia). The test measures the amount of the 
protein in the blood. As a fall in the Hb level is usually a late manifestation of iron deficiency so in 
a blood donor failing the Hb test other indices will already be abnormal (Provan, 2009). 
Red Cell Count (RCC)* 5.0 (±0.5) 4.3 (±0.5) 
x 10
12
/L 
An estimation of the number of red cells in a given volume, usually by electronic counting. A low 
count may be seen in chronic disease. 
Haematocrit (Hct)* 0.45 (±0.05) 0.41 (±0.05) L/L Sometimes referred to as packed cell volume (PCV) it is the volume percentage of red cells in 
blood plasma, typically reduced in anaemia. 
Mean Corpuscular / Cell 
Volume (MCV)* 
92 (±9) 92 (±9) fL The size of the red cells and, when coupled to a low Hb, allows classification as of a microcytic 
anaemia (MCV below normal range), of the type more commonly found in blood donors. 
Mean Cell Hb (MCH)* 29.5 (±2.5) 29.5 (±2.5) pg The average mass of Hb per red blood cell and can be derived from the Hb divided by the RCC. 
Mean Cell Hb 
Concentration (MCHC)* 
330 (±15) 330 (±15) g/L The average mass of Hb per unit volume of red blood cells and is derived from the Hb divided by 
the PCV. 
Ferritin (Serum or Red 
Cell) 
30 -300 10 -200 ng/mL The major iron storage protein (under normal conditions haemosiderin levels are very low), which 
occurs when ferritin leaks from tissue into the serum. Therefore, it is proportional to the amount of 
iron in storage (1 ng/mL equivalent to 8 -10 mg of iron in stores). When ferritin levels are low, it 
indicates a risk of iron shortage, which could lead to anaemia. Considered essential in its 
diagnosis, the most specific lab test for iron-deficiency anaemia is a low serum ferritin level 
(Thomas et al., 2013). In IDA, as iron stores become depleted, the ferritin value will decrease 
(Lesperance et al., 2002). 
Transferrins 240 -450 250 -370 
45-66  
μg/dL 
μmol/L 
These are iron-binding blood plasma glycoproteins that control the level of free iron in biological 
fluids and are raised in IDA.  
(Soluble) Transferrin 
receptor (TfR) 
9.6 – 29.6 9.6 – 29.6 nmol/L More TfR is produced when the body has low iron stores and is used when iron-deficiency 
anaemia is the presumed diagnosis. It is relatively expensive, not widely available and not yet 
subject to external quality assessment (Thomas et al., 2013).  Levels ~ 9% higher in Blacks. 
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Test Mean (±2SD) or Range Units Description 
Male  Female 
Net Iron Absorption   % Amount of iron ingested, less that recovered in faeces, given as a percentage. This would be 
increased in IDA. 
Serum/plasma Iron
#
 60-170 60-170 µg/dL Measures how much iron is in the blood [bound to Transferrin]. Serum iron is decreased in IDA 
due to depletion of stores (Lesperance et al., 2002). 
Total Iron Binding 
Capacity (TIBC)
#
 
250–370  
45-66 
250–370  
45-66 
μg/dL  
μmol/L 
A measure of how much transferrin (the iron-carrying protein) is present in the blood  which 
indicates iron availability to tissues and is raised in IDA. 
Transferrin Saturation 
Percentage
#
 
15 – 50 12 – 45 
 
% Abbreviated as TSAT and reported as a percentage, it is the ratio of serum iron and TIBC, 
multiplied by 100. It is the most used of the three indices in the UK (Thomas et al., 2013). Of the 
transferrin that is available to bind iron (transferrin has ~4500 iron binding sites per molecule) this 
value informs how much serum iron is actually bound, e.g. a value of 15% means that 15% of iron-
binding sites of transferrin are being occupied by iron. It is a measure of iron in transport, not in 
stores. A combination of high TIBC and low amounts of iron in IDA typically gives a TSAT of <5% 
(values of 5 -10% indicate possible, but not definitive, IDA). When used in combination with 
another variable (such as sTfR) it has improved sensitivity and specificity for response to iron 
therapy. 
Free Erythrocyte 
Protoporphyrin (FEP) 
160-360  
 
0.28-0.64 
160-360  
 
0.28-0.64 
μg/L red 
cells 
μmol/L 
red cells 
FEP is a heme precursor, which reflects incorporation of iron into the Hb molecule. The test 
assesses whether there is too little iron in the blood by measuring the non-complexed, non-heme 
protoporphyrin concentration and the levels are seen to rise in IDA. 
 
Zinc Protoporphyrin 
(ZPP) 
≤40 ≤40 µmol/ 
mol 
heme 
When an individual has anaemia, zinc is incorporated into protoporphyrin in place of iron. ZPP is a 
by-product of disordered heme synthesis, with higher ZPP levels indicating greater anaemia. It is 
not specific for IDA, being raised in conditions where iron is not deficient, such as lead poisoning 
and α- and β-thalassaemia traits. (Thomas et al., 2013). Current practice is to measure on washed 
red cells and report the molar ratio of ZPP to heme (μmol/mol). 
#
 The results of serum iron, TIBC and TSAT are usually reported together. 
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1.1.4.1 Measurement of IDA in blood donors 
Copper sulphate (CuSO4) screening 
Within the UK the routine anaemia screening test for blood donors is the copper 
sulphate (Cu2+SO4) gravimetric method (M. H. Miller, 1947). A drop of blood taken by 
finger-prick is placed on the surface of a 30 mL tube of Cu2+SO4 solution and has to 
sink to the bottom within a certain time (30 seconds). The Cu2+SO4 solution is of a 
specific gravity (SG) set to allow only red cells above a minimum Hb level to sink; the 
SG being different for men and women. The Hb threshold for men is set at 135 g/L; 
for women it is 125 g/L (NHSBT, n.d.-c). 
Point of Care Testing (POCT) by colorimetric determination  
If a donor has too low an Hb for the cells to sink, they are retested using a portable 
Hb meter (HemoCue®) which uses a cyanmethaemoglobin colorimetric determination 
system on a 10 μL blood sample from a fingerprick. These are reputedly as accurate 
as the automated haematology analyser mentioned below. 
Automated haematology analyser 
These are bench-based machines that rely on a variety of methodologies (usually 
colorimetric) and use a separate venous blood sample. They not only measure Hb but 
can determine a number of other useful parameters. Those concerned with the 
estimation of iron and iron-deficiency are shown as "*" in Table 1.1 (Lewis, 2006). 
Other tests 
At present, other than Hb and Hct, there appear to be no POCT devices that can be 
easily employed to screen donors prior to donation for any of the indices mentioned 
above. This means that a blood collection service is limited to only preventing 
donation from those donors with stage three ID, i.e. a drop in Hb levels to such an 
extent that the donor fails the anaemia screening tests. However, in the UK the low 
Hb threshold is set at such a level there is still a margin of 5 g/L before the donor 
becomes clinically anaemic according to the WHO definition (World Health 
Organization, 2011). It might be considered a duty of care to retrospectively test these 
donors who have passed the Hb screens after having given blood within a static 
testing laboratory for a marker of IDA such as ferritin. If there are indications of stage 
one or two ID, they may be temporarily deferred from donation until their iron stores 
have recovered (possibly after being offered a course of iron supplementation). These 
tests would attract a significant additional cost for the collection service which may not 
be offset by increased donor retention. 
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1.1.5  Iron Supplementation (IS) 
 
 
Figure 1-3: Iron Jelloids (Ferrous sulphate/Vitamin B1, B2 & C preparation) from 1930s. 
Photograph taken at Bucks Railway Museum, Quainton. 
 
Blaud's pills were the first iron pills and were named after P. Blaud of Beaucaire, the 
French physician who introduced the use of these medications as a treatment for 
patients with anaemia (Robinson, 1939). Since that time, the number of Iron 
supplements (IS) has proliferated, with the number of preparations listed in the 
catalog.md website reaching over 600 (catalog.md, 2013). 
 
1.1.5.1 Indications 
IS are primarily used to treat iron-deficiency and iron-deficiency anaemia, although 
parenteral (intra-venous, intra-muscular) iron preparations can be used to treat 
malabsorption problems, such as inflammation of the gut. It is only after other causes 
of anaemia have been excluded (vitamin B12/folate deficiency, lead poisoning, drugs) 
that IS should be considered. 
1.1.5.2 Administration 
Iron stores are regulated through absorption of iron and so interventions either 
directly or indirectly increase iron available for absorption. This could be in the form of 
dietary advice to increase the amount of iron-rich food or in the form of oral iron 
supplementation, such as iron salts. Parenteral iron is unlikely to be a common 
intervention for blood donors as invasive procedures are costly in terms of money, 
time and risk of infection.  
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1.1.5.3 Oral route 
The most common and cheapest iron salt is ferrous (II) sulphate but it is also 
available complexed to gluconate, dextran, carbonyl iron, and other salts. Ascorbic 
acid (Vitamin C) is sometimes added to the preparation (or taken as an 
accompanying medication) for better absorption. 
When standard preparations, such as ferrous sulphate or ferrous fumarate, are not 
tolerated or readily absorbed then heme iron in the form of a polypeptide (HIP) can be 
used. A clinical study demonstrated that HIP increased serum iron levels 23 times 
greater than ferrous fumarate on a milligram-per-milligram basis (Seligman, Moore, & 
Schleicher, 2000). 
Ferrous glycine sulphate is another alternative which has been shown not only to 
have  a very high bio-availability (especially as a liquid) but also to result in fewer GIT 
side-effects than regular iron supplements, such as ferrous fumarate (Aronstam & 
Aston, 1982).  
Ferrous (2+) salts are three times more bioavailable than ferric (3+) salts, as ferric 
salts have to be first reduced to the ferrous form by stomach acid before entry to the 
mucosal cells (Tom, 2008).  
A further option would be to offer blood donors dietary advice, especially in those who 
would be averse to taking pills. Not only could they be directed towards high iron-
containing foods, such as outlined in the introduction (Section 1.1.2), but there are 
commercial preparations of naturally-occurring spring water which have a high iron 
content. 
Oral iron has a higher frequency of intolerance and, coupled with a slower rate of 
improvement, is often replaced by parenteral iron in an acute setting. This would not 
be a common intervention for blood donors.  
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1.1.5.4 Parenteral routes 
Parenteral iron therapy (by intravenous or intramuscular injection) is usually given 
when oral therapy has failed (not tolerated by the recipient), oral absorption is 
seriously impaired (by illness, or by inability to swallow), benefit from oral therapy is 
unlikely or a rapid improvement is required (e.g. prior to an elective procedure). None 
of these conditions is likely to be found in the blood donor. Parenteral therapy is more 
expensive than oral iron preparations, requires an additional invasive procedure 
which requires more time and skilled staff to perform. As such, the number of studies 
of parenteral IS in blood donors is likely to be few.  
 
1.1.5.5 Side effects 
The most common side effects found with oral iron therapy are diarrhoea, 
constipation or epigastric (the area of central abdomen lying below the sternum and 
above the umbilicus) pain. Stools may become black. If iron supplements are given in 
liquid form teeth may become discoloured (although not irreversibly so) and the site of 
intramuscular injection can become sore and discoloured. Donors should be made 
aware of these symptoms so they may counteract their effect by taking stool 
softeners or adding fibre to their diet, or by discontinuing treatment. In the case of oral 
iron, symptoms are ameliorated if the supplement is taken after a meal. However, 
there is an increased risk of interaction with foodstuffs and alteration of pH that may 
decrease absorption.  
Side effects are dose-dependent, so the dose may need to be adjusted for the donor. 
Starting with a lower dose than the daily recommended amount, then gradually 
increasing to the full dose, may help minimise side effects (Hayhoe, 1960). 
Bivalent iron (Fe2+) salts, such as ferrous sulphate have been associated with more 
adverse effects than trivalent (Fe3+) salts (Santiago, 2012), especially if not in a 
prolonged-release formulation such as iron (Fe2+) bis-glycinate chelate (Ashmead, 
2001; Szarfarc, de Cassana, Fujimori, Guerra-Shinohara, & de Oliveira, 2001).  
However, although side effects tend to be reduced when trivalent iron (such as iron 
(III)-hydroxide polymaltose complex –IPC) is used, the treatments are absorbed more 
slowly and are more expensive (Geisser, 2007; Saha, Pandhi, Gopalan, Malhotra, & 
Saha, 2007; Toblli & Brignoli, 2007) when compared to treatments with iron (II) 
sulphate, although there is some evidence to the contrary (Tom, 2008). 
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1.1.5.6 Contraindications 
Before commencing treatment for anaemia it is essential to determine the type of 
anaemia present, as inappropriate dosing with iron salts can result in iron overload in 
non-IDAs. Hypersensitivity has been documented to all formulations. Some can be 
used in ID, others require IDA to be present. Some (especially parenteral 
preparations) are also contraindicated in those with a history of allergy, such as 
asthma and eczema, infection and rheumatoid arthritis (Joint Formulary Committee, 
2014). 
1.1.5.7 Interactions 
In addition to those with food, it is recommended an interval of 2 – 3 hours between 
the iron intake and that of other drugs is advisable. Donors would tend to be less 
likely to be on a course of medication (as many drugs would exclude them from 
donating) but any delay between having to take different drugs would make it less 
convenient and so may have an impact on compliance. 
1.1.5.8 Precautions  
Iron in too large a quantity acts on the mucosa and results in haematemesis (vomiting 
of blood) and diarrhoea with patients becoming hypovolaemic due to fluid and blood 
loss. It is recommended adults should not take any more than 45 mg of iron a day 
unless they are being treated with iron under close medical supervision (not a 
common situation for the blood donor). At an absorption rate of 10% this is close to 
the 3-4 mg suggested as being the recommended daily requirement needed to 
replenish lost RBC iron stores in a regular blood donor (C. Finch, 1994). 
 
With iron ingestion of 20 - 40 mg/kg individuals can demonstrate signs of gastro-
intestinal toxicity resulting in systemic iron toxicity. Severe overdose causes impaired 
oxidative phosphorylation and mitochondrial dysfunction, which leads to cellular 
death.  The liver is one of the organs most affected by iron toxicity, but other organs 
such as the heart, kidneys, lungs, and the haematologic systems also may be 
impaired.  
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Individuals with the hereditary disorder haemochromatosis can absorb up to 30% of 
the iron they ingest, much more than the 10 - 20% of normal individuals, and so have 
trouble regulating their iron absorption. As such, the iron in their body can more 
rapidly build up to the dangerous levels seen in iron overload, with the resultant iron 
deposits in organs leading to cirrhosis, heart failure and diabetes. For that reason, 
haemochromatosis sufferers have been excluded from this study as they should not 
take iron supplements. 
 
1.1.6 Iron Supplementation (IS) in Blood Donors 
To be able to donate, blood donors have to answer a number of questions regarding 
their lifestyle, health, risk of infection and travel prior to donation (donor health check - 
DHC), as well as exceed minimum physical requirements such as weight and Hb 
level. Donors with major illness, recent cold, fever, infection, gastrointestinal upset or 
generally feeling unwell are deferred from donating. 
A number of markers of iron-deficiency have been studied in existing Cochrane 
reviews, both of iron stores (ferritin) and circulating iron and iron available for 
erythropoiesis (serum iron, Total Iron Binding Capacity [TIBC] and percentage of Hb 
saturated with oxygen [% saturation]). Haemoglobin levels and measures of iron 
deficiency fall in regular blood donors, particularly in pre-menopausal women 
(Alvarez-Ossorio et al., 2000; C. A. Finch et al., 1977; Milman, 1996; Skikne et al., 
1984; Worwood & Darke, 1993). 
A blood collection service such as the NHSBT has a duty of care to maintain the 
health of its donor base. Not only does this mean not over-bleeding its donors, but 
also they should not be seen to be putting their donors at a potential risk of iron-
overdosing. Should they consider providing IS, then it would be a fine balance 
between providing sufficient iron to make a meaningful contribution to avoiding 
anaemia but not enough that a donor could inadvertently suffer from iron toxicity.  
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1.2 Evidence-based practice (EBP), the Cochrane Collaboration and 
the NHSBT Systematic Review Initiative (SRI) 
1.2.1 Evidence-based practice 
Although the belief in an evidence-base for medical intervention has been in 
existence for hundreds of years, momentum gathered pace in the UK during the early 
1990s and was crystallised in the paper by Sackett, Rosenberg, Gray, Haynes, and 
Richardson (1996). Here it was explicitly stated that that the current best evidence 
was to be used in the making of decisions regarding the care of individual patients. 
The current best evidence is a bottom up approach amalgamating both external 
evidence with individual clinical expertise and the wishes of the patient. It is a 
fundamental belief behind the National Institute for Health Research (NIHR), founded 
in 2006 to improve the research environment by patient  involvement, improved 
funding and reduced bureaucracy. The medical Royal Colleges informed Parliament 
on the 25th April 2013 that EBM was key to the success of modern healthcare 
(Academy of Medical Royal Colleges, 2013).  
How this is brought about varies between institution, from the five stages of EBP 
outlined on the evidence-based nursing practice website (Evidence Based Nursing 
Practice, n.d.) to the seven steps of EBP described by Melnyk, Fineout-Overholt, 
Stillwell, and Williamson (2010).  Whether they include the nurturing of a questioning 
environment, or the dissemination of the research as a separate step, they hold to a 
number of common processes: 
1. Ask the (research) question 
2. Find the evidence 
3. Appraise that evidence 
4. Act on it 
5. Evaluate and reflect on those actions 
1.2.2 The hierachy of evidence 
Not all evidence is created equal. It has been recognised for some years that 
research findings differ in their quality in terms of the risk of both error and bias. A 
number of different hierarchies exist (1979; Cook, Guyatt, Laupacis, & Sackett, 1992; 
Sackett, 1986; M. C. Wilson, Hayward, Tunis, Bass, & Guyatt, 1995; Woolf, Battista, 
Anderson, Logan, & Wang, 1990).  Although they agree in broad terms (see Figure 
1.4, below) they present their findings in a number of different ways.  
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Figure 1-4: Pyramid of evidence (Galili, 2010) 
N.B. TRIP is a search engine designed for rapid and simple location of high-quality 
clinical research evidence to support user's practice and/or care. 
 
In the absence of experimental evidence the best information on which to base 
practice is that of expert opinion. However, individuals, or even groups of like-minded 
individuals, are subject to a number of biases (Tidy, 2010).  
Individual studies, such as case-controlled, cohort and randomised-controlled trials 
(RCT), produce unfiltered ("raw") evidence of increasing quality, with the highest level 
of evidence being provided by RCT.  
1.2.2.1 Cohort studies 
Cohort studies are more at risk of bias than randomised controlled trials but less so 
than case-controlled studies. The potential for bias in cohort studies (Kanchanaraksa, 
2008) include: 
Selection   - where participants are selected into group A rather than group B 
 on  a characteristic that may affect outcome 
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Information  - the quality and extent of information differs between the groups, or 
 - there is different loss to follow-up between the two cohorts 
Misclassification  - participants exposure is wrongly identified 
With retrospective studies, confounding and bias are the principle causes of error 
(StatsDirect, 2000-2014), whereas loss to follow-up is the main cause of error for 
prospective studies (Euser, Zoccali, Jager, & Dekker, 2009). 
1.2.2.2 Cross-sectional studies 
Cross-sectional surveys examine the relationship between particular (health-related) 
characteristics and other variables as they are present in a defined population at a 
given point in time so that both exposure and outcomes are measured concurrently 
(Centre for Evidence-based Medicine, 2014). They are best for quantifying the 
prevalence of a disease or risk factor. 
Advantages: 
 cheap and simple 
 ethically safe 
Disadvantages: 
 establishes association at most, not causality 
 recall bias susceptibility 
 confounders may be unequally distributed 
 Neyman (selective survival) bias 
 group sizes may be unequal 
1.2.2.3 Randomised Controlled Trials 
An experimental comparison study in which participants are allocated to an 
intervention or control or placebo group using a mechanism of randomisation. These 
are best for study of the effect of an intervention.  
"Advantages:  
 unbiased distribution of confounders 
 blinding more likely 
 randomisation facilitates statistical analysis 
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Disadvantages:  
 expensive: time and money 
 volunteer bias 
 ethically problematic at times." (Centre for Evidence-based Medicine, 2014) 
CONSORT, the Consolidated Standards of Reporting Trials, provides an evidence-
based set of minimum standards for transparent reporting of RCTs (Begg, Cho, 
Eastwood, & et al., 1996). The World Health Organization (WHO) is responsible for 
the reporting of such trials through the International Clinical Trials Registry Platform 
(ICTRP). The AllTrials campaign (www.alltrials.net) is a movement that urges all past, 
present and future trials should be registered, and their results reported publicly, in 
line with the Declaration of Helsinki (the World Medical Association's assertion that all 
human clinical research should be officially recorded and reported). Perhaps the 
important point is not with whom the trial is registered, but that it is registered. 
1.2.2.4  Meta-analyses and systematic reviews 
 It might be logical to extrapolate that if one were to critically look at the data from a 
number of studies the findings might give a more accurate determination of an effect 
or might minimise the bias from individual investigations. As such, it should be able to 
provide one of the highest levels of evidence possible. 
Meta-analysis is a statistical method for combining the findings of two or more studies 
and is used most frequently to assess the effectiveness of clinical trials. It is often, but 
not exclusively, a component of systematic reviews and can be thought of as the 
quantitative component of a systematic review. 
Systematic Reviews 
What is a systematic review (SR)?  The Cochrane Handbook defines it as an attempt 
“to identify, appraise and synthesize all the empirical evidence that meets pre-
specified eligibility criteria to answer a given research question. Researchers 
conducting systematic reviews use explicit methods aimed at minimizing bias in order 
to produce more reliable findings that can be used to inform decision making.” (The 
Cochrane Collaboration, 2014).  
Although in the majority of instances a SR is regarded as the highest grade of 
evidence, the Centre for Evidence-Based Medicine (CEBM) suggest that the quality 
of the evidence is dependent of the context in which it is to be used (OCEBM Levels 
of Evidence Working Group, 2011) - Appendix 1. 
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Criticism has been levelled at SRs as being outdated at the time of publication. A 
recent study (Beller, Chen, Wang, & Glasziou, 2013) showed that although some 
(10%) SRs did not publish the time of their last search and those that did showed an 
average delay of eight months between search and publication. However, Shekelle, 
Motala, Johnsen, and Newberry (2014) reported a surveillance system to determine 
the degree by which the conclusions from SRs were out of date and to prioritise the 
need for updating. This was based on an limited search of top-rated medical journals 
and speciality journals from the field under study and had a predictive value (ϰ 
statistic) of 0.74 (0 = no agreement; 1 = complete agreement). 
1.2.3 Quality of evidence and strength of recommendations 
The Scottish Intercollegiate Guidelines Network (SIGN at www.sign.ac.uk) , an 
organisation formed in 1993 to develop evidence-based guidelines, developed a 
alpha-numerical indication of the size and strength of the evidence base for 
guidelines. The methodology used for each study is assessed to ensure its validity. 
The result affects the level of evidence allocated to that study, which influences the 
grade of recommendation based on that research (Table 1.2a,b).  
LEVELS OF EVIDENCE 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of confounding or bias and a 
high probability that the relationship is causal 
2+ Well-conducted case control or cohort studies with a low risk of confounding or bias and a 
moderate probability that the relationship is causal 
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk 
that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
Table 1.1a: Scottish Intercollegiate Guidelines Network Levels of Evidence (Scottish 
Intercollegiate Guidelines Network (SIGN), 2011). 
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GRADES OF RECOMMENDATIONS 
 
At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to 
the target population; or 
A body of evidence consisting principally of studies rated as 1+, directly applicable to the 
target population, and demonstrating overall consistency of results 
 
A body of evidence including studies rated as 2++, directly applicable to the target population, 
and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 1++ or 1+ 
 
A body of evidence including studies rated as 2+, directly applicable to the target population 
and demonstrating overall consistency of results; or 
Extrapolated evidence from studies rated as 2++ 
 
Evidence level 3 or 4; or 
Extrapolated evidence from studies rated as 2+ 
Good practice points 
 
Recommended best practice based on the clinical experience of the guideline development 
group 
 
Table 1.2b: SIGN Grades of Recommendation (Scottish Intercollegiate Guidelines 
Network (SIGN), 2011). 
 
1.2.3.1 The Cochrane Collaboration 
The Cochrane Collaboration (www.cochrane.org) is an international organisation  
which attempts to minimise the risks of bias and to quantify those that remain in a 
formalised structure that assists the reviewer and enables people to be as assured as 
possible of the evidence they are accessing in order to make well-informed decisions 
regarding healthcare. It aims to produce evidence that would be classified by SIGN 
50 as 1++, but does so using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system 
(http://www.gradeworkinggroup.org/index.htm).  
The quality of evidence is graded as: 
 A - high quality randomised clinical trials which further research is unlikely to 
undermine the confidence in the findings 
B - moderate quality evidence for which further research is likely to improve the 
confidence in the estimate of any effect and may even change that estimate 
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C - low quality studies where additional research is very likely to affect both the 
confidence in the findings and the findings themselves 
D - very low quality where there is a very uncertain estimate of effect  
Strong Grade 1 recommendations are made when there is confidence that the 
benefits clearly outweigh the undesirable effects of treatment (harm, burden or cost) 
and can be applied uniformly to most patients. 
Weak Grade 2 recommendations are made where the degree of benefit is less certain 
and those recommendations ("suggestions") require more careful application. 
This grading system represents a continuous scale which, although displaying some 
degree of being derived arbitrarily, provides a simple and clear recommendation. 
Thus, evidence graded as 1A has a strong recommendation based on high quality 
evidence (Atkins et al., 2004; Guyatt et al., 2008). 
This  grading system has been used by the National Institute of Health and Care 
Excellence (National Institute of Health and Care Excellance (NICE), 2012) as well as 
the British Committee for Standards in Haematology since January 2010 (with the 
exception that level D evidence is not used in BCSH guidelines (British Committee for 
Standards in Haematology (BCSH), n.d.). BCSH is the body which produces the 
majority of Blood Transfusion guidelines for the UK Blood Transfusion Services 
(Pavord et al., 2012; Qureshi et al., 2014; Tinegate et al., 2012; Treleaven et al., 
2011). 
Heterogeneity 
What is heterogeneity? A heterogeneous group is a diverse group. In an attempt to 
systematically review a cohort of studies it is highly likely they will differ in a number 
of key areas, areas which can be distinguished to aid to assessing their relative 
importance. 
Clinical (design) heterogeneity 
Clinical heterogenity is found where the intervention effect is affected by factors that 
vary across studies - what might be termed PICO factors (Population, Intervention, 
Comparators and Outcomes). Their variation means the true intervention effect will be 
different in different studies, and meta-analysis should only be undertaken when a 
group of studies is sufficiently homogeneous (Deeks, Higgins, & Altman, 2011). It is 
infrequent for there to be a formal evaluation of design heterogeneity prior to meta-
analysis, more common is for it to be used afterwards as an attempt to explain 
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statistical heterogeneity (Althuis, Weed, & Frankenfeld, 2014). Althuis et al. (2014) 
described, and illustrated using a worked example, an evidence-based mapping 
approach with which to assess clinical heterogeneity. 
Methodological heterogeneity (Risk of bias) 
Variation in the study design and risk of bias may be termed methodological 
heterogeneity. Bias is a systematic deviation from the truth which can result in an 
underestimate or exaggeration of the true effect of an intervention (J. P. T. Higgins & 
Altman, 2011). Examples of different biases which may be found within the study 
design are shown in Table 1.3. Differences in what intervention effects are seen may 
result from whether blinding or allocation concealment are employed. 
Statistical heterogeneity 
Statistical diversity is influenced by either, or both, clinical and methodological 
heterogeneity. It most often is apparent when the difference in observed intervention 
effects between studies is more than would be expected due to chance alone. The 
chi-squared (Χ2) test is a statistical measure of heterogeneity which is a part of the 
forest plots found within Cochrane reviews. A low probability (P) value (or a large Χ2 
value relative to its degrees of freedom, df), provides evidence of heterogeneity. By 
combining the Χ2 value with its df a useful statistic, I2,  is derived which allows a rough 
guide to interpretation of heterogeneity (J. P. Higgins, Thompson, Deeks, & Altman, 
2003) (Table 1.4) using the following formula: 
 
I2 =  
     
  
        
 
     
  
 
 
 
 Table 1.3: Interpretation of statistical heterogenity (Deeks et al., 2011). 
 
I
2 
(%) range 
Heterogeneity 
0 40 May not be important 
30 60 Moderate 
50 90 Substantial 
75 100 Considerable 
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Domain  Support for judgement  Review authors’ judgement  
Selection bias  
Random sequence generation.  
Describe the method used to generate the allocation sequence in 
sufficient detail to allow an assessment of whether it should 
produce comparable groups.  
Selection bias (biased allocation to 
interventions) due to inadequate generation of a 
randomised sequence.  
Allocation concealment.  Describe the method used to conceal the allocation sequence in 
sufficient detail to determine whether intervention allocations 
could have been foreseen in advance of, or during, enrolment.  
Selection bias (biased allocation to 
interventions) due to inadequate concealment 
of allocations prior to assignment.  
Performance bias. 
Blinding of participants and personnel  
Assessments should be made for each main 
outcome (or class of outcomes).   
Describe all measures used, if any, to blind study participants and 
personnel from knowledge of which intervention a participant 
received. Provide any information relating to whether the intended 
blinding was effective.  
Performance bias due to knowledge of the 
allocated interventions by participants and 
personnel during the study.  
Detection bias.  
Blinding of outcome assessment 
Assessments should be made for each main 
outcome (or class of outcomes).  
Describe all measures used, if any, to blind outcome assessors 
from knowledge of which intervention a participant received. 
Provide any information relating to whether the intended blinding 
was effective.  
Detection bias due to knowledge of the 
allocated interventions by outcome assessors.  
Attrition bias. 
 Incomplete outcome data Assessments 
should be made for each main outcome (or 
class of outcomes).   
Describe the completeness of outcome data for each main 
outcome, including attrition and exclusions from the analysis. 
State whether attrition and exclusions were reported, the numbers 
in each intervention group (compared with total randomized 
participants), reasons for attrition/exclusions where reported, and 
any re-inclusions in analyses performed by the review authors.  
Attrition bias due to amount, nature or handling 
of incomplete outcome data.  
Reporting bias.  
Selective reporting.  
State how the possibility of selective outcome reporting was 
examined by the review authors, and what was found.  
Reporting bias due to selective outcome 
reporting.  
Other bias. 
Other sources of bias. 
State any important concerns about bias not addressed in the 
other domains in the tool. 
If particular questions/entries were pre-specified in the review’s 
protocol, responses should be provided for each question/entry. 
Bias due to problems not covered elsewhere in 
the table. 
Table 1.4: The Cochrane Collaboration’s tool for assessing risk of bias, Table 8.5.a. Reproduced from The Cochrane Handbook (J. P. T. Higgins & 
Altman, 2011).
Chapter 1 – Introduction 
   
28 
 
1.2.3.2 PROSPERO 
It should be noted that Cochrane is not the only register of SRs. PROSPERO, an 
international prospective register of SRs, was launched in 2011 and is funded by the 
NIHR in the UK. Its aim was similar to that of Cochrane, to produce high quality, 
unique reviews whilst simplifying the process of registration as compared to Cochrane 
(Booth et al., 2013). Reviews registered on PROSPERO do not appear in Cochrane, 
and vice versa.  
1.2.4 NHSBT Systematic Review Initiative (SRI) 
SRI is a clinical research group that was created to support the R&D activities, not 
only of the English NHSBT but also of the other three (Northern Ireland, Scottish and 
Welsh) UK Blood Services. Based in NHSBT – Oxford at the John Radcliffe Hospital, 
it was formed in 2001 and receives funding from all four UK Blood Services (SRI, 
2014). 
Blood Transfusion practice is, in general, not supported by reliable evidence and the 
primary function of the SRI is to help increase the evidence base for the practice of 
transfusion medicine through evaluation of the scientific rigour of the current literature 
and its implications for further R&D (Brunskill et al., 2009). It hopes to accomplish this 
aim by building effective relationships with and between clinicians and researchers 
throughout the world. An independent steering committee identifies and prioritises 
those areas for investigation by SRI. It comprises of clinical experts and 
representatives from relevant professional bodies within the UK and North America. 
1.2.4.1 Handsearching 
Handsearching of the more important transfusion medicine publications is another 
activity performed by the SRI. In one study, it found between 92% and 100% of the 
total number of reports of randomised trials found by all the methods compared.  
(Hopewell, Clarke, Lefebvre, & Scherer, 2007). This procedure involves page-by-
page examination of journals, conference proceedings and other potential sources for 
relevant studies. Included in this is the checking of reference lists of journal articles 
and other documents retrieved from electronic searches in order to identify economic 
studies (ES), systematic reviews (SR) and randomised controlled trials (RCT) 
relevant to transfusion medicine. The process is both prospective and retrospective 
(SRI search from 1980 onwards) and is important because it finds items poorly 
indexed or not indexed at all. All the content in journal issues, supplements, special 
issues, or conference abstracts may not be indexed comprehensively, or not indexed 
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at all, by some databases. These include abstracts from the following annual 
meetings or congresses: American Association of Blood Banks (AABB), American 
Society of Hematology (ASH), British Blood Transfusion Society (BBTS), British 
Society of Haematology (BSH), European Group for Blood & Bone Marrow 
Transplantation (EBMT), European Haematology Association (EHA), Haematology 
Society of Australia & New Zealand (HSANZ), International, Regional & Asia Society 
of Blood Transfusion (ISBT), International Society on Thrombosis & Haemostasis 
(ISTH) and the Network for the Advancement of Transfusion Alternatives (NATA).  
Additionally, it allows researchers to scan content quickly for relevant studies from 
high-impact journals and ensures that relevant studies are not overlooked (University 
of Newcastle (Australia), 2014). 
1.2.4.2 Electronic searching 
SRI perform monthly electronic searches for SR of the major medical databases and 
appraised reviews from those searches are entered into the UKBTS SRI Transfusion 
Evidence Library. There is an annual submission of RCT to CENTRAL, the Cochrane 
Database of Controlled Trials (part of The Cochrane Library).  
1.2.4.3 The Transfusion Evidence Library (TEL) 
The UKBTS SRI Transfusion Evidence Library (TEL), launched in September 2009, 
contains SR, RCT, ES and handsearched references relevant to transfusion medicine 
which may be searched through various criteria (see Figure 1.2.2).  It can be 
accessed through the link: http://www.transfusionevidencelibrary.com/ 
 
 
Figure 1-5: Screenshot of UKBTS Transfusion Evidence Library search facility. 
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TEL aims to be a key and current (it is updated monthly) resource for transfusion 
practitioners, policy makers and researchers anywhere in the world. When accessed 
(19 September, 2014 through link above) it contained 762 SR, 4272 RCT and 58 EE.  
An in-house search strategy designed to be highly sensitive has been developed, 
although it has not been benchmarked with, or tested against, a 'gold standard' 
reference set of studies.  It will identify papers relevant to all aspects of transfusion 
medicine and was designed and combined with the SIGN SR and ES search filters.  
Exhaustive searches of The Cochrane Library, MEDLINE, EMBASE and from 
handsearching of the journals Blood Reviews and Transfusion Medicine Reviews 
identifies SR and ES suitable for inclusion. Only those that meet stringent criteria 
(based mainly on the quality of the SR’s search) are included in the TEL database. 
After an extensive critical appraisal by members of SRI (which are linked to the full 
references in the TEL) some reviews of special interest may be included.  
For inclusion in TEL the authors of a SR have to have searched PubMed/MEDLINE 
and at least one other database. Those reviews that had only searched MEDLINE 
have been excluded. ES are only included if they are based on a SR. By searching 
the NHS Economic Evaluations Database (NHSEED) ES of other types can be found. 
This database is compiled through either the Centre for Reviews and Dissemination 
from:  
http://www.crd.york.ac.uk/crdweb/  
or, the Cochrane Library at: 
http://www.thecochranelibrary.org/ 
Only where the participants have been randomly allocated (randomised) to the trial 
groups in a controlled clinical intervention are they included in TEL. 
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1.3 Research & Development (R&D) within the NHSBT 
The aim of R&D within NHSBT is to ensure the strategic objectives and targets of its 
Operating Divisions (Blood Supply, Organ Donation and Transplantation, Tissues, 
Diagnostic Services, Stem Cell Services and Specialist Therapeutic Services) are 
supported by a targeted programme of R&D. This extensive research programme is 
funded from both external sources and from within NHSBT (NHSBT, 2013).  
Supporting functions have been developed for all the R&D activities, such as the 
Clinical Biotechnology Centre (Bristol), which manufactures GMP-grade biologicals 
for Phase 1 clinical trials, the NHSBT/MRC Clinical Studies Unit (Oxford/ Cambridge/ 
London), which supports clinical studies and trials, the previously mentioned 
Systematic Review Initiative (Oxford), the Statistics and Clinical Audit team (Bristol) 
and the R&D office team, which provide support and guidance (NHSBT, 2014). When 
reviewed by external experts in 2010 NHSBT's R&D programme was assessed as 
outstanding and identified as making world-class contributions to Transfusion 
Medicine.  It was also recognised as high-quality when benchmarked against National 
and International standards as well as against other blood services. However, a 
parallel review identified that connections between R&D and operational areas of the 
NHSBT could be improved. 
1.3.1 NIHR R&D programmes 
In 2009 it was proposed by the NIHR that NHSBT R&D rebid for a new five-year cycle 
of funding that would replace any existing funding. Four programmes were submitted 
to a total of £14M and would form the major proportion of NHSBT's laboratory 
research. One of these, Programme D - Erythropoiesis in Health and Disease was 
successful in obtaining £3.5M and the programme began on 1st October, 2010. It was 
at this stage I was invited to join Programme D to join the Systematic Review Initiative 
in providing evidence for proposed randomised controlled trials (RCTs). 
1.3.1.1 Programme D - Erythropoiesis in Health and Disease 
The central ideology behind this research programme is to improve the health of 
blood donors and of the quality of the blood supply by a systematic analysis of the 
published data, advancing the understanding of the basis of iron deficiency in blood 
donors and suggesting how this may be predicted and prevented. 
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Erythropoiesis - the process by which red blood cells (erythrocytes) are produced - is 
fundamental to all human health; not only to that of blood donors but also in many 
patients requiring blood products. A number of related projects (termed "AIMS") 
comprise Programme D which intends to improve the supply of red blood cells by 
having a better understanding of ID in blood donors. It will suggest how it may be 
predicted and prevented (AIMS 1 & 2), develop ex vivo sources for producing RBC 
(AIMS 3 & 4) and investigating the basis of abnormal and deficient red blood 
production in the largest single group of chronically transfused (Myelodysplastic) 
patients in the UK (AIM 4). 
AIM 1 
In general terms, this AIM intends to review the current evidence of the efficacy and 
safety of IS in blood donors and describe the extent, associations and consequences 
of ID and anaemia in blood donors in England. It is divided into six sections (Roberts, 
2014):  
1A Review the effectiveness of IS in blood donors in preventing a fall in Hb and 
reducing deferral from donation due to anaemia (Table 1.5). 
1B Review the effectiveness of IS in reducing systemic, neurological or cognitive 
symptoms in ID but non-anaemic adults (Table 1.5). 
1C      Describe of the development of ID and IDA in blood donors (Table 1.5). 
1D      Define genetic traits associated with ID in blood donors. 
1E      Define sensitive and specific screening tests for ID in blood donors. 
1F      Develop algorithms to predict ID for repeat donors. 
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Review 
No. 
Objective AIM 1 
Objective 
Notes 
1 
A longitudinal study systematic review (LR) to 
identify and explore what demographic, donation 
and haematological factors have been examined 
or suggested as possible causes of deferral due 
to low Hb in blood donors. 
1C 
Non-UK studies 
published. No 
Cochrane 
review. 
2 
The efficacy and safety of iron supplementation 
in blood donors. 
1A, 1B 
Non-UK studies 
published. No 
Cochrane 
review. 
 
Table 1.5: Relationship between the systematic reviews and the relevant sections of 
AIM 1. 
 
1.3.2 New research strategy 
In response to the recommendations from the R&D quality reviews mentioned in 
section 1.1.2, a new four-year strategy was approved by the NHSBT Board.  In this, 
research was organised into eight themes, each linked to areas of NHSBT business, 
with a strategy group increasingly developing the programme for each theme. The 
strategy group would comprise of research, development and operational staff.  
 
The research themes approved in the 2011 strategy were:  
1. Donor health and behaviour 
2. Transfusion and transplantation virology and microbiology 
3. Appropriate and safe use of blood components 
4. Erythrocyte (red cell) biology and immunology 
5. Platelet biology and genomics 
6. Organ donation and transplantation 
7. Stem cells and immunotherapies 
8. Molecular and tissue engineering. 
 
These themes covered work already in place, but two new themes were added. One 
(Donor Health and Behaviour) would now specifically cover the area of this project. 
Although the Systematic Reviews with which I was involved still remained within the 
old NIHR Programme D, the RCTs which they were designed to inform have now 
been absorbed into Theme 1. 
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1.3.2.1 Theme 1: (Donor health and behaviour) 
Not only a new area of research for the NHSBT it has also been neglected by the 
wider international research community and so provides ample opportunity to build  a 
strong research reputation. The theme has been awarded approximately seven per 
cent of an £18.2 million national research budget, provided by a tariff on the price of 
blood and from external sources. 
The first project is a collaboration between NHSBT R&D and the University of 
Cambridge Department of Public Health and Primary care for a large strategic study 
(INTERVAL) which was commenced in June 2012. This aimed to provide evidence to 
determine policy on the optimal time between blood donations whilst minimising the 
risk of ID/IDA in donors and maximising the use of a diminishing donor pool. This 
study also has the potential to personalise the donor call up, by using genetic and 
other factors to predict tolerance to donation.  
Future projects include: 
1. Qualitative studies on the factors influencing the motivation of blood donors 
2. Collection of DNA, plasma and serum together with information on lifestyle 
and health into a large biobank from many thousand donors to allow studies 
on the associations between genes and diseases 
3. An RCT looking at the optimal use of IS in blood donors 
1.3.3 Governance 
NHSBT R&D is conducted within the DH Research Governance Framework for 
Health and Social Care (Department of Health, 2010). Intellectual Property (IP) 
support is provided by an external contract, which facilitates Freedom to Operate 
searches to be performed as well as the patenting and exploitation of new IP. 
1.3.4 Outputs and benchmarking 
Traditionally, successful academic research is measured by the numbers of both 
external grants awarded and/or high impact papers published (Fig 1-6).  
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Figure 1-6: Annual number of NHSBT peer reviewed papers, 2009-11 (NHSBT, 2013b). 
 
As all the Principal Investigators responsible for the various Themes are affiliated with 
academic institutions their outputs are assessed through the National Research 
Assessment Exercise, the last being performed in 2008 (http://www.rae.ac.uk/). 
Additionally, key measures for NHSBT would be making a significant impact on 
service activities and clinical practice. However, there may be a lag phase of up to 10 
years for the translation of research findings into routine practice. Benchmarking R&D 
activity against other, international, blood services has been made possible by the 
formation of a new R&D group under the auspices of the Alliance of Blood Operators 
(Alliance of Blood Operators (ABO), n.d.). 
 
1.4 Aims and objectives 
The aims of this thesis are, via systematic review, to provide a better understanding 
of the factors that lead to ID in blood donors and examine the current evidence of the 
benefits and costs of IS to blood donors. This knowledge will be used to inform the 
design of subsequent randomised controlled trials into donation frequency, with and 
without IS, in the expectation that blood donors will donate according to what is 
optimal for their continued health and wellbeing. 
 
My involvement has been, in collaboration with the Systematic Review Initiative, 
NHSBT-Oxford, in the provision of these reviews. 
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Chapter 2 – A systematic review of factors influencing 
the deferral of donors failing to meet low haemoglobin 
thresholds 
 
This chapter discusses the systematic review of literature describing the factors that 
have been identified as potentially having an effect on blood donors not meeting the 
low Hb thresholds of blood collection agencies from around the world.  
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2.1 Abstract 
2.1.1 Background  
Donors may be unable to donate blood due to a failure to meet low Hb thresholds set 
by the collecting organisation, leading to a temporary deferral from blood donation. A 
number of studies have identified factors, either singly or acting together, which 
influence the incidence of falling below these thresholds. However, there is no 
systematic review of the relative importance of those factors. 
 
2.1.2 Objectives 
To identify, define and quantify those factors which predispose a donor to temporary 
deferral from donation of whole blood (WB), red blood cells (RBCs) or platelets due to 
failure to meet Hb standards.  
 
2.1.3 Search Methods 
The following databases were searched for relevant studies: 
NHS Evidence National Library of Guidelines, the Cochrane library 2010,  
PUBMED (e-publications only), MEDLINE (1950 onwards), EMBASE (1980 onwards), 
CINAHL (1982 onwards); SRI TRANSFUSION EVIDENCE LIBRARY , LILACS, 
KOREAMED, INDMED, SRI SR & RCT HANDSEARCH DATABASES, Ongoing Trial 
Databases. 
 
2.1.4 Selection Criteria 
All types of studies (retrospective, prospective, cross-sectional etc.) were included. 
The minimum study size for inclusion was 100 (red blood cell donors) or 50 
(plateletpheresis) participants. Publications before 1980, foreign language 
publications, haemochromatosis studies, autologous donations, plasma donations 
and studies with donors pre-selected by Hb level were excluded. 
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2.1.5 Data Collection and Analysis  
Data were collected using customised data extraction forms using Microsoft Excel. 
Two co-authors independently extracted data which included demographic 
information, donor history, haematological and biological factors. The primary 
outcome was deferral due to failure to meet Hb thresholds for donation. 
The analyses were both descriptive and quantitative. Odds ratios from individual 
studies were pooled using meta-analyses using the systematic review software 
RevMan 5. 
 
2.1.6 Main Results  
Of the 6706 records identified from electronic searches a total of 55 studies met the 
inclusion criteria. A higher rate of low Hb deferral (LHD) was consistently reported in 
females as compared to males, with meta-analysis showing a significantly higher risk 
of LHD in females compared with males in studies with universal Hb thresholds for 
males and females (OR 14.91, 95% CI 12.82 to 17.34) as well as in studies with sex-
specific Hb thresholds (OR 8.19, 95% CI 4.88 to 13.74). LHD was also associated 
with ethnicity, increasing age, higher ambient temperature, low body weight, previous 
donation and inter-donation interval. Other factors gave less clear evidence for being 
a risk factor for low Hb deferral. 
 
2.1.7 Authors' Conclusions 
Female donors are strongly predisposed to falling below the minimum Hb thresholds 
set for their population. Increasing age is associated with a similar increase in deferral 
in males whereas a reduced body weight for both sexes results in Hb levels lower 
than acceptable for donation.  
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2.2. Plain Language Summary 
Factors influencing the deferral of donors failing to meet low haemoglobin 
thresholds  
Donors that fail to meet the lower Hb thresholds set by a blood collection organisation 
are deferred until a later date when it is hoped their Hb level will normalise. This 
phenomenon contributes a significant drain on that organisation in terms lost time and 
effort, and to the donor in demoralisation. Determination of exactly what factors might 
lead to low Hb deferral (LHD) would help an organisation target donors appropriately, 
enabling optimal donation schedules to be set. This review was performed to see if 
there was sufficiently robust and valid information upon which to base those 
schedules. Fifty seven studies looking at 55 independent trials were included, 
involving well over 40M subjects from 25 countries across six continents. Results 
from some of the studies showed conflicting evidence for certain of the factors (e.g. 
ethnicity and donation intensity in males). However, there was a clear difference in 
LHD between the genders, with women having an eleven-fold increased odds of LHD. 
Also, it was readily apparent that the older male donors become, the more likely they 
are to defer due to low Hb, especially after the age of 45-50. Black and Hispanic 
women are at an increased likelihood of LHD as compared to their White US 
counterparts. Donors of all persuasions are more prone to LHD in the warmer 
summer months than they are in winter. The study of donor body weight revealed the 
heavier a donor is the less chance they have of unsuccessful donation. Several other 
contributory factors were identified (first-time donation, education level, donating for 
friends and family) but with fewer studies looking at them the evidence was less 
convincing. Indeed, the fact that many of the studies looked at different types of donor 
(red cell and/or platelet), used dissimilar Hb thresholds and had diverse numbers of 
female participant showed that more studies are needed to see if donation strategies 
can be successfully tailored towards individual donors. 
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2.3 Background 
A systematic review is required to answer the question of what factors lead to the 
deferral of blood donors due to a low Hb level.  
Studies exist on the effect of different donation intervals but they have not been 
carried out on a UK population. Before such a study can be performed, an SR on the 
risk factors for deferral due to failure to meet Hb standards is required. A SR focuses 
on foreground knowledge (i.e. the difference between two options) using rigorous 
methods to improve the reliability of conclusions and can provide estimates of 
benefits and risks.  
2.4 Objectives 
This study will help inform a programme of research that will improve the health of 
blood donors and the blood supply by systematically analysing the published data, 
advancing our understanding of the basis of anaemia in blood donors and suggest 
how this may be predicted and prevented. This will be a longitudinal study SR to 
identify and explore what demographic, donation and haematological factors have 
been examined or suggested as possible causes of deferral due to low Hb in blood 
donors. 
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2.5 Methods 
This review is written in the style of a Cochrane Review to provide continuity with 
Chapter 3, which is a Cochrane Review. However, the methodology used for this 
review was not exactly the same as would be used in a Cochrane review. The 
purpose of the investigation was to provide evidence on which to base a future RCT. 
 
2.5.1 Criteria for considering studies for this review 
2.5.1.1 Types of studies 
The objectives for this review were to determine the risk factors for deferral so finding 
RCTs would be unlikely as they would prove both impractical and, possibly, unethical. 
The study design with the least risk of bias was expected to be cohort studies with 
retrospective or prospective data collection. The findings of any case-control studies 
retrieved were analysed separately due to the high risk of bias. It was agreed 
between the study team that the minimum number of participants had to be greater 
than 100 for donors of red blood cells (RBC) and greater than 50 for platelet donors 
(referred to as plateletpheresis). These cut-offs were chosen because: 
a)  Approximately 3% of donors are deferred due to low Hb (Baart et al., 2011). 
Studies with less than 100 participants would be difficult to investigate for the 
associations of multiple variables with low Hb deferral. 
b)  In England, approximately 1.7 million donations are collected annually (NHSBT, 
2010). Larger studies are more representative of higher quality studies. 
c)  Smaller studies are unlikely to yield meaningful findings due to the low frequency 
of people expressing the risk factor under study. A lower threshold for studies of 
platelet donors was chosen as fewer platelet donations are collected annually than 
RBC donations (an order of magnitude lower than those for RBCs), and fewer still 
of those platelet donations are by plateletpheresis (NHSBT, 2010). 
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A systematic review of cohort studies with a high degree of homogeneity would 
suggest a level of evidence assessed as Level 2a according to the Oxford Centre for 
Evidence-based Medicine (OCEBM), 2009. Under their latest revision (OCEBM 
Levels of Evidence Working Group, 2011) systematic review of cohort studies are not 
specifically mentioned. However, it is unclear how this type of study would be graded 
as these evidence tables are for interventions, not risk factors. The closest is the 
prognostic question, i.e. what happens if we do not treat inception cohorts, which is 
not the case here. 
2.5.1.2 Types of participants 
Any population is eligible for inclusion within the study. The study populations were 
compared to an English donor population and any differences discussed. How 
generalisable the findings of a study are a measure of its external validity. Particular 
consideration will be made as to the country, ethnicity, economic development and 
collection setting (mobile donation unit, hospital or transfusion service) of the study 
populations. 
2.5.1.3 Types of risk factors 
Any factor that might pre-dispose a donor to fail to meet a low Hb threshold was 
considered, but in particular included: 
 Age 
 Gender 
 Diet 
 Ethnicity 
 Education level/ socioeconomic class 
 Hb level at previous donation 
 Donation history (frequency, interval, total) 
 Other factors, as may be revealed during searching 
2.5.1.4 Types of outcome measures 
Primary outcomes 
Deferral of donors due to failure to meet Hb standards. The technical aspects of Hb 
measurement were not considered beyond noting the Hb screening method(s). 
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Secondary outcomes 
Changes in any additional factors related to low Hb in donors.  
In order to capture likely outcomes of importance a workshop was held in November 
2010 with participants from all the UK Blood Services. In July 2011 a meeting took 
place between relevant research arms of the NHSBT to inform them of the current 
findings so they might take account when formulating the study protocol for their RCT 
on donation interval and donor health (Chapter 4, Table 4.2).  
2.5.2 Search methods for identification of studies 
2.5.2.1 Electronic searches 
A comprehensive search strategy was developed in conjunction with the NHSBT 
Information Specialist (CD) from NHSBT covering the main bibliographic databases 
(MEDLINE, EMBASE and the Cochrane Library - searches shown in Appendix 2.1). 
2.5.2.2 Searching other resources 
Handsearching of reference lists 
The references of all identified studies, relevant review articles, and current treatment 
guidelines were checked for further literature and limited those searches to the ’first 
generation’ reference lists. 
Personal contacts 
Authors, study groups and worldwide experts of any relevant studies were contacted 
for any additional published or unpublished work of which they were aware. 
Ongoing trials 
The U.S. National Library of Medicine (NLM) at the National Institutes of Health (NIH 
at clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform  
(ICTRP) were searched for ongoing or unpublished trials. 
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2.5.3 Data collection and analysis 
2.5.3.1 Selection of studies 
One author (CD) screened all search hits at the title stage for relevance against the 
eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, two 
authors (GAS and SF) independently screened the abstracts of all the remaining hits 
for relevance against the full eligibility criteria. Full text papers were retrieved for all 
those references for which a decision of eligibility could not be made from title and 
abstract alone. Differences of opinion were resolved through discussion and 
consensus, and, where necessary, with reference to a third reviewer (DR).  
2.5.3.2 Data extraction and management 
Two reviewers (GAS and SF), independently extracted data onto a standardised 
Excel form developed in collaboration. These forms were piloted on two included 
studies and changes made to the data extraction form where appropriate and agreed. 
Again, throughout the data extraction process any disagreements were resolved by 
consensus. In this instance there was no need to resort to a third reviewer to resolve 
differences. There was no blinding to names of authors, institutions, journals or the 
outcomes of the trials during this process. The information collected was categorised 
thus: 
General information 
Review author's name, date of data extraction, study ID, first author of study, citation 
of paper, objectives of the trial. 
Study details 
Study design, location, setting, sample size, power calculation, methods of treatment 
allocation, inclusion and exclusion criteria, reasons for exclusion, comparability of 
groups, length of follow up, stratification, stopping rules described, statistical analysis, 
results and conclusion. 
Characteristics of participants 
Age, gender, ethnicity, total number recruited, total number analysed, losses to 
follow-up, drop outs with reasons, protocol violations, donation history, whether 
donors were paid. 
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Comparators/interventions 
Type of comparator (age, gender, ethnicity socioeconomic status, education, etc.), 
additional comparators, any differences between interventions. 
Outcomes 
Deferral due to low Hb, modelling of deferral due to low Hb. 
 
2.5.3.3 Dealing with missing data 
Authors of relevant studies were contacted for clarification, supply of missing data or 
to request any unpublished material they might possess. (Appendix 2.2.  Example of 
contact letter/e-mail).  
2.5.3.4 Data analysis 
Where possible, data were combined and meta-analysis performed as described in 
the Cochrane Handbook of Systematic Reviews of Interventions (Reeves, Deeks, 
Higgins, & Wells, 2011). Practically, this was only possible for one comparator, that of 
sex, as there was too much variation in the trials. The validity of the data was critically 
assessed in relation to the characteristics of the included study and noted in the 
Characteristics of Included Studies (Table 2.1). 
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2.6 Results 
2.6.1 Study selection 
A PRISMA flow diagram of study selection is given in Figure 2.1. Electronic database 
searches identified 6706 records, which were reduced to 1456 after initial screening 
for relevance and de-duplication. Further, separate, screening of these 1456 records 
by GAS and another reviewer (SF) resulted in 151 potentially eligible studies for 
inclusion (95 full papers and 56 conference abstracts). Of these, 93 records (55 full 
papers and 39 abstracts) were subsequently excluded as they failed to meet the 
inclusion criteria (Figure 2-1) 34 abstracts and 35 papers due to insufficient data, a 
further 11 papers because of pre-selection by Hb level, four were unobtainable, one 
study revealed on closer inspection to have too few participants (after translation) and 
four papers and five abstracts appeared to overlap with another included study.   
 
 
 
6706 records identified 
from electronic 
database searches 
1456 records after 
preliminary screening 
for relevance and de-
duplication  
1305 records excluded 
95 full papers and 56 
conference abstracts 
assessed for inclusion 
55 full papers and 39 abstracts excluded: 
Insufficient deferral data (35 papers; 34 
abstracts) 
Participants pre-selected by Hb level (11 
papers) 
Full paper unobtainable (4 papers) 
Sample size too low (1 paper) 
Participant overlap with another included 
study (4 papers; 5 abstracts) 
40 full papers and 17 
conference abstracts 
included in data 
synthesis 
1456 records screened 
independently by two 
reviewers 
Figure 2-1: PRISMA flow diagram of study selection 
Chapter 2 – A systematic review of factors influencing the deferral of donors failing to meet 
low haemoglobin thresholds 
   
47 
 
 
2.6.2 Description of studies 
The inclusion criteria were met by 40 full papers and 17 conference abstracts which 
described 55 independent studies (Summary of Characteristics of Included Studies -
Table 2.1 and referenced in Appendix 2.3).  Four studies involved both RBC and 
platelet donation, 27 studies included RBC/whole blood donation only and two studies 
included platelet donors only. The remaining studies did not explicitly state the 
donation type. Studies were undertaken in 25 countries across six continents.  
Hb thresholds for blood donation were reported in 38 studies; a further three used 
haematocrit (Hct) levels to determine donation eligibility and the remaining 14 reports 
did not report either (Table 2.1). Of the 21 studies using the same threshold for both 
males and females, 18 used an Hb of 125 g/L (including eight studies from the USA, 
seven from India and one each from, Nigeria, Iran and Papua-New Guinea). The 
lowest universal threshold was 110 g/L in a study from the Ivory Coast (Kouao et al., 
2012); the highest universal threshold was a Hct of 40% (approximately equivalent to 
an Hb of 135 g/L) in a Turkish study (Gulen et al., 2006). Of the 20 studies which 
employed gender-specific thresholds, 18 reported Hb and two reported Hct 
thresholds. Thirteen of these studies used an Hb of 135 g/L for males and 125 g/L for 
females (including all but one European study as well as studies from Trinidad and 
Tobago, India, Mexico and Malaysia).  
Those studies that reported methods of Hb determination used a variety of 
techniques: copper sulphate, microhaematocrit, portable photometric device and 
automated cell analyser - using both capillary and venous blood (Table 2.1). 
Most studies (43/55) reported deferrals due to other reasons as well as low Hb. 
However, eight studies excluded deferrals due to other reasons prior to the study and 
in a further four studies, the number of deferrals due to other reasons was not 
explicitly reported, or it was unclear whether deferrals due to other reasons were 
excluded from the study. Therefore, in order to provide a comparative measure of 
deferral across the maximum possible number of studies, the LHD rate was defined 
as the number of deferrals due to low Hb divided by the total number of potential 
donations, excluding all deferrals due to reasons other than low Hb. This estimate 
gives a slightly higher measure of the rate of low Hb deferral than that obtained for a 
population where other causes of deferral are included. 
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2.6.2.1  Discussion of bias 
The studies were a mixture of descriptive cross-sectional surveys and observational 
analytic cohort studies.  
With cohort studies, sample sizes for rarer factors may not have been sufficiently 
large and there may have been unknown confounders. Within some studies, the 
number of donors within certain sub-groups into which a factor had been stratified 
varied greatly (by a factor of 150, in the case of weight sub-groups in the study of 
Mast et al. (2010).  
Within the cross-sectional surveys these confounders may have been unequally 
distributed, especially with some of unequal group sizes seen. Neyman and recall 
bias should not have been a problem with these studies. 
Specific discussion of bias is given within each comparison.  
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Table 2.1: Summary of characteristics of included studies.  
Study  
Country of 
Study 
Donation 
Type
1
 
Hb 
screen
2
 
Hb 
Threshold 
(M/F)
2a
 
Donation Attempts
3
 
% 
Male 
Hb Deferrals (%)
4
 
Description of Study Participants 
All M F 
Agnihotri 2010  India RBC 
♂ C + H 
♀ H 
125 6032 [6357] 90.0 6.8 2.7 47.2 
Voluntary and replacement donors recruited 
over one and half years. 
Arslan 2007 Turkey RBC H
C
 135/125 83899 [94919] 89.5 3.4 2.1 15.2 
Hospital blood bank donors aged 18-65 
collected over 5 years 2001-2005.  
Baart 2012  The Netherlands RBC H
Cap
 135/125 220946 [220946] 
5
 50.9 5.8 4.1 7.7 
Previous donors who visited a blood 
collection centre during 2007-2009; previous 
two donations were whole blood donations. 
Bahadur 2011  India RBC C + H 125 6152 [6817]  98.3 2.0 1.2
 6
 34.2
 6
 
Tertiary care centre donors during 2009. 
Donations were replacement (99.5%) and 
voluntary (0.5%). 
Bischke 2011 
7
 Denmark n/r n/r 135/125 219 [219] 
5
 65.3 16.4
 8
 7.0 30.0 
Donors failing previous Hb test would have 
been offered iron tablets.  
Bryant 2009  USA RBC C 125 3549 [3730]  53.0 9.2 n/r n/r 
Consented donors >18yrs old attending a 
blood donor centre between 27/10/08 - 
10/04/09. 
Caiado 2011  Portugal n/r n/r
 cap
  n/r 79416 [95682]  61.0 6.0 n/r n/r 
11 year cohort of blood donors between 
2000 -2010. 
Charles 2010  Trinidad/Tobago RBC C 135/125 8199 [11346]  66.6 10.9 3.4 24.7 
Donor presentations during 2005. 
Replacement (93.7%) and voluntary (6.2%) 
donors. 
Chaudhary 1995  India RBC C 135/125  12363 [14269]  91.3 3.5 1.3 30.3 
Prospective donors over 15 months (Oct 
1992 – Dec 1993). All donor were unpaid 
voluntary relatives aged 18-60. Paid or 
professional donors were excluded. 
Custer 2004  USA RBC C 125 4987704 [5607922]  50.2 6.0 n/r 11.0  
Custer 2012/  
Mast 2010  
USA RBC/P 
C + H, 
Hct
U
, H, 
Hct
C
 
125 4987704 [5607922]  48.9 8.7 1.1 15.9 
Custer 2012 presents an expanded data 
cohort of Mast 2010. Some outcome data 
from the Mast 2010 are included where not 
reported by Custer 2012. 
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Study  
Country of 
Study 
Donation 
Type
1
 
Hb 
screen
2
 
Hb 
Threshold 
(M/F)
2a
 
Donation Attempts
3
 
% 
Male 
Hb Deferrals (%)
4
 
Description of Study Participants 
All M F 
Cortes 2005 
 9
 Colombia RBC H
Cap
 135/130 210 [210] 59.5 7.6 0 18.8 
300 donors presenting to a blood centre 
between April – June 2004, differentiated by 
altitude of city of residence. 
Dartote 2010  Mexico n/r n/r 135/125 52178 [82171]  71.0 9.8 n/r n/r Prospective donor study attending in 2009. 
Di Lorenzo 
2009/2011 
10
 
Brazil n/r Hct
c
 [40%/38%] 265173 [335109]  66.0 2.8 0.6
 6
 5.5
 6
 
Donor data collected in 2006 from 18
 
centres. Ethnic composition of participants 
was 41.7% white; 57.1% non-white; 1.2% 
not declared. 
Donovan 2011  USA n/r n/r 
cap
 n/r 3466 [3668] n/r 5.0 n/r n/r 
Selected individual collection operations  
from Jan 2008 – Dec 2010 that had a 
minimum of 600 donors attending. 
Eder 2010  USA n/r Mixed 125 7546213 [7871268] 49.3 7.7 1.4 13.9 American Red Cross donors during 2008. 
Gandhi 2012  USA RBC n/r 125 35053 [35053] 
5
 46.7 12.4 3.8 20.1 
WB donors recruited over a 12-month period 
from two hospital blood donation sites and 
one fixed site collection unit. 
Girish 2012  India RBC n/r 125 
11
 8732 [9113] 97.3 1.1 0.7 16.6 
Whole blood donors recruited Jan 2009 – 
Dec 2010 from one fixed site collection unit. 
Goncalez 2013 
12
 Brazil RBC Hb, Hct 130/125  787228 [963519] 65.9 5.2 0.9 13.5 
Blood donors recruited from three Brazilian 
blood banks (Aug 2007 – Dec 2009). 
Guerreiro 2011  Portugal RBC/A Hb n/r 4117 [4175] n/r 0.9 n/r n/r 
Retrospective records of donors attending 
during 2010. 
Gulen 2006  Turkey RBC/P Hct
c
 [40%] 1683 [2207] n/r 5.1 n/r n/r 
Prospective blood donors recruited at a 
blood centre at a children’s hospital over a 
6-month period (Jul–Dec 2002).  
Gupta 2011  India RBC n/r n/r 5605 [5989] n/r 1.5 n/r n/r 
Whole blood donors recruited Mar – Aug 
2011 from three fixed site collection units. 
Hillgrove 2011 
7
 Australia RBC H
Cap
 128/118 69686 [69686] 5 47.1 1.5 0.5 2.3 
Australian Red Cross Blood Service 
(ARCBS) - all donors attending in two states 
(New South Wales and South Australia). 
Hoekstra 2007  Netherlands RBC A, H
c
 135/125 520236 [520236] 
13
 59.6 4.7
 8
 2.5 8.0 
Participants had to have donated twice 
during the study period (Jan 2002 – Dec 
2004). 
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Study  
Country of 
Study 
Donation 
Type
1
 
Hb 
screen
2
 
Hb 
Threshold 
(M/F)
2a
 
Donation Attempts
3
 
% 
Male 
Hb Deferrals (%)
4
 
Description of Study Participants 
All M F 
Islam 2004  Bangladesh n/r n/r n/r 1942 [2196] 85.8 1.9 n/r n/r 
All non-remunerated and some directed 
donations included. 
Kagu 2010  Nigeria n/r H
Cap
 125 3724 [4032] n/r 10.9 n/r n/r 
Voluntary non-remunerated donors over 2 
years. 4.4% were previous donors; number 
of previous donations ranged from 1 - 6. 
Low Hb deferral donors were routinely given 
dietary advice with haematinic supplements. 
Kamel 2011 USA RBC n/r 125 1051720 [1051720]
 5
 50.2 6.1 0.6 11.2 WB and automated donors during 2010. 
Kouao 2012  Ivory Coast RBC Hct
C
, H
Cap
 110 22516 [24363] 75.0 3.4 n/r n/r 
Voluntary and non-remunerated donors 
presenting at a hospital blood bank 01/01/06 
– 31/12/08. 
Kuhnel 2011  Germany RBC n/r n/r 2658273 [2897377] n/r 2.3 n/r n/r 
Retrospective 10 year period mainly on 
mobile blood donation sites. 
Lau 1988  USA n/r C + Hct
C
 [41%/38%]  140197 [145094] n/r 4.6 n/r n/r 
Volunteer blood donors attending a blood 
centre between Jan 1981 – Dec 1984. 
Lim 1993  Singapore n/r n/r 125/120 242167 [278401] n/r 1.6 n/r n/r 
Prospective donors attending Singapore 
Blood Transfusion Service over four years 
1988-1991. 
Majumdar 1999  India RBC Col 125 1033 [1044] 92.1 10.2 n/r n/r 
Voluntary blood donors collected over 4 
years (excluding 9 month period of blood 
bank closure). 
Mathur 2012 
14
 India n/r C 125 31108 [35339] 74.4 10.6 n/r n/r 
Voluntary, non-remunerated, blood donors 
attending a blood centre, mobile vans and 
outdoor blood drives between Sep 2005 – 
Jul 2006 
Mirrezaie 2011  Iran n/r H 125 2000 [2000]
 15
 70.0 16.3 10.0 31.0 
Unselected, prospective blood donors had 
Hb measurement by haematology analyser 
and finger stick methods. 
Misso 2011  Italy n/r n/r n/r 1220 [1266] n/r 1.6 n/r n/r 
Study of donors attending during 2010. 
 
Moog 2004  Germany RBC/P n/r 135/125 437 [594] 73.3 7.6 n/r n/r 
Retrospective records of donors attending 
during 2002. Minimum interdonation time of 
3 months; minimum body weight of >60 kg. 
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Study  
Country of 
Study 
Donation 
Type
1
 
Hb 
screen
2
 
Hb 
Threshold 
(M/F)
2a
 
Donation Attempts
3
 
% 
Male 
Hb Deferrals (%)
4
 
Description of Study Participants 
All M F 
Munasinghe 2011  Sri Lanka RBC n/r n/r 6964 [7609] n/r 3.5 n/r n/r 
Donors attending a base hospital during 
2008 - 2010. 
Nadarajan 2010  Malaysia n/r C + H/A n/r 84989 [93807] n/r 2.1 n/r n/r 
Study of volunteer donors attending during 
2006 - 2008. 
Nikolic 2011  Serbia n/r n/r n/r 21417 [22352] n/r 2.1 n/r n/r 
Retrospective records of donors attending 
during 2010. 
O’Meara 2011  Switzerland RBC A 133/123 160612 [160612] 
5
 46.2 2.4 n/r n/r 
Includes first time and repeat donors. 
Median number of donations per volunteer 
over the 14 year study period (1996 – 2009) 
was 2 (range 1 - 56). Optional iron 
supplementation offered from 2004 
onwards. 
Pandey 2012  India P n/r 125 2312 [2558] n/r 1.1 n/r n/r 
Attendees of tertiary healthcare centre 
between Jan 2010 – Mar 2011. 
Pierelli 2011  Italy n/r 
New 
method? 
135/125 13196 [13347] n/r 3.0 n/r n/r 
Donors attending a hospital blood collection 
unit between Nov 2008 – Dec 2010. 
Rabeya 2008  Malaysia RBC n/r 135/125 4001 [4138] 70.0 2.3 0.9 5.6 
Donors attending a transfusion medicine unit 
between Jan 2006 – Dec 2006. 
Raka 2010 Macedonia RBC n/r n/r 21331 [21915] 79.3 4.6 n/r n/r 
Retrospective records of donors attending 
during 2009.  
Rosochova 2011  Switzerland RBC H
Cap
 135/125 19296 [19296] 
13
 n/r 2.0 n/r n/r 
Donors attending a transfusion centre for 12 
months. 
Sebok 2007  USA n/r C + Hct 125 23.1M [24.3M] n/r 7.8 1.0
 6
 13.8
 6
 
Retrospective records of donors attending 
during 2002 - 2004. 
Shaz 2010  USA n/r C + Hct
C
 125 547261 [576317] 52.8 8.9 1.2 15.7 
Voluntary allogeneic donors attending 
various locations during 2004 - 2008. 
Sundar 2010  India RBC C, Col 125 16132 [16706] 88.7 1.4 0.3 10.2 
Voluntary and replacement (approx 10% 
replacement) donors aged ≤60 years. . 
Retrospective donors attending various 
locations during 2005 – 2007. 
Talonu 1983 
Papua New 
Guinea 
n/r C 125 5068 [5279] 74.9 1.8 n/r n/r 
Volunteer donors  attending a blood bank or 
mobile teams during 14.09.79 – 02.10.80. 
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Study  
Country of 
Study 
Donation 
Type
1
 
Hb 
screen
2
 
Hb 
Threshold 
(M/F)
2a
 
Donation Attempts
3
 
% 
Male 
Hb Deferrals (%)
4
 
Description of Study Participants 
All M F 
Tondon  2008  India P A 125 1165 [1515] n/r 5.0 n/r n/r 
Volunteer donors  attending a blood bank or 
mobile teams during 14.09.79 – 02.10.80. 
Unnikrishnan 2011  India n/r n/r n/r 13097 [13722] 95.2 0.7 n/r n/r 
Donors, mostly under 25 and predominantly  
educated males attending a tertiary care 
hospital in 2008. 
Wilkinson 1982  Ireland n/r C 1225 1763903 [1763903] 
15 65.7 5.7 1.0 14.6 Volunteer donors aged 18 - 65. 
Wijesiri 2011   Sri Lanka RBC n/r n/r 24016 [25948] n/r 0.4 n/r n/r 
Volunteer donors attending f our mobile 
teams during April – Sept 2010. 
Zanella 1989  Italy n/r C 135/125 14641 [14641] 
13
 63.3 4.3 1.2 9.7 
First time donors  attending a blood centre 
during 1981 -1987. 
Ziemann 2006  Germany RBC A 135/125 81913 [81913]
 5
 57.5 6.4 n/r n/r 
Consecutive whole blood donors between 
May 2003 – Nov 2005 analyzed on diversion 
samples taken  from sample pouch 
 
n/r = not reported;  
1
 RBC = red blood cells; P = platelets, A = apheresis; 
2
 A = Analyser; C = CuSO4; H
(Cap or v)
 = Portable photometric device (capillary or venous blood); Hct
(U or 
c)
 = Haematocrit by ultrasound or centrifuge; Col = Colorimetric; Mixed;   
2a
 g/L (values in parentheses are % haematocrit thresholds);   3 number of donation attempts excluding 
deferrals due to reasons other than low Hb [total number of donation attempts];   
4
 where possible, the low Hb deferral rate is calculated as a percentage of the combined total 
number of Hb deferrals and accepted donations, i.e. deferrals due to other reasons were excluded in the calculation of the low Hb deferral rate;   
5
 deferrals due to reasons 
other than low Hb were excluded from the study;   
6
 the total number of donation attempts excluding deferrals due to other reasons was not reported for males and females; the 
deferral rate is calculated as a proportion of the total number of donation attempts reported;   
7
 studies in which data discrepancies deferrals were observed within the study 
report and in which the best estimate of deferral rate was made;   
8
 the combined low Hb deferral rate has been calculated from the estimated number of deferrals based on 
reported percentages in males and females;    
9
 this study included three cohorts with Hb thresholds defined according to altitude. Only the largest cohort from the Manizales 
area meet the inclusion criteria and are included here;   
10
 Di Lorenzo-Oliveira 2009/2011: where discrepancies are observed between the two reports, the most recently 
published data has been extracted;   
11
 although not explicitly reported, 125g/L is assumed as the current Indian thresholds.;  
12
 Hb and Hct thresholds were defined differently 
for different sites;   
13
 the number of deferrals due to reasons other than low Hb could not be determined; the deferral rate is therefore given as a percentage of all donation 
attempts, including those deferred due to other reasons;   
14
 Mathur 2012: only deferrals from the initial CuSO4 test are included here;   
15
 unclear whether deferrals due to 
other reasons were included in the total number of donation attempts or excluded from the study. The Hb deferral rate is calculated as a proportion of the total number of 
donation attempts reported. 
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2.6.3 Factors associated  with deferral through failure to meet  Hb threshold 
2.6.3.1 Sex 
The overall percentage of donation attempts which were deferrals due to failure to 
meet Hb standards ranged from 0.4% to 16.4% (Table 2.1). The ratio of male to 
female participants varied greatly across studies with a range of 46.2% to 98.3% for 
male participants. The highest proportion of male participants was found in studies 
based in India (median 91.3%, range 74.4% to 98.3%) compared with an 
approximately equal male: female ratio in US studies (median 50.2%, range 46.7% to 
53.0%).  Deferral rates were reported separately for men and women in 25 studies. 
Hb deferral was higher in females than males in all 25 studies, ranging from 2.3% to 
47.2% in females compared with 0% to 10.0% in males. Although most (22) of these 
studies used a threshold of 125 g/L for females, with LHD rates varying from 5.6% to 
47.2%, it is of interest to note the lowest percentage LHD for females (2.3%) was 
associated with the lowest Hb threshold (Hillgrove, Moore, Doherty, & Ryan, 2011).  
Meta-analysis showed a significantly higher risk of deferral due to low Hb in females 
compared with males in studies where the LHD level is set the same ("universal") for 
both male and female (OR 14.91, 95% CI 12.82 to 17.34) as well as in studies with 
sex-specific Hb thresholds (OR 8.19, 95% CI 4.88 to 13.74) (Figure 2.2). However, 
considerable heterogeneity was observed across studies for all subgroups  
(I2= 100%). 
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Figure 2-2: Meta-analysis of risk of deferral due to failing low Hb thresholds in males 
and females stratified by universal and sex-specific Hb threshold. 
N.B. Goncalez 2012 listed here is the e-publication of Goncalez 2013 
 
 
2.6.3.2 Ethnicity 
Three studies (Mast et al., 2010; Oliveira et al., 2011; Shaz et al., 2010) reported the 
relationship between LHD and ethnicity. One study, J. C. Lim, Tien, and Ong (1993), 
did not provide sufficient figures to determine Hb deferral rates either for the 
population presenting for donation or for those able to donate after surmounting other 
causes of deferral. The remainder showed what percentage of deferrals were due to 
low Hb levels (Table 2.2). The two US-based studies (Mast et al., 2010; Shaz et al., 
2010) both reported a significantly increased risk of LHD in Black or African-American 
compared with white females (adjusted OR 2.11, 95% CI 2.06 to 2.16 (Mast et al., 
2010); OR 1.49, 95% CI 1.45 to 1.53 (Shaz et al., 2010)).  
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A significant increased risk of LHD was also reported for Hispanic compared with 
white females in both US studies (adjusted OR 1.29, 95% CI 1.25 to 1.34 ((Mast et 
al., 2010); OR 1.17, 95% CI 1.10 to 1.25 (Shaz et al., 2010)). The first of these 
studies also reported a significant increased risk of LHD associated with Black or 
Hispanic ethnicity in males compared with white males (Black: adjusted OR 2.42, 
95% CI 2.21 to 2.65; adjusted Hispanic: OR 2.11, 95% CI 2.06 to 2.16). However, the 
second US study (Shaz et al., 2010) reported a significantly reduced risk of LHD in 
males in these two populations (Black: OR 0.89, 95% CI 0.79 to 0.99; Hispanic: 0.53, 
95% CI 0.38 to 0.73) compared to their white counterparts. No significant differences 
in LHD risk were observed between Asian and white males or females (Mast et al., 
2010). The third study (Oliveira et al., 2011) reported a slight increase in the risk of 
LHD in non-white donors compared with white donors (OR 1.06, 95% CI 1.01 to 
1.11); however, this study did not report LHD by ethnicity separately for males and 
females.  
 
Table 2.2: Deferral due to low Hb by ethnic origin. 
Study Donation 
group by 
Ethnicity 
Hb Deferral % 
(M/F)* 
Odds Ratio (95% CI) 
(M/F)*
#
 
Comments 
Di 
Lorenzo 
Oliveira 
2011 
White* 2.2 1 
Sex-specific odds ratios, or 
sufficient data to allow 
calculation of sex-specific odds 
ratios, were not reported. 
Non-
white 
2.3 1.06 (1.01 - 1.11) 
Mast  
2010 
White* 1.6 / 16.6 1 / 1 
Sex-specific odds ratios 
(male/female) are reported in 
original study as adjusted but by 
which other factors is unclear. 
Asian 1.3 / 20.5 
1.10 (0.94 - 1.28) / 
1.05 (1.00 -1.10) 
Black 2.4 / 29.2 
2.42 (2.21 - 2.65) / 
2.11 (2.06 -2.16) 
Hispanic 1.1 / 22.6 
1.06 (0.92-1.23) / 
1.29 (1.25 -1.34) 
Other 1.2 / 21.5 
1.15 (0.95 - 1.40) / 
1.27 (1.21 -1.33) 
Shaz  
2010 
African 
American 
1.1 / 19.0 
0.89 (0.79 - 0.99) / 
1.49 (1.45 -1.53) 
Unadjusted odds ratios are 
calculated from original data 
provided by authors. Unclear 
whether Asians included in 
“other” – need to confirm with 
authors who supplied data. 
White* 1.2 / 13.6 1 / 1 
Hispanic 0.6 / 15.6 
0.53 (0.38 - 0.73) / 
1.17 ( 1.10 -1.25) 
Other 2.5 / 34.5 
2.11 ( 1.87 - 2.39) / 
3.35 ( 3.23 -3.47) 
* Where results were given for males and females, both sets of data are shown separated by a "/". 
Where only one figure is shown the results are for a mixed sex population. 
# 
Odds ratios were calculated for the various ethnic groups as compared to the white population.  
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Given these reports of differences in LHD associated with ethnicity, particularly in 
females, the studies were stratified according to their geographical location (Figure 
2.3).  Of particular interest is the significantly increased risk of LHD for females as 
compared to males in four Indian studies (OR 34.04, 95% CI 28.92 to 40.07) when 
compared with four US studies (OR 10.55, 95% CI 8.80 to 12.64) (P value < 0.00001) 
despite identical Hb thresholds for these two groups of studies. A significant 
difference in the risk of LHD in females as compared to males was also observed 
between five European studies (OR 4.85, 95% CI 2.94 to 8.00) and three Southern 
American studies (OR 13.59, 95% CI 8.17 to 22.61) (P value = 0.005), all of which 
implement sex-specific thresholds of 135 g/L and 125 g/L for males and females, 
respectively.  
Table 2.3 shows the risk for female LHD increases according to the nationality of the 
study population, which may consist of different ethnic groups. Again, considerable 
heterogeneity was observed across studies for three of the subgroups (I2= 99 - 100%) 
but not for those studies from India (I2= 0%). 
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Figure 2-3: Meta-analysis of risk of deferral due to failing low Hb thresholds in males 
and females, stratified by study setting. 
N.B. Goncalez 2012 listed here is the e-publication of Goncalez 2013 
 
 
 
Table 2.3: Increasing risk of low Hb deferral in women (as compared to men) by 
nationality. 
 European American South American Indian 
OR 4.85 10.67 13.59 34.04 
95% CI 2.94 - 8.00 8.98 - 12.67 8.17 - 22.61 28.92 - 40.07 
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2.6.3.3 Age 
Sixteen studies reported LHD by age; eight of these (Arslan, 2007; Gandhi, Duffy, 
Benike, Jenkins, & Stubbs, 2012; Hillgrove et al., 2011; Hoekstra et al., 2007; Mast et 
al., 2010; Sebok, Notari, Chambers, Benjamin, & Eder, 2007; Shaz et al., 2010; 
Zanella et al., 1989) reported LHD rates for males and females separately, whilst the 
remaining eight studies either reported LHD rates by age for males and females 
combined (Agnihotri, 2010; Baart, de Kort, Atsma, Moons, & Vergouwe, 2012; Di 
Lorenzo Oliveira, Loureiro, de Bastos, Proietti, & Carneiro-Proietti, 2009; Girish, 
Chandrashekhar, Ramesh, & Kantikar, 2012; Goncalez et al., 2013; Tondon et al., 
2008), or did not report sufficient data to calculate LHD rates for both males and 
females (Custer et al., 2004; Sundar, Sangeetha, Seema, Marimuthu, & Shivanna, 
2010). When LHD by age was assessed across all 16 studies, no relationship 
between age and deferral was apparent (data not shown). However, in those eight 
studies which reported LHD separately for males and females, all studies showed an 
increase in LHD with increasing age in males (Figure 2-4A). In particular, these 
studies suggested a low and stable deferral rate for males under 40 years old of 
typically less than 3%, whereas the deferral rate for men over 45 - 50 increased with 
age in the majority of studies. The change in Hb deferral with age in females was less 
clear; some studies reported the highest rates of LHD for the youngest age group 
(Gandhi et al., 2012; Hillgrove et al., 2011; Hoekstra et al., 2007; Mast et al., 2010), 
e.g. 3.1% for females less than 18 compared to 1.9% for those greater than 65 
(Hillgrove et al., 2011) while others reported the maximum LHD rate for older age 
groups (Sebok et al., 2007; Zanella et al., 1989) e.g. 7.6% for females aged 18 - 30 
compared to 18.6% for those greater than 50 (Zanella et al., 1989) (Figure 2.4B). 
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Figure 2-4: Low Hb deferral by age. 
The percentage of deferrals is shown for the midpoint of each age group as described in individual studies for (A) men and (B) women. Data from each 
included study is plotted as indicated. 
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2.6.3.4 Seasonal temperature 
Four studies reported LHD deferral rates by season/temperature (Baart et al., 2012; 
Hoekstra et al., 2007; Lau, Hansen, & Sererat, 1988; Sebok et al., 2007), although 
one study did not provide sample sizes by season to enable calculation of ORs 
(Sebok et al., 2007). All four studies showed a higher LHD rate during summer 
months or at high mean maximum monthly temperatures compared with winter 
months or low mean maximum monthly temperatures. In one study, the risk of LHD 
(adjusted for body weight) increased consistently with each 5°C rise in temperature 
(from less than 5°C to greater than 25°C) with the highest temperature range 
conferring a 96% increased risk of deferral in males (OR 1.96, 95% CI 1.76 to 2.18) 
and an 80% increased odds of LHD  in females (OR 1.80, 95% CI 1.68 to 1.94) 
(Hoekstra et al., 2007).  The OR for LHD also rose consistently with mean maximum 
monthly temperature in one study (Lau et al., 1988) with a 1.7-fold increased odds 
ratio associated with the highest temperature range (18 to 24°C) compared with the 
lowest (less than -4°C) (OR 1.68, 95% CI 1.53 to 1.86). In the second study (Baart et 
al., 2012) which calculated the OR for each season, a significant increased OR was 
associated with donation during Spring (OR 1.44, 95% CI 1.31 to 1.57 in males; OR 
1.20, 95% CI 1.13 to 1.29 in females) and Summer months (OR 1.44, 95% CI 1.31 to 
1.57 in males; OR 1.20, 95% CI 1.13 to 1.29 in females) compared with Winter 
months.  In this study, the OR for LHD was reduced during the Autumn season, 
although this only reached statistical significance in females (OR 0.89, 95% CI 0.83 to 
0.96). 
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Table 2.4: Low Hb deferral by seasonal temperature. 
Study Donation Group by 
Seasonal 
Temperature 
Hb Deferral (%) 
(M/F)* 
Odds Ratio (95% CI) 
(M/F)* 
Comments 
Baart 
2012 
Winter (Dec - Feb) 3.4 / 7.1 1 
Hb deferral rate and 
odds ratios given 
separately for males 
and females. Odds 
ratios are unadjusted. 
Spring (Mar – May) 4.8 / 8.4 
1.44 (1.31 - 1.57) / 
1.20 (1.13 -1.29) 
Summer (Jun -  Aug) 4.7 / 8.5 
1.41 (1.29 - 1.54) / 
1.21 (1.14 -1.30) 
Autumn (Sep – Nov) 3.1 / 6.4 
0.92 (0.83 - 1.01) / 
0.89 (0.83 -0.96) 
Hoekstra 
2007 
Mean of max. monthly temperature at donation: Hb deferral rate and 
odds ratios given 
separately for males 
and females.  Odds 
ratios are adjusted for 
weight. 
<5°C 1.8 / 6.5 1 
5-10°C 2.0 / 7.1 
1.13 (1.02 - 1.24) / 
1.09 (1.02 -1.16) 
10-15°C 2.2 / 7.3 
1.19 (1.08 - 1.31) / 
1.12 (1.05 -1.20) 
15-20°C 2.5 / 7.9 
1.42 (1.29 - 1.56) / 
1.21 (1.14 -1.29) 
20-25°C 3.2 / 9.1 
1.78 (1.62 - 1.96) / 
1.40 (1.32 -1.50) 
>25°C 3.6 / 11.1 
1.96 (1.76 - 2.18) / 
1.80 (1.68 -1.94) 
Lau 
1988 
Mean of max. monthly temperature at donation: Hb deferral rate and 
odds ratios given 
separately for males 
and females.  Odds 
ratios and confidence 
intervals are 
calculated from 
reported numbers of 
non-deferrals and Hb 
deferrals in each 
group, excluding 
deferrals for other 
reasons. 
15.1-25°F([-9] – [-4]°C) 3.7 1 
25.1-35°F([-4] – 2°C) 3.5 0.93 (0.83 - 1.04) 
35.1-45°F(2 – 7°C) 3.7 1.00 (0.89 - 1.12) 
45.1-55°F(7 – 13°C) 4.8 1.32 (1.18 - 1.46) 
55.1-65°F(13 – 18°C) 4.8 1.30 (1.16 - 1.45) 
65.1-75°F(18 – 24°C) 6.1 1.68 (1.53 - 1.86) 
Seebok 
2007 
Winter (Dec - Feb) 0.8 / 12.9 n/r 
No sample sizes are 
provided to enable 
calculation of odds 
ratios. 
Spring (Mar – May) 1.0 / 13.8  
Summer (Jun -  Aug) 1.3 / 14.9  
Autumn (Sep – Nov) 1.0 / 13.4  
 
* Where results were given for males and females, both sets of data are shown separated by a "/". 
Where only one figure is shown the results are for a mixed sex population. 
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2.6.3.5 Body weight 
LHD by weight was reported in two studies (Figure 2-5) (Hoekstra et al., 2007; Mast 
et al., 2010). In both studies, the OR for LHD decreased consistently with increasing 
body weight in both males and females. In the Dutch study, the age-adjusted risk of 
LHD in a male donor weighing more than 100 kg was just 22% of the risk in males 
weighing less than 60 kg (OR 0.22, 95% CI 0.178 to 0.27) (Hoekstra et al., 2007).  In 
the US study, the OR in males in the highest body weight group of greater than 200 lb 
(approximately 91 kg) was 50% lower than those in the lowest body weight category 
(less than 109 lb (approximately 50 kg) (OR 0.50, 95% CI 0.32 to 0.79) (Mast et al., 
2010). In females, the OR for donors in the highest body weight group was reduced 
by 43% (OR 0.57, 95% CI 0.50 to 0.66) compared with the lowest weight group in the 
Dutch study (Hoekstra et al., 2007). A consistent reduction in LHD OR associated 
with increasing body weight was also observed in the US study (Mast et al., 2010). 
Compared with the lowest body weight group, the reduced risk of LHD was 
statistically significant in females of between 150 lb and 200 lb (approximately 68 – 90 
kg), although the reduced risk in the highest weight category (>200 lb) did not reach 
statistical significance (OR 0.85, 95% CI 0.71 to 1.01) (Mast et al., 2010).  
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Figure 2-5: Low Hb deferral by body weight 
Odds ratios are shown for each weight group relative to the reference group of lowest body weight, separately for males and females. Error bars 
indicate 95% confidence intervals.  Figures shown within the bars indicate the LHD rate for each weight group. 
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2.6.3.6 Donation characteristics 
Donation intensity 
Four studies reported LHD by donation intensity in RBC donors (Table 2.5), which 
was defined as the inter-donation interval (Ziemann et al., 2006), number of donations 
in the past 12 months (Mast et al., 2010; Zanella et al., 1989), or number of donations 
in the past two years as a continuous variable (Baart et al., 2012).  One study 
described LHD stratified by the number of platelet donations in the past 12 months 
(Mast et al., 2010).  
Baart et al. (2012) showed significantly increased risk of LHD was seen to be 
associated with the number of donations during the previous two years in males, but 
a significantly decreased comparative risk in females. A second study (Mast et al., 
2010) also reported for females a reduced risk of LHD associated with five or more 
donations in the previous 12 months (for example, a 50% reduction in LHD risk for ≥6 
donations). Conversely, this study found a significantly reduced risk of LHD in males 
only donating one or two times in the previous year. This study also showed a 
protective effect against LHD from a higher platelet donation intensity (four or more in 
the previous 12 months) and an increased LHD with a lower frequency (one to three 
donations per year). However, the results were not separated by gender.  
In a third study (Zanella et al., 1989) the deferral rate of male and female donors was 
reported graphically, stratified into three groups giving low, medium and high annual 
rates of donation. By the time of the eighth donation, the trend was for LHD rates in 
males of all three groups to fall to similar levels irrespective of donation intensity, and 
continue to fall with each subsequent donation. Similarly for women in the medium 
and high frequency donation groups, by donation eight it appeared they were less 
likely to fail Hb thresholds, whereas females giving less frequently showed an 
increasing likelihood of LHD with each successive donation.  
In the final study (Ziemann et al., 2006) reported a significantly reduced risk of LHD in 
donors who had donated within the past year (for those having donated less than six 
months, and those having donated in the past 6 -11 months, prior to the present visit  
having OR 0.70, 95% CI 0.56 to 0.87, and OR 0.68, 95% CI 0.54 to 0.86, 
respectively) when compared to donors who had not donated within the previous two 
years, This study did not report results separately for males and females. 
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Table 2.5: Low Hb deferral by donation characteristics: Donation intensity 
Study 
 
Donation 
Group 
Hb Deferral 
Rate (%)* 
OR (95% CI)
*3
 
 
Baart  
2012 
Number of whole blood donations in past two years 
Continuous n/r 1.14 (1.12 – 1.15) / 0.92 (0.90 - 0.93) 
Custer  
2012  
[Mast 2010] 
Number of whole blood donations during previous 12 months 
0 1.3 / 18.2 1 
1 1.1 / 17.5 0.72 (0.67 - 0.77) / 0.99 (0.98 - 1.01) 
2 1.5 / 18.1 0.84 (0.79 - 0.90) / 1.07 (1.05 - 1.09) 
3 2.1 / 18.1 1.04 (0.97 - 1.11) / 1.09 (1.06 - 1.12) 
4 2.3 / 16.4 1.08 (1.01 - 1.15) / 0.97 (0.94 - 1.00) 
5 2.6 / 13.4 1.07 (0.99 - 1.16) / 0.76 (0.73 - 0.80) 
≥6 2.8 / 8.8 1.00 (0.89 - 1.13) / 0.45 (0.40 - 0.51) 
Mast  
2010 
Number of platelet donations during previous 12 months 
0 (RBC donors) 10.0 1 
1- 3 12.0 1.18 (1.12 – 1.23) 
4+ 5.6 0.68 (0.65 - 0.71) 
Zanella  
1989# 
Annual rate of donation: 
M: <2/year 
F: <1.5/year 
M: trend is to fall over the 16 donations.  
F: trend is to rise over the 18 donations. 
M: 2-3/year 
F: 1.5-2.5/year 
M: trend is to fall over 23 donations (slight rise 18-21).  
F: stable over 11 donations then varies. 
M: >3/year 
F: >2.5/year 
M: falls over the 22 donations.  
F: falls to 12 donations then rises. 
Ziemann  
2006 
Interdonation interval: 
<6 mths  6.3 0.70 (0.56 - 0.87) 
6 to 11 mths 6.2 0.68 (0.54 - 0.86) 
12 to 23 mths 7.7 0.87 (0.67 - 1.13) 
≥24 mths 8.8 1 
* values reported separately for males and females where available. 
# Incidence of Hb deferrals is reported graphically as a function of number of donations in repeat 
donors according to sex and annual rate of donations. 
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New versus repeat donors 
LHD rates for new versus repeat donors were reported in five studies (Custer et al., 
2004; Custer et al., 2012; Goncalez et al., 2013; Kouao et al., 2012; Wilkinson, 1982) 
(Table 2.6). In four studies a significantly lower risk of LHD was found in repeat 
donors as compared to those who had not donated previously (Custer et al., 2004; 
Custer et al., 2012; Goncalez et al., 2013; Wilkinson, 1982); this effect was apparent 
in both male and female donors (Custer et al., 2004; Wilkinson, 1982). Only one study 
(Kouao et al., 2012) showed a significantly increased risk in repeat donors.   
 
Table 2.6: Low Hb deferral by donation characteristics: New/repeat donors. 
Study 
 
Donation 
Group 
Hb Deferral Rate (%) 
(M/F)* 
OR (95% CI)* 
 
Goncalez  
2013 
New 7.9 1 
Repeat 3.9 0.47 (0.47 - 0.48) 
Kouao  
2012 
New 2.6 1 
Repeat 4.0 1.61 (1.23 - 2.11) 
Custer  
2012 
New 8.8 1 
Repeat 8.1 0.87 (0.86 - 0.88) 
Custer  
2004^ 
New 0.7 / 12.6 1 / 1 
Repeat 0.5 / 10.3 0.69 (0.47 - 1.03) / 0.80 (0.76 - 0.85) 
Wilkinson  
1982 
New 1.2 / 17.6 1 / 1 
Repeat 1.0 / 13.2 0.78 (0.75 - 0.81) / 0.71 (0.70 - 0.72) 
* Where results were given for males and females, both sets of data are shown separated by a "/". 
Where only one figure is shown the results are for a mixed sex population. 
^ Males restricted to those aged ≥ 40. 
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Reason for deferral at previous visit 
Two studies (Baart et al., 2012; Hillgrove et al., 2011) reported LHD according to the 
reason for deferral at the previous visit (Baart et al., 2012) or during the previous 12 
months (Hillgrove et al., 2011); both studies showed a significantly increased risk of 
LHD in donors who had been previously deferred for LHD. This increased risk was 
six-fold in the Australian study (OR 6.22, 95% CI 3.72 to 10.4) (Hillgrove et al., 2011), 
with a similar risk in males (OR 6.16, 95% CI 5.64 to 6.73) and a slightly lower risk in 
females (OR 4.82, 95% CI 4.54 to 5.12) in the Dutch study (Baart et al., 2012). 
 
Table 2.7: Low Hb deferral by donation characteristics: Previous deferral reason. 
Study Donation 
group 
Hb 
Deferral 
(%) 
(M/F)* 
Odds Ratio (95% 
CI) (M/F)* 
Comments 
Baart  
2012 
Due to 
low Hb 
18.9 / 25.3 
6.16 (5.64 - 6.73) /  
4.82 (4.54 - 5.12) 
Sex-specific odds ratios 
(male/female) are reported 
in original study as adjusted 
but by which other factors is 
unclear. 
Due to 
other 
reasons 
1.4 / 3.0 1 
Hillgrove 
2011 
Due to 
low Hb 
8.2 6.23 (3.72 - 10.4) 
Sex-specific odds ratios, or 
sufficient data to allow 
calculation of sex-specific 
odds ratios, were not 
reported. 
Due to 
other 
reasons 
2.0 1 
* Where results were given for males and females, both sets of data are shown separated by a "/". 
Where only one figure is shown the results are for a mixed sex population. 
 
Donation at a static versus mobile donation session 
A small but significant increased risk of LHD associated with donation at static blood 
centres compared to mobile donation units was reported in two studies (OR 1.11, 
95% CI 1.06 to 1.17 (Lau et al., 1988); OR 1.18 (1.17 to 1.18) (Custer et al., 2012)).  
 
Table 2.8: Low Hb deferral by donation characteristics: Donation site. 
Study Donation 
group 
Hb Deferral (%) Odds Ratio (95% CI) 
Lau 1988 
Blood Centre 5.1 1.11 (1.06 - 1.17) 
Blood Mobile 4.6 1 
Custer 2012 
Fixed 9.5 1.18 (1.17 - 1.18) 
Mobile 8.2 1 
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Directed versus voluntary donors 
Two studies (Agnihotri, 2010; Charles, Hughes, Gadd, Bodkyn, & Rodriguez, 2010) 
compared LHD in directed (i.e. family and friends) donors with normal volunteer 
donors. Both showed decreased LHD in the directed groups (3.4% v 9.0%; 7.8% v 
9.1%), but the difference reached significance only in the Indian study (OR 0.34, CI 
0.30 – 0.52). 
 
 
Table 2.9: Low Hb deferral by donation characteristics: Donor type 
Study Donation group  Hb Deferral (%) Odds Ratio (95% CI) 
Agnihotri  
2010 
Related 3.4 0.34 (0.30 – 0.52) 
Voluntary 9.0 1 
Charles  
2010 
Directed 7.8 0.85 (0.66 - 1.11) 
Voluntary 9.1 1 
 
 
 
Education 
One study showed a slight decreased risk (OR = 0.84; 95% CI = 0.84 – 0.85) in LHD 
in those who were older than 21 and had completed education to at least first degree 
level as compared to those who had not progressed further than a high school 
education (Data not shown - Custer et al. (2012)). 
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2.7 Discussion 
The dominant factor in the differences in rates of LHD is clearly gender. A wide range 
of other factors, including age, ethnicity, weight, seasonal temperature and donation 
characteristics, appear to be associated with differences in rates of LHD but these 
differences are likely to be confounded by the ratio of females included in the studies 
and so should be stratified by that characteristic. However, the high levels of 
variability (shown by the majority of I2 statistics which would be classified as 
"considerable" by the Cochrane Collaboration (Deeks et al., 2011)), the lack of 
consistency in data classification and reporting across studies prohibits formal 
comparison of results and accurate risk estimates.  
All studies showed increased LHD in women compared to men, but high levels of 
heterogeneity were observed. Meta-analysis of gender effect has shown that women 
are 11 times (ORs ranging from 1.96 – 59.6) more likely than men to be deferred due 
to having an Hb level deemed too low for donation; this effect is present irrespective 
of whether universal or sex-specific Hb thresholds are used. Both physiological and 
social causes have been suggested for this phenomenon.  Pre-menopausal women 
are known to have reduced iron stores resulting from the effects of menstruation and 
pregnancy (C. A. Finch et al., 1977) whereas men have increased testosterone levels 
which are linked to higher Hb levels (Bhasin et al., 2001). Additionally, smoking is 
associated with an increase in Hct (Mast et al., 2008) and in general men display a 
higher incidence of cigarette smoking (Action on Smoking and Health (ASH), 2007). 
Indeed, it has been  suggested that Hb thresholds may not be set at appropriate 
levels for women (Beutler & Waalen, 2006). In the US, where blood donation eligibility 
guidelines set by the US Food and Drug Administration state a universal minimum Hb 
threshold of 125 g/L, sex-specific thresholds are being considered by the United 
States Food and Drug Administration (2008).   
Studies showing gender effects can be seen to have high heterogeneity (Figures 2-2 
and 2-3), even when sub-group analyses are performed. A likely cause for such high 
values of statistical heterogeneity, I2 (99-100%), could be the result of high variance in 
the ethnic mix within the study populations (clinical heterogeneity). This may explain 
why subgroup analysis of  the studies from India, where the population is likely to be 
ethnically homogenous, has a low I2 value (0%). Interestingly, although the overall I2 
statistic was high, all studies agree on the direction of the effect.  Had a more formal 
evidence-based mapping of design (clinical) heterogeneity been performed then 
perhaps the I2 statistic could be reduced (Althuis et al., 2014). 
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Ethnicity has also been shown as a contributory factor in determining whether a 
prospective donor meets the specified Hb threshold for donation (Mast et al., 2010; 
Oliveira et al., 2011; Shaz et al., 2010). In particular, Black or African-American 
women have a higher rate of LHD, although the picture in men is less clear (Mast et 
al., 2010; Shaz et al., 2010). The study by Mast et al. (2010) states that leiomyoma 
and heavier menstrual bleeding are known to be more common in African American 
women. Additionally, as stated in Chapter 1, there are different inherited genotypes 
that are associated with lower Hb levels. High frequencies, of 80% or more in some 
populations, may be carriers for the condition -thalassaemia, which may result in a 
mild microcytic anaemia (Harteveld & Higgs, 2010). The study of  J. C. Lim et al. 
(1993) from Singapore has shown a greater proportion of Indian donors deferred due 
to lower Hb than either Chinese, Malay or ”other” ethnic groups, although this finding 
was not reflected in a US study (Mast et al., 2010). Shaz et al. (2010) described an 
“other” ethnic group which did have a higher rate of LHD which may have included 
the Asian donors. Nutritional differences may account for some ethnic variation. For 
example, a recent survey (Yadav & Kumar, 2006) suggests that 31% of the Indian 
population may be vegetarian with certain religious groups having an even higher 
percentage. Vastly different proportions of vegetarians have been reported in different 
countries (European Vegetarian Society).  One study, after controlling for individual 
factors and socioeconomic characteristics, showed a daily diet of meat, fish, and eggs 
was associated with lower odds of being moderately or severely anaemic  
(Rammohan, Awofeso, & Robitaille, 2012). A recent study (Rigas et al., 2014) has 
shown a diet rich in meat is protective of iron-deficiency for men and pre-menopausal 
women. Beutler and Waalen (2006) have proposed different low Hb thresholds for 
males and females according to their ethnic origin.  
Overall, the deferral patterns for different populations within the 55 studies under 
review, albeit at different time points with varying Hb cut-offs and other inclusion 
criteria, show wide variation in LHD rates – ranging from 0.7% in an Indian study 
(Unnikrishnan et al., 2011) to 16.4% in a Danish population (Bischke & Michelsen, 
2011) (Table 2.1). The absolute rate of deferral must reflect at least in part the Hb 
threshold and the proportion of female donors and so these rates are not in 
themselves comparable. However, the risk of LHD in women compared with men 
varies according to the country of study with identical thresholds used in studies 
within each setting, a further indication of ethnic differences in the ability to meet 
specified Hb thresholds. 
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All studies reporting LHD with increasing age show an increase in LHD with 
increasing age in males. This is likely to be associated with a slow decline in 
testosterone levels and the average Hb in males falls with age (Bhasin et al., 2001; 
Guralnik, Eisenstaedt, Ferrucci, Klein, & Woodman, 2004; Guralnik, Ershler, Schrier, 
& Picozzi, 2005; Nilsson-Ehle, Jagenburg, Landahl, Svanborg, & Westin, 1988). The 
effect of age on deferral and Hb is less clear in females, probably due to the 
combined effect of menstruation and pregnancy in younger women and the effect of 
menopause in older women. In older donors, falling Hb is associated caused by a 
number of factors, including nutritional changes and underlying medical conditions, 
such as arthritis, kidney disease and “anaemia of aging” (Mast et al., 2008). An 
increased incidence of these conditions with age may account for increased LHD with 
age but the contribution of individual factors is impossible to quantify without more 
detailed information on the medical condition of donors.  
Increasing rates of LHD are associated with rising temperatures (Baart et al., 2012; 
Hoekstra et al., 2007; Lau et al., 1988; Sebok et al., 2007). In the Hoekstra study, 
which reported temperature effects separately for males and females, there was an 
increase in LHD over the temperatures studied of 1.8% to 3.6% for men and 6.5% to 
11.1% for women. Although the effect seems more profound in females the increase 
in ORs is more marked in males, suggesting that increased temperature has more of 
an effect on males. It was proposed the effect might be due to transient haemodilution 
as an element of the heat balance mechanism (Watanabe, 1958), although 
alternative indirect factors of influence on Hb level such as nutrition, physical activity 
and virus infections have been proposed (Hoekstra et al., 2007). However, seasonal 
effects on the techniques used for measurement of Hb levels might also be an 
explanation, especially in the case of gravimetric CuSO4 determination (Lau et al., 
1988). 
A reduction in the risk of LHD is also associated with increasing body weight 
(Hoekstra et al., 2007; Mast et al., 2010). Heavier individuals might be expected to 
have a greater blood volume and so would donate proportionally less than a smaller 
person and so better withstand the loss of iron (Mast et al., 2010). Less clear results 
for females in one study (Mast et al., 2010) may result in a similar effect being 
masked by differences in menstrual bleeding independent of the donor’s weight. 
Obesity may cause a female to have no (amenorrhea); infrequent (oligomenorrhea) or 
heavy or long periods (menorrhagia) or no ovulation (anovulation). Likewise, 
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underweight female donors may stop menstruation (in the UK the general lower limit 
for donation is 50 kgs - 7st 12lb). A low BMI may result from excess physical training, 
lack of calorie intake or genetics (Wonderly, 2014).  
Donation characteristics associated with LHD include donation intensity (Baart et al., 
2012; Mast et al., 2010; Zanella et al., 1989; Ziemann et al., 2006), previous donation 
(Custer et al., 2004; Custer et al., 2012; Goncalez et al., 2013; Kouao et al., 2012; 
Wilkinson, 1982) and previous deferral due to Hb (Baart et al., 2012; Hillgrove et al., 
2011).  Results suggest a reduced risk of LHD associated with a high frequency of 
donations in females, but the corresponding risk in males is less clear. One study  
showed that in women who were experienced donors (i.e. who had donated on more 
than six occasions) donating at a higher intensity were less likely to defer due to low 
Hb (Zanella et al., 1989). This is likely to be in part due to women with a 
predisposition to a lower Hb having been selected out at earlier visits but does not 
explain why the same effect was not seen in males. Some high intensity donors may 
be preferentially selected due to self-medication with iron supplements (Mast et al., 
2008). As males have larger iron stores than female, typically two to four times 
greater (C. A. Finch et al., 1977) which are better suited to produce new blood cells 
after repeated donation, it would be expected that males are better suited to high 
intensity donation than women. Donating at a frequency of four or more times per 
year may be close to the limit of dietary iron absorption for replacement, but high 
donation frequency may be advantageous for blood collection from female donors.  
A higher risk of LHD has also been observed in new donors (Custer et al., 2004; 
Custer et al., 2012; Goncalez et al., 2013; Wilkinson, 1982) where those with low or 
borderline Hb and/or iron stores will be first revealed. Donors who have previously 
been deferred for LHD also have a higher rate of LHD (Baart et al., 2012; Hillgrove et 
al., 2011), which must reflect a slow restoration of iron.  
Two studies showed that individuals that donate in response to the needs of a friend 
or family member (“directed” donations) show a reduced likelihood of being unable to 
give blood due to failing the lower Hb threshold (although this difference only reached 
significance in one study (Agnihotri, 2010). Agnihotri postulated that these “directed” 
donors have a tendency to self-deferral rather than compromise the integrity of the 
donation to a patient known to them.  
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Both studies that looked at LHD at fixed static sites as compared to mobile donating 
sessions found a lower rate of deferral at the latter.  Lau et al. (1988) suggested the 
recruitment characteristics for donors attending static blood centres would differ from 
those donating in mobile donation units (often these donors give more specialised 
products and so may experience less stringent donor health checks). Although Custer 
et al. (2012) offered no explanation for the phenomenon, Donovan (2011) suggested 
that the more "mobile" donors are, the less likely they are to fail the Hb test, as likely 
at mobile sites.  
One study in the US looking at the effect of education on LHD suggested that 
socioeconomic factors may have a slight effect on LHD (Custer et al., 2012). It may 
well be those who have successfully progressed through further education have 
better opportunity to gain well paid jobs and so are more likely to eat more healthily 
than those who have limited options available. 
This study has a number of limitations. Firstly, a number of important sources of 
heterogeneity exist across studies, including type of donation (RBCs, platelets or 
both), Hb donation thresholds (sex-specific versus universal as well as study-
specific), ethnic mix within the study population and the ratio of male to female donors 
in the study. Hb levels were determined using a variety of techniques applied to both 
capillary and venous blood; this has an effect on the degree of accuracy of Hb 
measurement leading to variability across studies. Secondly, some studies included a 
single donation attempt per donor whereas others included multiple donation attempts 
which would introduce a potential confounding effect in the comparison of study 
results. Thirdly, most studies reported only one reason for deferral for each 
prospective donor, i.e. the first that prohibited the donor from further consideration for 
donation. Therefore, dependent on the donor screening protocol, low Hb levels may 
be over- or under-represented. The likelihood is the latter, as most protocols would 
visit non-invasive deferral criteria before taking blood for Hb. Furthermore, reasons for 
deferral other than low Hb have not always been reported, or have been reported to a 
different extent across studies. Finally, many studies presented results for male and 
female donors combined and therefore, despite the clear differences in LHD between 
males and females, sex-specific risk estimates could not be obtained.  
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2.8 Author's conclusions 
2.8.1 Implications for practice 
Donating at a frequency of four or more times per year may be close to the limit of 
dietary iron absorption for replacement, but high donation frequency may be 
advantageous for blood collection from female donors. 
Deferrals have a cost implication for blood collection organisations and a negative 
effect on donor motivation. If organisations can reduce the level of deferral, especially 
LHD which is a major cause of deferral, they may maximise donor return and reduce 
costs. This systematic review has highlighted the effects of sex, ethnicity, age, 
ambient temperature, body weight and donation history on LHD.  By tailoring donation 
characteristics (frequency, season, etc.) to the individual donor may donor retention 
and blood supply may be improved. 
2.8.2 Implications for research 
A number of important sources of potential heterogeneity exist across the studies 
including the type of donation, country of study, Hb donation threshold.  These 
parameters and their effect on risk estimates and conclusions should be investigated. 
Beutler and Waalen (2006) proposed different lower thresholds for males and females 
according to their ethnic origin. Given the vastly higher incidence of LHD, separate 
analyses for males and females is clearly warranted in any future study. Identification 
of the causal relationship between these factors and LHD remains a challenge. 
Any study of LHD may do well to note sociological factors such as smoking habit, 
education and diet.  
Further larger prospective studies with statistical modelling are required in order to 
establish the combined effect of these multiple factors on deferral of blood donors due 
to failure to meet Hb standards. 
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Chapter 3 – Oral or parenteral iron supplementation to 
reduce deferral, iron deficiency and/or anaemia in blood 
donors 
 
This chapter discusses the systematic review (SR) of literature describing studies of the 
provision of iron supplements, either through oral or non-oral (e.g. intra-muscular or 
intra-venous) routes, to blood donors with the aim of improving their health and ability to 
meet the low Hb thresholds of blood collection agencies from around the world 
(hereinafter termed the "Iron Supplementation SR"). The intention was to submit the 
review to The Cochrane Collaboration (http://www.cochrane.org/) and so this Chapter is 
written in the style of a Cochrane Review. In doing so, it will provide continuity with 
Chapter 2. The purpose of the investigation was to provide evidence on which to base a 
proposed future RCT. 
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3.1 Abstract 
3.1.1 Background 
Donors may be unable to donate blood due to a failure to meet low Hb thresholds set by 
the collecting organisation, leading to a temporary deferral from blood donation. More 
importantly, collecting organisations have a duty of care to maintain the health of their 
donor base. A number of studies have investigated the provision of iron supplements as 
a means to increase the iron levels in donors, so improving health and reducing the 
incidence of falling below low Hb thresholds. However, there is no Cochrane systematic 
review of the relative efficacy and safety of those studies. 
3.1.2 Objectives 
To assess the efficacy and safety of iron supplementation to reduce iron deficiency 
and/or anaemia in blood donors of whole blood (WB), red blood cells (RBCs) or platelets 
when compared with placebo or other treatments.  
3.1.3 Search Methods 
The Cochrane Injuries Group Specialised Register, CENTRAL, PubMed, MEDLINE 
(OvidSP), EMBASE (OvidSP), CINAHL (EBSCO Host) and six other databases were 
searched for relevant trials up to 18 November 2013. Clinical trials registers and 
screened guidelines reference lists were also searched. 
3.1.4 Selection Criteria 
Randomised controlled trials (RCTs) comparing iron supplementation versus placebo or 
control, oral versus parenteral iron supplementation, iron supplementation versus iron-
rich food supplements, and different doses, treatment durations and preparations of iron 
supplementation in healthy blood donors. Autologous blood donors were excluded. 
3.1.5 Data Collection and Analysis 
Two authors independently extracted data using customised data extraction forms using 
Microsoft Excel. Data were combined using random effects meta analyses. 
Heterogeneity was evaluated using the I2 statistic and considerable heterogeneity (I2 > 
75%) was explored using subgroup analyses. The impact of trial quality on the findings 
was assessed using sensitivity analyses. 
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3.1.6 Main Results 
Thirty RCTs including a total of 4,704 participants met the eligibility criteria, including 19 
comparisons of iron supplementation and placebo or control, one comparison of oral and 
parenteral iron supplementation; four comparisons of different doses of iron 
supplementation; one comparison of different treatment durations of iron 
supplementation and 12 comparisons of different iron supplementation preparations. 
The methodological quality of the studies was low or uncertain for many studies resulting 
in an unclear or high risk of bias. For many outcomes the quality of evidence was 
assessed as moderate. There was a significantly reduced risk of deferral due to low Hb 
in donors who received iron supplementation compared with donors who received no 
iron supplementation, both at the first donation visit after commencement of iron 
supplementation (risk ratio [RR] 0.34; 95% confidence interval [CI] 0.21 to 0.55: four 
studies; 1194 participants; P value <0.0001) and at subsequent donations (RR 0.25; 
95% CI 0.15 to 0.41; three studies; 793 participants; P value <0.00001). Meta-analyses 
also showed that iron supplementation resulted in significantly higher levels of Hb (mean 
difference [MD] 2.36 g/L; 95% CI 0.06 to 4.66; eight studies: 847 participants: P value = 
0.04), and iron stores, including serum ferritin (MD 13.98 ng/mL; 95% CI 8.92 to 19.03; 
five studies; 640 participants; P value <0.00001) and transferrin saturation (MD 3.91%; 
95% CI 2.02 to 5.80; four studies; 344 participants; P value <0.0001) prior to further 
donation, and that these significant differences were maintained after subsequent 
donation(s). Results were robust to sensitivity analyses; no significant differences in the 
effects of iron supplementation between male and female donors were found. 
Adverse effects were widely reported and were more frequent in donors who received 
iron supplementation than those who did not (RR 1.60; 95% CI 1.23 to 2.07: 4 studies: 
1748 participants: P=0.0005), with a significantly increased risk of constipation, 
diarrhoea, nausea/vomiting and taste disturbances. Some participants stopped treatment 
due to side effects. 
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3.1.7 Author's Conclusions 
Iron deficiency is a significant cause of deferral for people wishing to donate blood . 
Blood donation intervals are set to minimise iron deficiency in repeat blood donors. and 
all donors are screened at each repeat visit for low Hb levels. However, donors who are 
deferred through failure to pass the Hb threshold have a high risk of not returning to 
donate in the future. Minimising iron deficiency in repeat blood donors is therefore 
essential not only to reduce morbidity from iron deficiency or anaemia, but also to reduce 
the inconvenience and costs associated with deferral. Iron supplementation for blood 
donors has been considered and in some jurisdictions has been implemented for some 
groups of donors. Rigorous evidence for the cost and benefits of iron supplementation is 
essential to guide policy. 
There is moderate evidence to suggest that rates of donor deferral due to low Hb are 
considerably less in those taking iron supplements compared with those without iron 
supplementation, both at the first donation visit and at subsequent donation. Iron 
supplemented donors also show elevated Hb and iron stores. These beneficial effects 
are balanced by more frequent adverse events in donors who received iron 
supplementation than in those who did not which is likely to limit acceptability and 
compliance. 
The long term effects of iron supplementation without measurement of iron stores are 
unknown. These considerations are likely to preclude widespread use of iron 
supplementation by tablets. Blood services may consider targeted use of 
supplementation at groups or individuals at greater risk of iron deficiency, personalised 
donation intervals and provision of effective dietary advice. 
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3.2 Plain Language Summary 
The effects of iron supplementation on iron deficiency and deferral in blood 
donors 
Iron deficiency (ID), even without anaemia, can cause symptoms of tiredness, impaired 
wound healing, lack of attention and RLS so the interval between blood donations is set 
by independent regulators to minimise ID in donors. Potential blood donors are screened 
each time they visit to give blood to see if they are anaemic. Donors who do not pass 
this screening test and so cannot give blood are deferred from giving blood, but many of 
these donors do not return. If blood donors take iron tablets then the risk of becoming ID 
may be reduced. However, the balance between the benefits of giving iron and the 
possible side effects are not clear. All the randomised trials testing the benefits of giving 
blood donors iron have been reviewed. The evidence is current up to 18 November 
2013. 
There were 30 randomised trials of iron supplementation (IS) in blood donors with a total 
of 4704 participants. Some of the studies did not report details of their design very well 
and people in some of the studies left the study early and did not contribute data. By 
combining the results from four studies, it was shown that around 3% of donors who 
were given IS were unable to give blood when they next came to donate because the 
levels of iron in their blood were too low, compared with 10% of donors who did not take 
iron. More than this, 4% of IS donors were unable to give blood at any future donation 
due to low iron levels, compared with around 20% of donors not given IS. 
However, 29% of donors who took iron tablets experienced side effects compared with 
17% of donors who were given dummy tablets. Combined data from two studies showed 
that the iron-supplemented donors had nearly ﬁve times more stomach upsets and 
changes in their taste compared to donors who did not take these tablets. 
Due to the issues around how reliable the studies were, the quality of evidence is 
moderate and these results could change with more research. 
Donors can beneﬁt from iron tablets but the rate of side effects is high, which means in 
practice giving all donors iron tablets is unlikely to be acceptable; it is not known whether 
giving iron causes extra problems over a long period of time. Blood services may target 
IS at groups or individuals who are at risk of ID, may try to reduce deferral by adjusting 
donation intervals to suit the donor’s ability to give blood without becoming ID or may 
give donors speciﬁc dietary advice.  
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Table 3.1: Summary of findings for the main comparison. 
Iron supplementation for iron deficiency and/or anaemia in blood donors 
Patient or population: patients with iron deficiency and/or anaemia in blood donors 
Intervention: iron supplementation 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of the 
evidence (GRADE) 
Comments 
Assumed risk Corresponding risk 
Control Iron supplementation 
Low Hb deferral - at 
first donation visit 
after commencement 
of treatment 
Study population
1
 RR 0.34  
(0.21 to 
0.55) 
1194 
(4 studies) 
⊕⊕⊕⊝ 
moderate
2
 
 
105 per 1000 36 per 1000 
(22 to 58) 
Low
1
 
28 per 1000 10 per 1000 
(6 to 15) 
High
1
 
237 per 1000 81 per 1000 
(50 to 130) 
Low Hb deferral - 
after multiple 
donation visits 
Study population
1
 RR 0.25  
(0.15 to 
0.41) 
793 
(3 studies) 
⊕⊕⊕⊝ 
moderate
2
 
 
199 per 1000 50 per 1000 
(30 to 81) 
Low
1
 
50 per 1000 12 per 1000 
(8 to 20) 
High
1
 
456 per 1000 114 per 1000 
(68 to 187) 
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Table 3.1: Summary of findings for the main comparison (continued). 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of the 
evidence (GRADE) 
Comments 
Assumed risk Corresponding risk 
Control Iron supplementation 
Hb (g/L) - before 
further donation 
Scale from: 123 to 152. 
The mean Hb (g/L) - 
before further donation 
in the control groups 
was 
135.2 g/L 
The mean Hb (g/L) - before 
further donation in the intervention 
groups was 
2.36 higher 
(0.06 to 4.66 higher)
3
 
 847 
(8 studies) 
⊕⊕⊕⊝ 
moderate
4
 
 
Hb (g/L) - after 
subsequent 
donation(s) 
Scale from: 127.3 to 
129. 
The mean Hb (g/L) - 
after subsequent 
donation(s) in the 
control groups was 
127.8 g/L 
The mean Hb (g/L) - after 
subsequent donation(s) in the 
intervention groups was 
6.37 higher 
(2.36 to 10.39 higher)
3
 
 406 
(3 studies) 
⊕⊕⊕⊝ 
moderate
5
 
 
Serum ferritin 
(ng/mL) - before 
further donation 
Scale from: 12.9 to 
57.8. 
The mean serum 
ferritin (ng/mL) - 
before further donation 
in the control groups 
was 
21.1 ng/mL 
The mean serum ferritin (ng/mL) - 
before further donation in the 
intervention groups was 
13.98 higher 
(8.92 to 19.03 higher)
3
 
 640 
(5 studies) 
⊕⊕⊕⊝ 
moderate
6
 
 
Serum ferritin 
(ng/mL) - after 
subsequent 
donation(s) 
Scale from: 18 to 19. 
The mean serum 
ferritin (ng/mL) - after 
subsequent 
donation(s) in the 
control groups was 
18.6 ng/mL 
The mean serum ferritin (ng/mL) - 
after subsequent donation(s) in 
the intervention groups was 
9.01 higher 
(5.76 to 12.25 higher) 
 619 
(3 studies) 
⊕⊕⊕⊝ 
moderate
7
 
 
Adverse effects (any) 171 per 1000 274 per 1000 
(210 to 354) 
RR 1.6  
(1.23 to 
2.07) 
1748 
(4 studies) 
⊕⊕⊕⊝ 
moderate
8
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Table 3.1: Summary of findings for the main comparison (continued). 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; Hb: Haemoglobin; RR: Risk ratio; 
GRADE Working Group grades of evidence 
High quality:   Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality:  Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality:   Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the  
   estimate. 
Very low quality:  We are very uncertain about the estimate. 
Footnotes 
1
 Control risks will depend on study-specific low haemoglobin deferral thresholds. Low and high control risks correspond to the minimum and maximum 
control risks in the included studies. 
2
 Most of the information is from studies with an unclear risk of bias. All but one study had a high risk of attrition bias and two studies were partially 
commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect. 
3
 The range of scores is based on the lowest and highest estimate of the scores in the control groups in individual trials. 
4
 Most of the information is from studies with an unclear risk of bias. Four studies had a high risk of attrition bias, one study received assistance with data 
analysis from suppliers of the iron supplementation, and one study did not blind participants. Potential limitations are likely to lower confidence in the 
estimate of the effect. 
5
 Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias. Potential limitations are likely to lower 
confidence in the estimate of the effect. 
6
 Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias and one study was partially commercially 
funded. Potential limitations are likely to lower confidence in the estimate of the effect. 
7
 Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias and one study was partially commercially 
funded. Potential limitations are likely to lower confidence in the estimate of the effect. 
8
 Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias. Potential limitations are likely to lower 
confidence in the estimate of the effect.
Chapter 3 – Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or 
anaemia in blood donors 
   
85 
 
3.3 Background 
3.3.1  Description of the Condition 
Currently, IS for blood donors is not a standard of care in NHSBT although it was once 
employed by individual Blood Transfusion Centres prior to Nationalisation (personal 
observation). There are a limited number of completed or planned randomised 
controlled trials (RCTs) of IS in regular blood donors (Cable, Morse, Keltonic, Kakaiya, 
& Kiraly, 1988; Garry, Koehler, & Simon, 1995; Gordeuk, Brittenham, Bravo, Hughes, & 
Keating, 1990; Mackintosh & Jacobs, 1988; Maghsudlu et al., 2008; Magnussen, Bork, 
& Asmussen, 2008; Pedrazzini et al., 2009; Radtke, Mayer, Röcker, Salama, & 
Kiesewetter, 2004; Radtke, Tegtmeier, Röcker, Salama, & Kiesewetter, 2004).  Those 
studies that do exist have not been carried out on a UK population. Interestingly, there 
is some evidence from RCTs of improvement of exercise tolerance, mood disturbance 
and restless legs syndrome after treatment of iron-deficient but non-anaemic adults 
(Earley et al., 2009; Grote, Leissner, Hedner, & Ulfberg, 2009). However, there are at 
present no formal systematic reviews of the benefits of such IS interventions in terms of 
improved Hb, iron status, subjective symptoms of fatigue or mood disturbance or 
cognitive function in blood donors or, of crucial interest to the blood services, of their 
deferral for low Hb at the next attendance at donor clinics, nor of the side effects and 
costs of these supplementation strategies. 
In spite of medical, logistic and even ethical problems that may be faced in 
implementing a programme of IS for blood donors, a pragmatic review of the benefits 
and costs for the donor and the blood service is essential to inform policy. A 
systematic review has been undertaken to answer the specific questions of the 
efficacy and safety of IS in blood donors in preventing a fall in Hb, improving iron 
stores and reducing systemic, neurological or cognitive symptoms in donors. 
 
3.3.2  Description of the Intervention 
A detailed description of iron supplementation is given in Chapter 1 (1.1.5) 
 
3.3.3  How the Intervention Might Work 
Iron supplementation interventions aim to increase iron stores in blood donors by 
making available more iron for them to absorb.  
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3.3.4 Why it is Important To Do This Review 
This review is important since maintaining the supply and health of blood donors is 
imperative for health services. The role of IS in maintaining the health of donors and 
their ability to donate is poorly understood and the available evidence has not been 
synthesised. A systematic review of the current evidence of the efficacy and safety of 
IS in blood donors in crucial to inform future trials and policy of IS in donors. 
 
3.4 Objectives 
To define the efficacy and benefits of IS to reduce deferral, iron deficiency and/or 
anaemia in blood donors. 
 
3.5 Methods 
3.5.1 Criteria for considering studies for this review 
3.5.1.1 Types of studies 
The Cochrane Review process is primarily concerned with the systematic review of 
randomised controlled trials (RCT) – only in a few fields (such as Occupational 
Health) are non-randomised observational studies considered (Scholten, Clarke, & 
Hetherington, 2005).  
3.5.1.2 Types of participants 
Healthy, prospective, first-time or repeat blood donors of whole blood (standard one 
unit collections), double-dose red blood cell (RBC) donors by apheresis or platelets 
by apheresis (referred to as plateletpheresis) from any population. Autologous blood 
donors (donors who donate for their own subsequent use) were excluded.  
3.5.1.3 Types of interventions 
Therapy with any preparation, dose or regimen of oral or parenteral iron-containing 
compounds, with particular reference to:  
o Iron supplementation versus placebo or control. 
o Oral versus parenteral iron supplementation. 
o Iron supplementation versus iron rich food supplements (fortified foods with a 
quantifiable amount of iron).  
o Iron supplement: dose A, versus dose B. 
o Iron supplementation: treatment duration A, versus treatment duration B. 
o Iron supplement: preparation A, versus iron supplement, preparation B. 
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3.5.1.4 Types of outcome measures 
Primary outcomes 
The primary outcome in this review was the risk ratio of deferral of blood donors 
(number of prospective blood donors who are at least temporarily rejected from blood 
donation) due to low Hb. 
The low Hb deferral threshold differs across studies according to the population and 
sex of the donor studied (see Summary of Characteristics of included studies Table 
3.2). 
Secondary outcomes 
Secondary outcomes included any changes in any additional factors related to donors 
or donor health, including the following:  
o Mean levels of Haemoglobin (Hb), mean cell volume (MCV), other blood 
indices and iron stores before further donations. 
o Mean levels of Hb, MCV, other blood indices and iron stores after 
subsequent donations. 
o Health-related Quality of Life (QoL), especially changes in cognitive 
function, 'mood' disturbances, aerobic power, fatigue score, physical 
activity. 
o Adverse effects from interventions received. 
o Compliance. 
Analysis of blood indices were restricted to Hb, MCV, serum ferritin, serum or plasma 
iron, total iron binding capacity (TIBC) and transferrin saturation. Other reported blood 
indices were noted and are described in the Characteristics of included studies 
tables. 
3.5.2 Search methods for identification of studies 
The NHSBT Information Specialist (Carolyn Doree - CD) and the Cochrane Injuries 
Group developed a comprehensive search strategy covering the main bibliographic 
databases. In order to reduce publication and retrieval bias the search was not 
restricted by language, date or publication status. 
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3.5.2.1 Electronic searches 
The following databases were searched for RCT and systematic reviews (Appendix 
3.8): 
o Cochrane Injuries Group Specialised Register (December 2013) 
o CENTRAL (Cochrane Central Register of Controlled Trials, The Cochrane 
Library, 2013, Issue 10)  
o PubMed (epublications only) 
o MEDLINE (OvidSP) (1948 to 18 November 2013)  
o EMBASE (OvidSP) (1974 to 18 November 2013)  
o CINAHL (EBSCO Host) (1982 to 18 November 2013) 
o British Nursing Index and Archive (1985 to 18 November 2013)  
o SRI Transfusion Evidence Library (1980 to 18 November 2013)  
o LILACS (1982 to 18 November 2013)   
o IndMed (1985 to 18 November 2013)   
o KoreaMed (1997 to 18 November 2013)  
o PakMediNet (1995 to 18 November 2013)  
o Web of Science Conference Proceedings Citation Index-Science (CPCI-S) 
(1990 to 18 November 2013) 
The following clinical trials registers were searched:  
o ClinicalTrials.gov (www.clinicaltrials.gov) (18 November 2013)  
o ISRCTN Register (18 November 2013) 
o WHO International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/) (18 November 2013)  
o UMIN-CTR Japanese Clinical Trials Registry (http://www.umin.ac.jp/ctr/)  
(18 November 2013)  
o Hong Kong Clinical Trials Registry (http://www.hkclinicaltrials.com/)  
(18 November 2013), 
 Search strategies used to search the registers are listed in Appendix 3.8.13. 
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In MEDLINE, the search strategy was combined with the Cochrane highly sensitive 
filter for identifying RCT, as described in Chapter 6.4.11 of the Cochrane Handbook 
for Systematic Reviews of Interventions (Lefebvre, Manheimer, & Glanville, 2011). In 
EMBASE and CINAHL, the search strategies were combined with adaptations of the 
relevant SIGN RCT filters (http://www.sign.ac.uk/methodology/filters.html). No 
language restrictions were applied. 
Two of the ongoing trial databases listed in the protocol (the Chinese Clinical Trials 
Registry and the Sri Lanka Clinical Trials Registry) are now included within the WHO 
ICTRP database. 
3.5.2.2 Searching other resources 
Handsearching of reference lists 
References of all identified studies, relevant review articles and current treatment 
guidelines were checked for further literature with searches limited to the "first 
generation" reference lists. 
 
3.5.3 Data collection and analysis 
3.5.3.1 Selection of studies 
The NHSBT Information Specialist, CD, initially screened all search hits for relevance 
against the eligibility criteria and discarded all those that were clearly irrelevant. 
Thereafter, two authors (Graham Smith - GAS - and Sheila Fisher - SF) 
independently screened the abstracts of all the remaining references (titles, abstracts 
and full text) for relevance against the full eligibility criteria. Full text papers were 
retrieved for all those references for which a decision of eligibility could not be made 
from title and abstract alone. Where possible, further information was sought from the 
authors where articles contained insufficient data to make a decision about eligibility. 
Differences of opinion were resolved through discussion and consensus; any 
remaining unresolved were referred to a third reviewer (David Roberts - DR). Studies 
which did not meet the eligibility criteria are detailed in the 'Characteristics of 
excluded studies' table (Appendix 3.2). 
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3.5.3.2 Data extraction and management 
GAS, and a second reviewer (SF), independently extracted data onto a standardised 
Excel form developed in collaboration. These forms were piloted on two included RCT 
studies and changes made to the data extraction form where appropriate and agreed 
by both reviewers. Again, throughout the data extraction process any disagreements 
were resolved by consensus and we referred to a third reviewer (DR) to resolve any 
remaining differences. There was no blinding to names of authors, institutions, 
journals or the outcomes of the trials during this process.  
 
Categorisation of extracted information  
The information extracted was categorised thus: 
General information 
Review author's name, date of data extraction, study ID, first author of study, citation 
of paper, objectives of the trial. 
Trial details 
Trial design, location, setting, sample size, power calculation, methods of treatment 
allocation, randomisation and blinding, inclusion and exclusion criteria, reasons for 
exclusion, comparability of groups, length of follow up, stratification, stopping rules 
described, statistical analysis, results, conclusion, funding and possible conflicts of 
interest. 
Characteristics of participants 
Age, gender, ethnicity, total number recruited, total number randomised, total number 
analysed, losses to follow-up, drop outs (percentage in each arm) with reasons, 
protocol violations, donation history, whether donors were paid. 
Comparators/Interventions 
Experimental and control interventions, type of IS given, type of comparator given, 
timing of intervention, dosage of intervention and comparator given, compliance to 
interventions, additional comparators or interventions given, any differences between 
interventions. 
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Outcomes 
 Reduction in deferral rates of blood donors due to low Hb.  
 Number of blood donors with increased iron stores.  
 Total number of successful donations (per donor and per intervention).  
 Number of donors with increased Hb levels, mean cell volume (MCV) and 
other blood indices before donations.  
 Rate of increase in Hb levels, mean cell volume (MCV) and other blood 
indices between donations.  
 Health related QoL, especially changes in cognitive function, 'mood' 
disturbances, aerobic power, fatigue score, physical activity.  
 Side effects from interventions received.  
 Compliance. 
Adverse events from interventions received are often overlooked. Examination of 
such effects are warranted when the difference between benefits of treatment and its 
adverse events are small; where the treatments, although effective, have different 
degrees of safety and when those side effects deter a patient from continuing the 
treatment (Loke, Price, & Herxheimer, 2011). 
Dealing with graphical data 
Three studies (Devasthali et al., 1991; Gordeuk et al., 1990; Simon et al., 1984) 
presented relevant data graphically and the graphs were of sufficient quality to extract 
data. In order to obtain this information we obtained enlarged photocopies of the 
graphs from the papers. These were duplicated and an independent estimate made 
of the data presented by two reviewers (GAS, SF). The two estimates were assessed 
for comparability and, where they differed markedly, a consensus sought. When 
estimates agreed an average value across both estimates was used. 
Combining data 
Where possible, data were combined and meta-analysis performed as described in 
the Cochrane Handbook of Systematic Reviews of Interventions (Reeves et al., 
2011). Practically, this was only possible for one comparator, that of gender, as there 
was too much variation in the trials. Several studies reported outcomes separately for 
males and females. In these studies, data for males and females were combined to 
enable comparisons with other studies. 
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Obtaining standard deviations from standard errors and confidence intervals for group 
means 
Standard Deviations were obtained according to the Cochrane-recommended formula 
for meta-analyses (J. P. T.  Higgins & Deeks, 2011). 
3.5.3.3 Assessment of risk of bias in included studies 
Two review authors (GAS and SF) independently assessed all included studies for 
possible risk of bias and made explicit judgements about whether studies were at risk 
of bias according to the criteria given in the Cochrane Handbook of Systematic 
Reviews of Interventions (J. P. T. Higgins & Altman, 2011). The design, conduct and 
analysis of the trial was assessed using a three-point scale: yes (low risk of bias), no 
(high risk of bias), or unclear. To assess risk of bias, the authors included the 
following questions in the "Risk of bias" table for each included study: 
 Was the allocation sequence adequately generated? 
 Was allocation adequately concealed? 
 Was knowledge of the allocated intervention adequately prevented (i.e. 
blinded) throughout the study? 
 Was knowledge of the outcome assessment adequately prevented (i.e. 
blinded)? 
 Were incomplete outcome data adequately addressed for every outcome? 
 Were reports of the study free of selective outcome reporting? 
 Was the study apparently free of any other problems that could put it at risk of 
bias? 
The impact of the level of bias was explored by undertaking sensitivity analyses (see 
Sensitivity analysis). 
In many of the included studies, reporting of randomisation and blinding methods 
used was poor. Several studies reported only that the trial was "double-blind". We 
interpreted "double-blind" in the context of IS trials as an indication that the 
participants (but not necessarily the outcome assessors) were blinded, and have 
classified such studies as having a low risk of performance bias. Use of a placebo 
was not considered sufficient alone to indicate blinding of participants. 
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3.5.3.4 Measurement of treatment effect 
Dichotomous outcomes are presented as risk ratios (RR) with 95% confidence 
intervals (CI). For continuous outcomes, the mean and standard deviation was 
recorded. For continuous outcomes measured using the same scale, the effect 
measure is the mean difference (MD) with 95% CI.  
3.5.3.5 Unit of analysis issues 
Within each comparison of interventions of this review, for studies with more than two 
treatment arms, multiple pairwise comparisons of treatment groups were avoided by 
pooling treatment groups as appropriate. For dichotomous variables, count data were 
summed across groups and for continuous variables, the mean and standard 
deviation of the combined group was calculated from the mean and standard 
deviations of each subgroup. 
Thus, for the comparison of IS versus placebo, multiple IS trial arms were combined 
for an overall comparison with the control or placebo arm. Similarly, in the comparison 
of different iron preparations, different doses of an identical preparation were 
combined for comparison with an alternative iron preparation. 
For studies in which results were reported separately for males and females, these 
data were combined for the main analyses. Standard errors, P values and confidence 
intervals were converted to standard deviations where necessary. Studies in which 
continuous variables were reported as medians or geometric means without a 
measure of variation were excluded from the analysis. 
Conversion of units of total iron from µmol/L to µg/dL was undertaken using 1 µg/dL = 
0.179 µmol/L where necessary to allow meta-analysis across studies reporting 
outcome values using different units. 
3.5.3.6 Dealing with missing data 
In view of the time that had elapsed since publication of the majority of studies, no 
attempt was made to contact individual study authors or institutions regarding missing 
data. The number of patients lost to follow-up for each trial was recorded as 
unexplained or undocumented differences between the number of patients 
randomised and the number of patients analysed, and incorporated into the 
assessment of risk of bias. The preferred analysis was intention-to-treat (ITT), but 
where insufficient data were presented in the included studies, per-protocol analysis 
was used. Studies which performed ITT analyses are shown in the Characteristics of 
included studies tables (Appendix 3.1). 
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3.5.3.7 Assessment of heterogeneity 
Statistical heterogeneity of treatment effects between trials was assessed using a 
Chi2 test with a significant level at P <0.1. The I2 statistic was used to quantify the 
amount of possible heterogeneity, (I2 >30% moderate heterogeneity and I2 >75% as 
considerable heterogeneity). Uncertainty in I2 values was assessed with 95% 
confidence intervals calculated using the test based method (J. P. Higgins & 
Thompson, 2002). Potential causes of heterogeneity were explored by sensitivity and 
subgroup analyses. 
Clinical heterogeneity was assessed based on individual study characteristics (e.g. by 
examining differences in study quality, in the donation history and donor 
characteristics, and in the definition or measurement of outcomes of each study). 
3.5.3.8 Assessment of reporting biases 
Every effort was made to identify unpublished studies through searching of 
conference abstracts and ongoing trial databases as described in the Search 
methods for identification of studies (section 3.5.2). It was intended to assess 
publication bias using funnel plots but the number of included studies was lower than 
the minimum suggested for evaluation of funnel plot asymmetry for all outcomes (J. 
P. T. Higgins & Altman, 2011) therefore formal assessment of publication bias was 
not possible. 
3.5.3.9 Data synthesis 
Meta-analysis was performed using the Review Manager software ("Review Manager 
(RevMan)," 2014). It was intended to carry out meta-analyses using fixed effect 
models initially. However, in view of the differences in study participants (first time 
donors, repeat donors, deferred donors) in the included studies and the likely 
heterogeneity between these groups, random-effects models were used for all meta-
analyses. 
The dichotomous outcome of rate of low Hb deferral at the first post-treatment 
donation visit as well as after multiple post-donation visits (i.e. the final visit over study 
period) and cumulatively over all donation visits during the study period was 
assessed. 
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Few studies reported continuous outcomes as mean change from baseline values 
and therefore endpoint (follow-up) values for all comparisons were compared, with 
the exception of one study (Borch-Iohnsen, Halvorsen, Stenberg, Flesland, & 
Mowinckel, 1993) in which no endpoint values were reported. Data from this study 
were reported graphically with no measures of variation and therefore were not 
analysed. Continuous outcomes were assessed at the first post-donation visit prior to 
donation, and after post-treatment donation or donations. One study in which 
measurements were taken at the first post-treatment visit was excluded as it was 
unclear whether the measurement was taken prior to, or after, donation (Blot et al., 
1980). 
A Summary of Findings table was created using the GRADE profiler, as suggested in 
the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann et 
al.). 
3.5.3.10 Subgroup analysis and investigation of heterogeneity 
Heterogeneity was investigated by visual inspection of forest plots and by formal 
subgroup analyses by sex for the comparison of IS versus placebo by comparing 
outcomes between male- and female-specific studies as well as sex-specific results 
reported within individual studies. One study of predominantly (98.8%) male 
participants was included as a male-specific study in subgroup analyses of sex 
(Radtke, Tegtmeier, et al., 2004). The number of studies for all other comparisons 
precluded subgroup analysis. 
3.5.3.11 Sensitivity analysis 
How robust the findings were for the primary outcome, risk ratio of low Hb deferral 
and for Hb and serum ferritin levels was assessed using sensitivity analyses, 
including only those trials at low risk of performance bias and including only those 
trials in which 25%, or less, of randomised participants were lost to follow up. 
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3.6 Results 
3.6.1 Description of studies 
3.6.1.1 Results of the search 
Searches of electronic databases carried out in April 2011 and updated in May 2013 
and November 2013 identified a total of 1951 references. Removal of duplicates 
resulted in 1032 references which were screened independently by two reviewers 
(GAS, SF). Discrepancies were resolved through discussion with a third reviewer 
(DR). Initial screening of these 1032 references for eligibility against the inclusion 
criteria excluded a further 964 references. Of the remaining 68 references, 21 were 
excluded after closer inspection of the full text showed that they did not fully meet the 
eligibility criteria (as described in the Characteristics of excluded studies - Appendix 
3.2, referenced in Appendix 3.6.2). Eight additional references describing seven 
independent trials met the inclusion criteria but did not report sufficient data for 
inclusion; details are given in Studies awaiting classification - Appendix 3.3, 
referenced in Appendix 3.6.3). One other reference described a trial protocol (see 
Characteristics of ongoing studies - Appendix 3.4, referenced in Appendix 3.6.4). 
Searches of ongoing trial databases resulted in 33 ongoing trials for screening, six of 
which were unpublished trials relevant to this review and are included as ongoing 
studies. Study classification is summarised by a PRISMA flow diagram (Figure 3.1). 
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Figure 3-1: PRISMA study flow diagram 
 
 
 
3.6.1.2 Included studies 
A total of 38 references (31 full papers and seven conference abstracts) describing 30 
independent trials met the inclusion criteria (detailed in Appendix 3.1, referenced in 
Appendix 3.6.1). In one study, participants were stratified into two subgroups 
according to serum ferritin levels and each of the two treatments was randomised 
within both subgroups. For the purposes of this review, these two independent 
participant subgroups were treated as two separate trials (Mackintosh 1988_HSF; 
Mackintosh 1988_LSF). Throughout this review they will be referenced only once as 
Mackintosh and Jacobs (1988) but will, at all times, refer to both trials (Mackintosh 
1988_HSF and Mackintosh 1988_LSF) unless explicitly stated otherwise. 
1951 records identified 
from database searches 
1032 records after 
duplicates removed 
964 records excluded 
68 references assessed 
for eligibility against 
inclusion criteria 
30 references excluded: 
 
21 references did not meet the inclusion 
criteria 
 
8 references (7 independent studies) gave 
insufficient information for inclusion; included 
in "Studies awaiting classification" 
 
1 reference described an ongoing trial 
protocol 
38 references (31 full 
papers and 7 abstracts) 
described 30 
independent trials 
included in qualitative 
and quantitative 
synthesis 
1032 records screened 
independently by two 
reviewers 
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Studies were carried out worldwide, including seven studies from the United States 
(Brittenham et al., 1996; Cable et al., 1988; Devasthali et al., 1991; Gordeuk et al., 
1990; Gordeuk, Brittenham, Hughes, Keating, & Opplt, 1987; Gordeuk, Brittenham, 
Hughes, & Keating, 1987; Simon et al., 1984), six from Sweden (Birgegård, 
Schneider, & Ulfberg, 2010; Ehn, Lieden, & Oldfelt, 1968; Frykman, Bystrom, 
Jansson, Edberg, & Hansen, 1994; Lieden, 1975; Lindholm, Creutzer, & Skinhoj, 
1981; Rybo & Sölvell, 1971) four from South Africa (Jacobs, Fransman, & Coghlan, 
1993; Jacobs, Wood, & Bird, 2000; Mackintosh & Jacobs, 1988)(Mackintosh 
1988_HSF; Mackintosh 1988_LSF), three from Germany (Busch & Gohrbandt, 1972; 
Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004), three from Switzerland 
(Bucher, Baumann, & Keller, 1973; Buzi & Siegenthaler, 1980; Waldvogel et al., 
2012), two from Iran (Maghsudlu et al., 2008; Mirrezaie, Parsi, Torabgahromi, & 
Askarian, 2008); two from Norway (Borch-Iohnsen et al., 1993; Røsvik, Hervig, 
Wentzel-Larsen, & Ulvik, 2010) and one each from France (Blot et al., 1980), Italy 
(Landucci & Frontespezi, 1987), and Thailand (Linpisarn et al., 1986). 
Seven references describing six independent studies required translation into English 
language (Blot et al., 1980; Bucher et al., 1973; Busch & Gohrbandt, 1972; Buzi & 
Siegenthaler, 1980; Ehn et al., 1968; Lindholm et al., 1981). 
Participants 
Six studies were of male donors only (Ehn et al., 1968; Lieden, Hoglund, & Ehn, 
1975; Lindholm et al., 1981; Linpisarn et al., 1986; Mackintosh & Jacobs, 1988) and 
in a further study (Radtke, Tegtmeier, et al., 2004), 98.8% of participants were male. 
Eleven studies included only females (Borch-Iohnsen et al., 1993; Brittenham et al., 
1996; Cable et al., 1988; Devasthali et al., 1991; Gordeuk et al., 1990; Gordeuk, 
Brittenham, Hughes, Keating, et al., 1987; Gordeuk, Brittenham, Hughes, & Keating, 
1987; Maghsudlu et al., 2008; Mirrezaie et al., 2008; Simon et al., 1984; Waldvogel et 
al., 2012); eight of these were studies of women who were menstruating or of child-
bearing age (Borch-Iohnsen et al., 1993; Devasthali et al., 1991; Gordeuk et al., 1990; 
Gordeuk, Brittenham, Hughes, Keating, et al., 1987; Gordeuk, Brittenham, Hughes, & 
Keating, 1987; Maghsudlu et al., 2008; Mirrezaie et al., 2008; Waldvogel et al., 2012). 
Of the remaining 12 studies, five reported results separately for males and female 
donors (Birgegård et al., 2010; Frykman et al., 1994; Radtke, Mayer, et al., 2004; 
Røsvik et al., 2010; Rybo & Sölvell, 1971), and six studies reported results pooled 
across male and female donors (Blot et al., 1980; Bucher et al., 1973; Busch & 
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Gohrbandt, 1972; Buzi & Siegenthaler, 1980; Jacobs et al., 1993; Landucci & 
Frontespezi, 1987); one study did not specify the sex of the participants (Jacobs et 
al., 2000). In studies of male and female donors, the percentage of male participants 
ranged from 3.1% to 71.2%.  
With the exception of those studies of women of child-bearing age, only two studies 
reported an age restriction on participants which was from 18 to 56 years (Landucci & 
Frontespezi, 1987) and from 18 to 25 years (Lieden, 1975). Participants in a third 
study were exclusively military service recruits (Ehn et al., 1968).  
Studies included both regular/repeat and first-time donors. Thirteen studies recruited 
regular donors, defined as having donated at least five donations in the previous two 
years (Birgegård et al., 2010), at least four donations (Mackintosh & Jacobs, 1988) or 
two donations (Mirrezaie et al., 2008) in the past year, or with an undefined donation 
history (Blot et al., 1980; Borch-Iohnsen et al., 1993; Brittenham et al., 1996; Frykman 
et al., 1994; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004; Rybo & 
Sölvell, 1971; Simon et al., 1984). Donors in six studies had made at least one 
previous donation (Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 
1987; Landucci & Frontespezi, 1987; Lindholm et al., 1981; Linpisarn et al., 1986; 
Røsvik et al., 2010) or included a majority (89%) of repeat donors (Waldvogel et al., 
2012). Only two studies recruited participants with no previous history of donation 
(Ehn et al., 1968; Lieden et al., 1975); the donation history was unknown in two 
studies (Bucher et al., 1973; Busch & Gohrbandt, 1972). Five studies were of 
deferred donors with Hb  <130 g/L (Buzi & Siegenthaler, 1980), haematocrit <35% 
(Devasthali et al., 1991), low haematocrit (Gordeuk, Brittenham, Hughes, Keating, et 
al., 1987) or failing a copper sulphate test  at enrolment (Jacobs et al., 1993; Jacobs 
et al., 2000), or donors deferred at their previous visit (Cable et al., 1988). 
Interventions 
Nineteen studies included two trial arms; which included comparisons of IS versus 
placebo (Cable et al., 1988; Gordeuk et al., 1990; Linpisarn et al., 1986; Maghsudlu et 
al., 2008; Mirrezaie et al., 2008; Radtke, Tegtmeier, et al., 2004; Waldvogel et al., 
2012) or no IS (Blot et al., 1980; Brittenham et al., 1996; Røsvik et al., 2010), oral 
versus parenteral IS (Birgegård et al., 2010), different doses of the same iron 
preparation (Lieden et al., 1975) and different preparations of IS (Borch-Iohnsen et 
al., 1993; Buzi & Siegenthaler, 1980; Devasthali et al., 1991; Frykman et al., 1994; 
Gordeuk, Brittenham, Hughes, Keating, et al., 1987; Landucci & Frontespezi, 1987; 
Lindholm et al., 1981). 
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In one report, participants were stratified according to serum ferritin levels and two 
independent trials were carried out, comparing IS with placebo (Mackintosh & Jacobs, 
1988). 
Seven studies involved three trial arms, of two different iron preparations versus a 
placebo (Busch & Gohrbandt, 1972; Gordeuk, Brittenham, Hughes, & Keating, 1987; 
Rybo & Sölvell, 1971), two different doses of IS versus placebo (Ehn et al., 1968; 
Radtke, Mayer, et al., 2004), IS and/or vitamin C (Simon et al., 1984), and IS versus 
two doses of an alternative iron preparation (Jacobs et al., 1993). 
One four-arm study compared different durations of IS or placebo, administered in 
vials, with IS administered in sachets at the full dose or replaced with placebo for the 
latter part of the trial (Bucher et al., 1973); a second four-arm study compared IS with 
two different levels of glycerophosphate and with an alternative iron preparation 
(Jacobs et al., 2000). 
From these studies, 19 comparisons of IS and placebo or control, one comparison of 
oral and parenteral IS, four comparisons of different doses of IS, one comparison of 
different durations of IS and 12 comparisons of different iron preparations were 
included.  
Iron preparations included carbonyl or elemental iron, ferrous compounds (ferrous 
sulphate, ferrous carbonate, ferrous gluconate, ferrous glycine, ferrous fumarate, 
ferrous sulphate heptahydrate), and ferric compounds (ferric polymaltose, ferric 
protein succinylate, ferric sucrose, ferric glycerophosphate). The dose and duration of 
IS varied greatly across studies; from 50 mg ferrous sulphate three times daily for 
seven days, to 100 mg ferrous carbonate daily for one year (Lieden et al., 1975). Four 
studies described iron preparations which included Vitamin C (Blot et al., 1980; 
Borch-Iohnsen et al., 1993; Busch & Gohrbandt, 1972; Simon et al., 1984).  
Full details of the interventions in each trial are given in Table 3.2. 
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Table 3.2: Summary of included study characteristics. 
Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Birgegard 2010 Fe
2+
SO4 (Duraferon) [20 mg daily for 20 
days] 
Hb, SeFe, RLS, 
AE 
Week 4 and week 8 (non-
donation); Donation 2-4 (♀) 
or  2-5 (♂); last donation is 
≥ 1yr post-1
st
  donation. 
Experienced donors having given at least five 
donations in last 1 - 2 years. 
Fe
3+
sucrose (Venofer) [1 x 200 mg 
given intravenously] 
Blot 1980* Fe
2+
SO4 + Vit C (Ferro-Grad Abbott) 
[105 mg (+ 500 mg Vit C) daily for 
"following months"] 
Hb, MCV, 
SeFe, TIBC, 
AE, SI, Sat 
At second donation. Regular donors. 
Control (no placebo) 
Borch-Iohnsen 
1993 
Fe
2+
 fumarate + Vit C (Collett Iron) [20 
mg (+ 120 mg Vit C) daily, treatment 
duration unclear] 
Hb, SeFe, 
transferrin 
Five months after baseline 
measures. 
Female blood donors with depleted iron stores 
(serum ferritin <20 μg/L and Hb  >120 g/L). 
Fe
2+
 fumarate (Vitalia Hemojern) [16 mg 
(+ 2 mg heme iron from porcine blood) 
daily, treatment duration unclear] 
Brittenham 
1996 
Carbonyl iron [100 mg daily for 56 days] 
with scheduled visits 
Mean no. 
donations per 
year 
After 30 months. Females pledged to donate four times each year. 
  
 
 
 
 
 
Control (scheduled visits only) 
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Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Bucher 1973* Fe
2+
SO4 (Resoferon) [37 mg three times 
daily for 28 days (one vial)] 
Low Hb 
deferral, Hb, 
Hct, MCHC, 
transferrin, AE, 
PI 
Day 14 and day 28 post-
donation. 
Healthy blood donors blood group B; Hb 125 - 135 
g/L. 
  
 
 
 
 
Fe
2+
SO4 (Resoferon) [37 mg three times 
daily for 28 days (28 sachets)] 
Fe
2+
SO4 (Resoferon) [37 mg three times 
daily for 4 days (4 sachets) followed by 
placebo for 24 days (24 sachets)] 
Placebo [three times daily for 28 days 
(one vial)] 
Busch 1972* Fe
2+
SO4 (Eryfer) [50 mg (+ 222 mg Vit C 
+ 84 mg NaHCO3) twice daily for 30 
days] 
AE After 30 days of treatment. Blood donors. 
Fe
2+
SO4 (alternative) [50 mg (+ 222 mg 
Vit C) twice daily for 30 days] 
Placebo [273.8 mg maize starch + 1.2 
mg aerosil twice daily for 30 days] 
Buzi 1980* Fe
2+
SO4 (Tardyferon) [80 mg (+ 80 mg 
muco-protein) daily for 30 days] 
Hb, Hct, TIBC, 
AE, SI 
Day 2 after end of 
treatment. 
Deferred donors with an Hb < 130 g/L  [Hct <37%] 
and no history of medical pathology for anaemia. 
 Fe
2+
 fumarate [66 mg twice daily for 18 
days] 
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Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Cable 1988 Fe
2+
 gluconate (Fergon) [37.5 mg twice 
daily for trial duration] 
Low Hb 
deferral, Hb, 
SeFe, 
transferrin, ZP 
≥8 weeks since previous 
donation or 4 weeks since 
deferral, for 5 visits 
including initial visit. 
Female donors failing previous Hb screen (some 
were eligible to donate at start of study) 
 Placebo [calcium phosphate twice daily 
for trial duration] 
Devasthali 
1991 
Carbonyl iron [100 mg daily for 84 days] Hb, MCV, 
SeFe, 
transferrin, 
TIBC, AE, SI 
Weeks 0, 1, 3, 6, 12, 16 
(none were donation 
visits). 
Menstruating, non-pregnant women 18 - 40 yrs old 
recently deferred from donation (Ht <35%) with an 
absence of known medical disorders and no iron 
supplementation since deferral from blood donation 
and a MCV <85fL and ferritin <12 μg/L. 
Fe
2+
SO4 [100 mg daily for 84 days] 
 
Ehn 1968* 
(Adolfsson 
1968*; Lieden 
1975) 
Fe
2+
 succinate (Ferromyn S) [74 mg 
(+220 mg succinic acid) twice daily for 
two weeks] 
Hb, Hct, TIBC, 
PA, SI 
2 months after 6 
subsequent donations 
(inter-donation interval 2 
months). 
Young healthy male conscripts with no past history of 
haematological, gastrointestinal or renal disorder. 
None had previous haemorrhage or had served as 
blood donors. 
Fe
2+
 succinate (Ferromyn S) [34 mg 
(+110 mg succinic acid) twice daily for 
two weeks] 
Placebo (twice daily for two weeks) 
Frykman 1994 Fe
2+
 fumarate (Hemofer) [8 mg (+1.2 mg 
heme iron from porcine blood) twice 
daily for first month then 2nd or 3rd mth] 
Hb, SeFe, AE After 3 months. Regular blood donors. 
Fe
2+
 fumarate (Erco-Fer) [60 mg daily 
for first month then second or third 
month] 
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Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
 
Gordeuk 
1987a 
  
Carbonyl iron [600 mg three times daily 
for 7 days] 
Hb, MCV, 
SeFe, TIBC, 
AE, SI, Sat,  
FEP 
Day 56 after successful 
donation. 
Previous (at least once) female donors of child-
bearing age who were not pregnant and came to 
donate blood. 
Fe
2+
SO4 [60 mg three times daily for 7 
days] 
Placebo [three times daily for 7 days] 
Gordeuk, 
1987b 
Carbonyl iron [600 mg three times daily 
for 21 days] 
Hb, MCV, 
SeFe, TIBC, 
AE, SI, Sat,  
FEP 
Weeks 1, 3, 6, 12, 16. Female blood donors of child-bearing age who were 
not pregnant recently deferred from repeat donation 
due to low Hct. 
Fe
2+
SO4 [60 mg three times daily for 21 
days] 
Gordeuk 1990 
  
Carbonyl iron [100 mg daily for 56 days] Low Hb 
deferral, Hb, 
MCV, SeFe, 
transferrin, 
TIBC, AE, SI 
Day 56 after successful 
donation. 
Repeat female donors  of child-bearing age who were 
not pregnant and came to donate blood. 
 
Placebo [daily for 56 days] 
Jacobs 1993 Fe
2+
SO4 [60 mg twice daily for 84 days] Low Hb 
deferral, Hb, 
SeFe, NIA, AE, 
SI, Sat 
 
 
Weeks 1, 2, 4, 8, 12. Not 
donation visits. 
Donors failing CuSO4 Hb screening test, i.e. deferred 
donors. 
Fe
3+
 polymaltose [100 mg daily for 84 
days] 
Fe
3+
 polymaltose [100 mg twice daily for 
84 days] 
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Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Jacobs 2000 Fe
3+
 polymaltose [100 mg (+3.6 mMol/L 
GlyP) twice daily for 84 days] 
Hb, SeFe, 
transferrin, AE, 
SI, RCF 
Weeks 4, 8 and 12. Not 
donation visits. 
Regular donors failing CuSO4 Hb screening test. 
Fe
3+
 polymaltose [100 mg (+1.9 mMol/L 
GlyP) twice daily for 84 days] 
Fe
3+
 polymaltose [100 mg twice daily for 
84 days] 
Fe
2+
SO4 [ “equivalent dose” twice daily 
for 84 days] 
Landucci 1987 
  
Fe
3+ 
protein succinylate (Legofer) [80 
mg daily for 30 days] 
Hb, Hct, MCV, 
MCH, MCHC, 
SeFe, 
transferrin, AE, 
SI 
End of trial: mean 30 +/- 2.2 
days (range 23-33) 
Blood donors aged 18 - 56 with low levels of stored 
iron (serum ferritin <30 ng/100mL). 
Fe
2+
SO4 [105 mg daily for 30 days] 
Lieden 1975 Fe
3+ 
carbonate [100 mg daily for one 
year] 
Low Hb deferral, 
TIBC, NIA, AE, 
SI, PCV 
After 4th and 6th donations. Young male first-time donor conscripts with no 
history of bleeding. 
Fe
3+
carbonate [20 mg daily for one year] 
Lindholm 
1981* 
Fe
2+
SO4 (ACO) [100 mg daily for 30 
days] 
Low Hb deferral, 
Hb, TIBC, AE, 
SI 
After 1st, 2nd and 3rd  
donations. 
Previous donors (all except 14/500) without iron 
deficiency anaemia during the most recent years, 
could tolerate different iron preparations and 
intended to continue to give blood. Fe
2+
 fumarate (Erco-Fer) [60 mg daily 
for 30 days] 
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Mackintosh 
1988_HSF 
Fe
3+
 polymaltose (Ferrimed DS) [100 
mg twice daily for 56 days] 
Hb, SeFe, AE After 56 days of treatment 
(not donation visit). 
Regular donors (at least four donations in previous 
year) passing the Hb test and with high serum 
ferritin (between 50 and 150 μg/L). 
  
Placebo [twice daily for 56 days] 
Maghsudlu 
2008 
  
Fe
2+
SO4 [150 mg three times daily for 7 
days] 
Low Hb deferral, 
Hb, Hct, SeFe, 
TIBC, AE, SI, 
Sat 
Visits 1 (4 months), 2 (8 
months) and 3 (12 months). 
Female successful blood donors aged <45years 
who were not pregnant. 
Placebo [three times daily for 7 days] 
Mirrezaie 2008 Fe
2+
SO4 [50 mg daily for 56 days] SeFe, AE Day 7, 28 and 56. Not 
donation visits. 
Regular (at least two donations in past year) 
healthy female donors of childbearing age. 72% 
had previously been taking iron supplements. Placebo [daily for 56 days] 
 
Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Linpisarn 1986 
  
“Elemental” iron [56 mg daily for 90 
days] 
Hb, Hct, SeFe, 
transferrin 
After ~3 months (assumed 
no donations). 
Male volunteer and paid blood donors who had 
previously donated. 
Placebo [daily for 90 days] 
Mackintosh 
1988_LSF 
Fe
3+
 polymaltose (Ferrimed DS) [100 
mg twice daily for 56 days] 
Hb, SeFe, AE 
After 56 days of treatment 
(not donation visit). 
Regular donors (at least four donations in previous 
year) passing the Hb test and with low serum 
ferritin (less than 20 μg/L). 
Placebo [twice daily for 56 days] 
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Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Radtke, 2004a Fe
2+
 gluconate [20 mg (+ 400 mg Vit C) 
twice daily for 6 months] 
Low Hb deferral, 
SeFe, 
transferrin, AE 
♂ = 2/4/6 months; ♀ = 3/6 
months. All were donation 
visits. 
Regular healthy donors. 
Fe
2+
 gluconate (+ 400 mg Vit C ) [10 mg 
twice daily for 6 months] 
Placebo (+400 mg Vit C) [twice daily for 
six months] 
Radtke, 
2004b 
Fe
2+ 
Glycine SO4 (ferro sanol duodenal) 
[100 mg daily for 8 - 10 weeks] 
Low Hb deferral Before donation visits 1, 2, 3. 
Inter-donation interval 8-10 
weeks. 
Regular healthy donors with a minimum body wt. of 
68 kg and an Hb of 145 g/L giving two-unit RBC by 
apheresis. 
  
Placebo [daily for 8 - 10 weeks] 
Rosvik 
2010 
  
Fe
2+ 
Glycine SO4 (Niferex©) [100 mg 
daily for 8 days] 
Hb, SeFe, 
transferrin 
Day 8 (+/- 2) after initial 
donation. 
Donors with at least one prior donation. 
Control (no placebo) 
Rybo 
1971 
  
Fe
2+
SO4 [100 mg twice daily for 14 days] AE Day 14 post-donation. Regular blood donors. 
Fe
2+
SO4 heptahydrate [100 mg twice 
daily for 14 days] 
Placebo [twice daily for 14 days] 
 
Chapter 3 – Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors 
  
   
108 
 
 
Study
a
 
  
Intervention
b
 [elemental iron dose] Reported 
outcomes
c
 
Follow-up timepoints
d
 Description of study participants 
Simon 
1984 
  
Fe
2+
SO4  [37 mg daily for 56 days] Hb, SeFe, TIBC Donation visits 2,3,4,5 etc. 
(inter-donation interval 8 - 12 
weeks, mean 9.5 weeks) 
with at least 4 donation visits 
Regular female blood donors committing to donate 
blood every 8 weeks for one year. 
Fe
2+
SO4  [37 mg (+75 mg VitC) daily for 
56 days] 
[100 mg Vit C daily for 56 days] 
Waldvogel 
2012 
Fe
2+
SO4 (Tardyferon) [80 mg daily for 28 
days] 
Hb, SeFe, Cog, 
PA, AE 
1 week after donation 
(randomisation) & 4 weeks 
post- randomisation. 
Successful female blood donors (non-anaemic but 
iron-deficient after donation). 
Placebo [daily for 28 days] 
 
a
 * = translated 
b
 Fe
2+
 SO4 = Iron (II) sulphate; Fe
3+
sucrose = Iron (III) sucrose;
 
Fe
2+
 = ferrous (II) salt; Fe
3+
 = ferric (III) salt; Vit C = Vitamin C; GlyP-= glycerophosphate; All 
treatments were administered orally with the exception of ferric sucrose given intravenously in Birgegard 2010.  
c 
Hb = haemoglobin, Hct = haematocrit; MCV = Mean Cell Volume; MCH = Mean Cell Hb; MCHC = MCH concentration; SeFe = serum ferritin; TIBC = Total 
Iron Binding Capacity, NIA = Net Iron Absorption; Cog = cognitive function; PA = physical activity; RLS = restless legs syndrome; SI = serum iron; Sat = 
percentage saturation; PI = plasma iron; FEP =  free erythrocyte protoporphyrin; ZP = zinc protoporphyrin; AE = adverse effects 
d 
♂ = males, ♀ = female
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Outcomes 
The duration of follow-up varied greatly between studies. Ten studies reported 
outcomes after up to five donations subsequent to the administration of IS (Birgegård 
et al., 2010; Brittenham et al., 1996; Cable et al., 1988; Ehn et al., 1968; Lieden et al., 
1975; Lindholm et al., 1981; Maghsudlu et al., 2008; Radtke, Mayer, et al., 2004; 
Radtke, Tegtmeier, et al., 2004; Simon et al., 1984). In two studies it was unclear 
whether any donations following treatment had taken place at the time of follow-up 
(Blot et al., 1980; Frykman et al., 1994). The remaining 18 studies measured 
outcomes before further donation. Timepoints ranged from a mean of 8 days (Røsvik 
et al., 2010) to 16 weeks (Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, 
Keating, et al., 1987) with a median follow-up time before further donation of 56 days. 
The primary outcome of this review, risk ratio of low Hb deferral, was reported in only 
eight studies (Bucher et al., 1973; Cable et al., 1988; Gordeuk et al., 1990; Lieden, 
1975; Lindholm et al., 1981; Maghsudlu et al., 2008; Radtke, Mayer, et al., 2004; 
Radtke, Tegtmeier, et al., 2004). Haemoglobin and serum ferritin levels were widely 
reported; other reported blood indices included mean cell/corpuscular volume (MCV), 
serum or plasma iron, total iron binding capacity (TIBC) and transferrin saturation. 
Health related QoL measures were poorly reported; only two studies included 
measures of physical activity and fatigue (Ehn et al., 1968; Waldvogel et al., 2012), 
and no studies reported measures of mood disturbance or cognitive function. The 
majority of studies described adverse effects. Reported outcomes (including those not 
considered in this review) and endpoints in individual studies are shown in Table 3.2. 
3.6.1.3 Excluded studies 
Twenty studies described in 21 references were excluded from the review following 
full-text assessment against the eligibility criteria (see Characteristics of excluded 
studies Appendix 3.2). In summary, three studies included a single treatment arm, 
two studies allocated treatment without randomisation, in two studies randomisation 
of treatment could not be confirmed, three studies were of short-term iron absorption 
levels, one study randomised vitamin C dose with all participants receiving identical 
iron supplementation, two observational studies included no IS, two studies were of 
non-donors, one study was of plasmapheresis donors, one study reported results for 
both blood donors and non-donors combined, one study was a commentary of iron 
deficiency in blood donors, one study administered erythropoietin to autologous blood 
donors, one study was no longer available in print. 
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3.6.2 Risk of bias in included studies 
Two review authors independently assessed risk of bias for each study using the 
criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions 
(J. P. T. Higgins & Altman, 2011). Disagreements were restricted to where one 
reviewer deemed risk of bias as unclear rather than high or low and were mainly 
concerned with the interpretation of "double-blind" (see assessment of "Risk of bias" 
in Characteristics of included studies, Appendix 3.1). All disagreements were resolved 
by discussion and with further reference to the Cochrane Handbook for Systematic 
Reviews of Interventions (J. P. T. Higgins & Altman, 2011). 
Overall, the risk of bias varied from low to high, with the majority of studies being 
unclear as to their quality (see Characteristics of included studies, Appendix 3.1). This 
was mainly due to the age of the studies, with more recent studies using more 
rigorous methodologies. A summary of the risk of bias is shown in Figure 3.2. 
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Figure 3-2: Risk of bias summary: review authors' judgements about each risk of bias 
item for each included study. 
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3.6.2.1 Allocation (selection bias) 
Of the 30 included studies only seven were assessed as having a low likelihood of 
selection bias (Birgegård et al., 2010; Blot et al., 1980; Jacobs et al., 1993; Mirrezaie 
et al., 2008; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004; Simon et al., 
1984; Waldvogel et al., 2012). In these studies, treatment allocation was randomised 
using web-based systems, computer-generated charts (n=2), random block design 
(n=3) and participant choice of randomised cards in envelopes. The risk of selection 
bias in the remaining studies was unclear as none reported their method of 
randomisation. 
No method for concealment of allocation was reported in 23 studies. Of the seven 
remaining studies, two did not conceal allocation (Jacobs et al., 2000; Røsvik et al., 
2010) and one used computer-generated charts (Jacobs et al., 1993); these were 
assessed as having a high risk of selection bias. The remaining four studies were 
assessed as being of low risk due to the use of code-marked prescriptions (Lindholm 
et al., 1981; Rybo & Sölvell, 1971; Simon et al., 1984; Waldvogel et al., 2012). 
3.6.2.2 Blinding (performance bias and detection bias) 
There was no blinding of participants in six of the studies so these were considered to 
have a high risk of performance bias (Birgegård et al., 2010; Blot et al., 1980; Borch-
Iohnsen et al., 1993; Jacobs et al., 1993; Jacobs et al., 2000; Røsvik et al., 2010). 
Eleven studies gave no indication of participant blinding so were recorded as having 
an unclear risk. Of the 13 studies assessed as low risk, nine stated the studies as 
being double-blind, either with the use of a placebo (Busch & Gohrbandt, 1972; 
Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, Keating, et al., 1987; Gordeuk, 
Brittenham, Hughes, & Keating, 1987; Mirrezaie et al., 2008) or assumed to include 
participant blinding without explicitly stating so (Devasthali et al., 1991; Frykman et 
al., 1994; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004). Four used 
coded bottles for the prescriptions (Lindholm et al., 1981; Rybo & Sölvell, 1971; 
Simon et al., 1984; Waldvogel et al., 2012). 
Only three of the 30 studies described any blinding of the outcome assessment and 
were rated as “low risk” (Lindholm et al., 1981; Simon et al., 1984; Waldvogel et al., 
2012); the remainder were classified as “unclear risk”. 
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3.6.2.3 Incomplete outcome data (attrition bias) 
Completeness of data was investigated and the reasons for attrition or exclusion 
where reported for each included study and whether missing data were balanced 
across groups have been described. Ten studies were rated as being low risk 
(Birgegård et al., 2010; Borch-Iohnsen et al., 1993; Gordeuk, Brittenham, Hughes, 
Keating, et al., 1987; Landucci & Frontespezi, 1987; Lindholm et al., 1981; 
Mackintosh & Jacobs, 1988; Radtke, Tegtmeier, et al., 2004; Rybo & Sölvell, 1971; 
Waldvogel et al., 2012), two were of unclear risk (Brittenham et al., 1996; Ehn et al., 
1968) and the remainder had high risk of attrition bias, with a difference in missing 
data of greater than 5% between treatment arms, a high rate of loss to follow-up, or in 
one case because the number of participants randomised to each arm was not 
reported (Bucher et al., 1973). 
3.6.2.4 Selective reporting (reporting bias) 
All of the pre-specified outcomes published in the protocol for the study of Waldvogel 
et al. (2012) were reported and this study was deemed to have a low risk of bias. A 
high risk of bias was associated with one study in which the authors failed to report 
three pre-speciﬁed outcomes of interest (Lindholm et al., 1981). In all 29 remaining 
studies, where all outcomes listed in the manuscript were reported but no study 
protocol was available to determine the full list of pre-specified outcomes, the risk of 
reporting bias was unclear. No unpublished data was received, so there is currently 
no additional evidence of reporting bias. 
3.6.2.5 Other potential sources of bias 
Each included study was assessed for other factors that might contribute to additional 
risk of bias. We have noted any concerns we had about other possible sources of 
bias and rated them thus: 
 high risk of further bias - where the manufacturer has provided support in 
terms of a grant (Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004) 
and additional help (Bucher et al., 1973; Ehn et al., 1968; Lieden et al., 1975) 
or where the manufacturer supplied some co-authors (Lindholm et al., 1981). 
 unclear - where the risk of further bias is uncertain, most commonly where a 
study has been supplied with iron supplements and/or placebo by a particular 
manufacturer (Borch-Iohnsen et al., 1993; Jacobs et al., 1993; Jacobs et al., 
2000) or there was limited data available from a conference abstract 
(Brittenham et al., 1996). 
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 low risk of further bias - where there was explicit declaration of independence 
from study sponsors (Birgegård et al., 2010; Waldvogel et al., 2012) or where 
no other sources of bias could be identified (18 studies). 
3.6.3 Effects of interventions 
See: Table 3.1 Summary of findings for the main comparison. Iron supplementation 
for iron deficiency and/or anaemia in blood donors. 
3.6.3.1 Iron supplementation versus placebo/control 
Nineteen studies compared IS with placebo or control (see Table 3.2). Hb, serum 
ferritin and TIBC were reported graphically in one study (Simon et al., 1984); data for 
this study were estimated from the graphs as described in the Methods section. 
Risk ratio of low Hb deferral (primary outcome) 
Four studies reported LHD rates (Gordeuk et al., 1990; Maghsudlu et al., 2008; 
Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004). One other study 
reported the mean number of donations per donor per year (Brittenham et al., 1996). 
At the first donation visit after commencement of treatment, all four studies reported a 
lower rate of LHD in donors who received IS than those who had not, with three 
studies reporting a significant difference between treatment arms (Gordeuk et al., 
1990; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004). Combined 
evidence from all four studies showed a significantly reduced risk of LHD at the first 
donation visit after treatment in donors who received IS (risk ratio [RR] 0.34; 95% 
confidence interval [CI] 0.21 to 0.55; four studies; 1194 participants; P value <0.0001) 
(Appendix 3.5.1 - Analysis 1.1) (Figure 3.3). There was no evidence of heterogeneity 
between studies (I2 = 0%; 95% CI 0% to 79.3%). This LHD risk reduction was 
maintained after multiple donation visits reported in three studies (RR 0.25; 95% CI 
0.15 to 0.41: three studies: 793 participants: P value <0.00001) (Maghsudlu et al., 
2008; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004) and over 
cumulative donation visits (RR 0.31; 95% CI 0.18 to 0.52; four studies; 2740 
participants; P value <0.00001) (Appendix 3.5.1 - Analysis 1.1) (Figure 3.3). 
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Subgroup analyses revealed no significant differences between male and female 
donors in LHD rates at first donation (P value = 0.90) (Appendix 3.5.10.1 - Analysis 
10.1), after multiple donation visits (P value = 0.81) (Appendix 3.5.10.2  - Analysis 
10.2) or over cumulative donation visits (P value = 0.85) (Appendix 3.5.10.3  - 
Analysis 10.3). Results were robust to performance bias (Appendix 3.5.11.1 - 
Analysis 11.1) and attrition bias (Appendix 3.5.12.1 - Analysis 12.1).
Figure 3-3 (Analysis 1.1): Forest plot of comparison: 1 Iron supplementation vs. 
placebo/control, outcome: 1.1 Low Hb deferral (primary outcome). 
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Hb levels, mean cell volume (MCV), other blood indices and iron stores 
Haemoglobin (Hb) 
Mean Hb levels were reported in 12 studies (Bucher et al., 1973; Cable et al., 1988; 
Ehn et al., 1968; Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 
1987; Linpisarn et al., 1986; Mackintosh & Jacobs, 1988; Maghsudlu et al., 2008; 
Røsvik et al., 2010; Simon et al., 1984; Waldvogel et al., 2012) although in one study, 
results were reported graphically and data extraction could not be undertaken (Ehn et 
al., 1968); this study reported no significant differences between treatment groups. 
In eight studies which reported Hb levels at follow-up prior to further donation (Bucher 
et al., 1973; Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 1987; 
Linpisarn et al., 1986; Mackintosh & Jacobs, 1988; Røsvik et al., 2010; Waldvogel et 
al., 2012), meta-analysis showed that IS resulted in significantly higher levels of Hb at 
follow-up (mean difference [MD] 2.36 g/L; 95% CI 0.06 to 4.46; eight studies; 847 
participants; P value = 0.04). A moderate level of heterogeneity was observed 
between studies (I2 = 69%; 95% CI 34.3% to 85.1%) (Appendix 3.5.1.2 - Analysis 1.2) 
(Figure 3.4). 
Sensitivity analyses showed that the effect of IS on Hb levels before further donation 
remained significant when five studies with a high or unclear risk of performance bias 
were excluded (MD 4.76 g/L; 95% CI 1.07 to 8.45; three studies: 270 participants: P 
value = 0.01) (Appendix 3.5.11.2 - Analysis 11.2), and when studies with less than 
75% of randomised participants included in the analysis were excluded (MD 2.90 g/L; 
95% CI 0.23 to 5.57; six studies: 698 participants: P value = 0.03) (Appendix 3.5.12.2 
- Analysis 12.2). 
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Figure 3-4 Forest plot of comparison 1: Iron supplementation vs. placebo/control, outcome: 1.2 Hb (g/L). 
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Subgroup analysis by sex revealed that the difference in Hb level between treatment 
arms was found in female donors (MD 3.56 g/L; 95% CI 0.21 to 6.92; four studies: 
431 participants: P value = 0.04) but not male donors (MD 0.08 g/L; 95% CI -1.90 to 
2.05; four studies: 297 participants: P value = 0.94). A test for subgroup differences 
was not significant (P value = 0.08) (Appendix 3.5.10.4 - Analysis 10.4) although the 
number of studies provided low power to detect a difference between subgroups. No 
heterogeneity was observed across four studies reporting Hb levels in males (I2 = 0%; 
95% CI 0% to 32.8%); however, four studies reporting Hb levels in females showed 
high heterogeneity (I2 = 80%; 95% CI 48.3% to 92.6%)  with no obvious clinical 
differences apparent between these studies. 
Hb after subsequent donation(s) was reported in three studies (Cable et al., 1988; 
Maghsudlu et al., 2008; Simon et al., 1984). A significant difference in Hb levels was 
found between treatment arms in favour of IS after donation (MD 6.37 g/L; 95% CI 
2.36 to 10.39; three studies: 406 participants: P value = 0.002) (Appendix 3.5.1.2 - 
Analysis 1.2) (Figure 3.4) with high heterogeneity across studies (I2 = 84%; 95% CI 
50.9% to 94.6%) . Visual inspection of the forest plot showed a particularly strong 
effect from one study of menstruating female blood donors with an interdonation 
interval of between eight and 12 weeks (Simon et al., 1984).There was no residual 
evidence for heterogeneity when this study was excluded (I2 = 0%). 
Mean corpuscular volume (MCV) 
Two studies reported MCV before further donation; both studies reported higher 
mean MCV levels in donors who received IS compared with those who did not 
(Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 1987). However, 
meta-analyses of these two studies did not provide evidence for a difference in MCV 
between treatment arms (MD 1.37 fL; 95% CI -0.17 to 2.92; two studies; 127 
participants: P value = 0.08) (Appendix 3.5.1.3 - Analysis 1.3). 
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Serum ferritin 
Serum ferritin (ng/mL) before further donation was reported as an outcome in nine 
studies (Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 1987; 
Linpisarn et al., 1986; Mackintosh & Jacobs, 1988; Mirrezaie et al., 2008; Radtke, 
Mayer, et al., 2004; Røsvik et al., 2010; Waldvogel et al., 2012). However, three 
studies reported serum ferritin as geometric mean (Gordeuk et al., 1990; Gordeuk, 
Brittenham, Hughes, & Keating, 1987; Røsvik et al., 2010) and a fourth study reported 
median serum ferritin values, with no suitable measure of variation for inclusion of the 
data from these studies in a quantitative synthesis (Linpisarn et al., 1986). In these 
four studies, one reported a significant difference in serum ferritin between treatment 
arms in favour of IS (Røsvik et al., 2010); two reported significant increases in serum 
ferritin from baseline in the IS group but not the placebo/control group (Gordeuk et al., 
1990; Gordeuk, Brittenham, Hughes, & Keating, 1987) and one reported no difference 
in serum ferritin between treatment groups (Gordeuk, Brittenham, Hughes, & Keating, 
1987). 
In five studies, significantly higher mean serum ferritin levels at follow-up were found 
in donors who received IS compared with those who did not in all but one study 
(Mackintosh 1988_HSF), in which donors were pre-selected for high serum ferritin 
(between 50 and 150 ng/mL). Meta-analysis of all five studies showed that IS resulted 
in significantly higher levels of serum ferritin (MD 13.98 ng/mL; 95% CI 8.92 to 19.03; 
five studies; 640 participants; : P value < 0.00001). A moderate level of heterogeneity 
(I2 = 68%; 95% CI 16.0% to 87.5%) was found between studies (Appendix 3.5.1.4 - 
Analysis 1.4) (Figure 3.5). The effect remained significant when the study with high 
baseline serum ferritin levels was excluded (MD -13.67 ng/mL; 95% CI 8.39 to 18.95; 
four studies; 617 participants; P value < 0.00001). 
Subgroup analysis showed the significant improvement in serum ferritin associated 
with IS was found in both male and female donors (males: MD 10.94 ng/mL; 95% CI -
1.00 to 20.88; three studies; 265 participants; P value =0.03; females: MD 14.39 
ng/mL; 95% CI -9.90 to 18.88; three studies; 375 participants; P value < 0.00001; test 
for subgroup differences: P value = 0.53) (Appendix 3.5.10.5 - Analysis 10.5). 
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Sensitivity analyses showed that the increase in serum ferritin levels associated with 
IS before further donation remained significant when two studies with a unclear risk of 
performance bias were excluded in a sensitivity analysis (MD 13.31 ng/mL; 95% CI 
7.22 to 19.40; three studies; 594 participants; P value < 0.0001) (Appendix 3.5.11.3 - 
Analysis 11.3) and when studies with less than 75% of randomised participants 
included in the analysis were excluded (MD 15.24 ng/mL; 95% CI 12.37 to 18.11; 
three studies; 189 participants; P value < 0.00001) (Appendix 3.5.12.3 - Analysis 
12.3). 
Mean serum ferritin levels after subsequent donation(s) were reported in three trials 
(Cable et al., 1988; Maghsudlu et al., 2008; Radtke, Mayer, et al., 2004). One other 
study reported serum ferritin levels graphically as geometric mean values (Simon et 
al., 1984). Meta-analysis of the three trials reporting mean values showed that the 
significant difference in mean serum ferritin in favour of IS was maintained after 
subsequent donation(s) (MD 9.01 ng/mL, 95% CI 5.76 to 12.25; three studies; 619 
participants; P value <0.00001), with no evidence for heterogeneity across studies 
(I2=0%; 95% CI 0% to 86.7%) (Appendix 3.5.1.4 - Analysis 1.4) (Figure 3.5). 
 
 
Figure 3-5: Forest plot of comparison: 1 Iron supplementation vs. placebo/control, 
outcome: 1.4 Serum ferritin (ng/mL).  
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Serum or plasma iron 
Serum or plasma iron concentration was reported in five studies (Bucher et al., 1973; 
Ehn et al., 1968; Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 
1987; Maghsudlu et al., 2008) although in one study, results were reported 
graphically and data extraction could not be undertaken (Ehn et al., 1968); no 
significant differences between treatment groups were reported in this study. In three 
studies which reported serum or plasma iron concentration before further donation 
(Bucher et al., 1973; Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 
1987), meta-analysis showed no evidence for a difference between treatment arms 
(MD 11.76 μg/dL, 95% CI -1.67 to 25.20; three studies; 246 participants; P value = 
0.09), with moderate heterogeneity across studies (I2=59%; 95% CI 0% to 88.4%). 
Only one study (Maghsudlu et al., 2008) reported serum or plasma iron concentration 
after post-treatment donation(s); this study found significantly higher levels of serum 
iron in donors receiving IS (MD 7.89 μg/dL; 95% CI 1.12 to 14.66; 252 participants; P 
value = 0.02) (Appendix 3.5.1.5 - Analysis 1.5). 
Total iron binding capacity (TIBC) 
TIBC was reported in five studies (Ehn et al., 1968; Gordeuk et al., 1990; Gordeuk, 
Brittenham, Hughes, & Keating, 1987; Maghsudlu et al., 2008; Simon et al., 1984) 
although in one study results were reported graphically and data extraction could not 
be undertaken (Ehn et al., 1968); this study reported no significant differences 
between treatment groups. Two studies reported TIBC before further donation 
(Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 1987) and two 
studies reported values after subsequent donation(s) (Maghsudlu et al., 2008; Simon 
et al., 1984). Iron supplementation resulted in significantly lower levels of TIBC 
consistent with a beneficial effect for IS both before further donation (MD 32.05 μg/dL; 
95% CI 2.65 to 61.45; two studies; 127 participants; P value = 0.03) and after 
subsequent donations (MD 42.64 μg/dL; 95% CI 28.28 to 56.99; two studies; 315 
participants; P value < 0.00001) with low to moderate heterogeneity across studies 
(I2=43%; I2=29% respectively) (Appendix 3.5.1.6 - Analysis 1.6). 
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Transferrin saturation (%) 
Transferrin saturation (also described as saturation of TIBC) was reported in four 
studies (Bucher et al., 1973; Cable et al., 1988; Gordeuk et al., 1990; Linpisarn et al., 
1986). Meta-analysis of these four studies showed a significant difference in mean 
transferrin saturation levels in favour of IS (MD 3.91%; 95% CI 2.02 to 5.80; four 
studies; 344 participants; P value < 0.0001) with no evidence for heterogeneity across 
studies (I2=0%; 95% CI 0% to 60.9%) (Appendix 3.5.1.7 - Analysis 1.7). Evidence 
from two studies showed that an increase in transferrin saturation in iron 
supplemented donors compared with placebo was maintained after subsequent 
donations (MD 4.84%; 95% CI 2.78 to 6.90; 2 studies; 343 participants; P value < 
0.00001) (Cable et al., 1988; Maghsudlu et al., 2008)  (Appendix 3.5.1.7 - Analysis 
1.7). 
Health related quality of life and physical activity 
One study reported health-related quality of life as an outcome which was assessed 
by fatigue (level of fatigue on a visual analogue scale and a subjective fatigue severity 
scale), quality of life (SF-12V2 self-questionnaire: vitality, physical and mental 
condition) and aerobic capacity (Chester step test) (Waldvogel et al., 2012). In this 
study, there were no differences in health-related quality of life measures after four 
weeks of treatment in any of the measures used, with the exception of physical 
condition (MD 2.40; 95% CI 0.93 to 3.87; one study; 133 participants; ; P value = 
0.001) (Appendix 3.5.1.8 - Analysis 1.8). 
In one other study which reported physical capacity using a bicycle test, no standard 
deviations were provided and therefore a formal assessment of the results from this 
study was not possible (Ehn et al., 1968). No significant differences between 
treatment groups were reported. 
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Adverse effects 
Fourteen studies reported adverse effects as an outcome although two studies (Blot 
et al., 1980; Røsvik et al., 2010) reported adverse effects in the treatment group only 
and five studies did not report adverse effects separately for each treatment arm 
(Bucher et al., 1973; Mackintosh & Jacobs, 1988; Radtke, Mayer, et al., 2004; 
Radtke, Tegtmeier, et al., 2004). Reported adverse effects included constipation, 
diarrhoea, nausea, vomiting, gastric discomfort, abdominal cramps, headache, 
dizziness and taste disturbances. Four studies reported the occurrence of cumulative 
adverse events (Gordeuk, Brittenham, Hughes, & Keating, 1987; Maghsudlu et al., 
2008; Rybo & Sölvell, 1971; Waldvogel et al., 2012). Meta-analysis of these four 
studies showed a significant increased risk of adverse effects associated with IS (RR 
1.60; 95% CI 1.23 to 2.07; four studies; 1748 participants; P value = 0.0005) 
(Appendix 3.5.1.9 - Analysis 1.9) (Figure 3.6). 
Meta analysis of studies reporting specific adverse effects showed that IS was 
associated with an increased risk of constipation (RR 1.63; 95% CI 1.16 to 2.31; five 
studies; 1849 participants; P value = 0.005), diarrhoea (RR 2.17; 95% CI 1.38 to 3.42; 
five studies; 1555 participants; P value = 0.0008), nausea/vomiting (RR 1.75, 95% CI 
1.20 to 2.56; six studies; 1922 participants; P value = 0.004) and taste disturbances 
(RR 5.78, 95% CI 2.10 to 15.95; two studies; 171 participants; P value = 0.0007), 
whilst there was insufficient evidence for an increased risk of abdominal pain and/or 
cramps (RR 2.21, 95% CI 0.95 to 5.16; four studies; 683 participants; P value = 0.07), 
gastric/epigastric pain (RR 1.26, 95% CI 0.73 to 2.19; two studies; 1242 participants; 
P value = 0.41), or headache (RR 0.91, 95% CI 0.53 to 1.56; five studies; 681 
participants; P value = 0.72) (Appendix 3.5.1.9 - Analysis 1.9) (Figure 3.6).  
Compliance 
Three studies reported compliance as continuation of treatment (IS or placebo) 
(Busch & Gohrbandt, 1972; Gordeuk, Brittenham, Hughes, & Keating, 1987; Rybo & 
Sölvell, 1971). Meta-analysis showed a high risk of discontinuation of treatment in 
participants who received IS compared with those who received placebo although this 
difference failed to meet statistical significance (RR 0.83; 95% CI 0.99 to 1.47; three 
studies; 1336 participants; P value = 0.06) (Appendix 3.5.1.10 - Analysis 1.10). 
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Figure 3-6: Forest plot of comparison: 1 Iron supplementation vs. placebo/control, 
outcome: 1.9 Adverse effects. 
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Five studies reported the number of individuals who achieved a high compliance rate, 
defined as 100% compliance (Gordeuk et al., 1990; Røsvik et al., 2010) or over 90% 
compliance (Mirrezaie et al., 2008; Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et 
al., 2004); however only two trials reported compliance rates separately for both 
treatment groups (Gordeuk et al., 1990; Mirrezaie et al., 2008). Meta-analysis of 
these two trials showed no evidence for a difference in compliance rates between 
treatment groups (RR 0.76; 95% CI 0.51 to 1.15; two studies; 146 participants; P 
value = 0.19) (Appendix 3.5.1.10 - Analysis 1.10). Compliance (ingestion of over 90% 
of tablets) was poor in one third of men and one quarter of women in one study 
(Radtke, Mayer, et al., 2004); a second study by the same group (Radtke, Tegtmeier, 
et al., 2004) reported that compliance was "largely similar in both groups". One study 
(Røsvik et al., 2010) reported that full compliance was achieved in 92.8% of 
participants who received iron supplementation. In the study of Blot et al. (1980), IS 
was "well adhered to" in 81.8% of patients although no definition of compliance was 
given. 
One study reported the number of days over a total treatment period of 28 days on 
which tablets were taken (Bucher et al., 1973); tablets were taken for between 87.7% 
and 93.4% of total treatment days in participants who received IS compared with 
88.2% in the placebo group. One study reported a mean of 1.6 (standard deviation 
[SD ] = 0.4) tablets per day were taken in the IS group compared with 1.5 (SD 0.7) in 
the placebo group (Cable et al., 1988). A compliance rate of 96% was reported in the 
study of Waldvogel et al. (2012) with similar adherence in both groups. In the Ehn et 
al. (1968) study, no more than 10 tablets were not consumed by any participant over 
the entire study period. 
Seven studies identified reasons for non-compliance or discontinuation of treatment 
associated with adverse effects (Blot et al., 1980; Busch & Gohrbandt, 1972; Cable et 
al., 1988; Gordeuk et al., 1990; Gordeuk, Brittenham, Hughes, & Keating, 1987; Rybo 
& Sölvell, 1971; Waldvogel et al., 2012). 
 
3.6.3.2 Iron supplementation: oral versus parenteral 
Only one study (Birgegård et al., 2010) compared oral and parenteral iron 
supplementation. 
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Risk ratio of low Hb deferral (primary outcome) 
Low Hb deferral was not reported in this study. 
Hb levels, MCV, other blood indices and iron stores 
Haemoglobin (Hb) 
Hb was reported as an outcome in this study, although results were given 
descriptively, whereby "no significant differences in Hb between the treatment groups 
were seen". 
Mean corpuscular volume (MCV) 
MCV was not reported in this study. 
Serum ferritin 
Mean serum ferritin was reported both before further donation and after four (women) 
or five (men) subsequent donations. There was no difference in post-treatment serum 
ferritin levels at follow-up prior to further donation between treatment arms (MD 2.10 
ng/mL; 95% CI -5.91 to 10.11; 120 participants; P value = 0.61) (Appendix 3.5.2.1 - 
Analysis 2.1). However, after further multiple donations, the mean serum ferritin level 
was significantly higher in donors who received IS intravenously in a single dose after 
each donation, compared with those who were administered oral iron supplements 
(MD 7.65 ng/mL; 95% CI 0.36 to 14.94; 120 participants; P value = 0.04) (Appendix 
3.5.2.1 - Analysis 2.1). 
Serum or plasma iron 
Serum or plasma iron levels were not reported in this study. 
Total iron binding capacity (TIBC) 
TIBC was not reported in this study. 
Transferrin saturation (%) 
Transferrin saturation was not reported in this study. 
Health related quality of life and physical activity 
No measures of health-related quality of life or physical activity were measured in this 
study. 
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Adverse effects 
No serious adverse effects occurred during the trial. In donors who received oral iron 
supplementation, two cases of constipation and two cases of diarrhoea were 
reported. In addition, six donors who received oral IS reported gastric discomfort. A 
non-severe headache in one donor was the only adverse event reported in the 
intravenous iron group. 
This study also compared the frequencies of restless leg syndrome, measured by the 
International Restless Legs Syndrome Study Group Severity Scale (IRLS) in each 
treatment group. A significant difference in IRLS score between treatment groups in 
favour of intravenous administration of iron was reported; however, no standard 
deviations were reported to enable an estimation of the effect size. 
Compliance 
Treatment compliance (defined as 100% of medication taken) between visit four and 
seven ranged from 88% to 91.7% for oral IS compared with 88% to 100% for iron 
administered intravenously. 
 
3.6.3.3 Iron supplementation versus iron rich food supplements 
No studies comparing IS versus iron rich food supplements were identified. 
 
3.6.3.4 Iron supplementation: dose A versus dose B 
Four studies (Ehn et al., 1968; Jacobs et al., 1993; Lieden et al., 1975; Radtke, 
Mayer, et al., 2004) compared different doses of iron supplementation. Details of the 
doses and duration of treatment in individual studies are given in Table 3.2. 
Risk ratio of low Hb deferral (primary outcome) 
Two studies reported LHD at donation although in the first of these, discrepancies in 
the paper prevented reliable extraction of the data (Jacobs et al., 1993; Radtke, 
Mayer, et al., 2004). In the second study there was no evidence for a difference in the 
rate of LHD between treatment groups, either at the first donation visit after 
commencement of IS (RR 0.66; 95% CI 0.11 to 3.92; 351 participants; P value = 
0.65), after subsequent donation visits (RR 1.87; 95% CI 0.17 to 20.33; 236 
participants; P value = 0.61), or over cumulative donation visits (RR 0.98; 95% CI 
0.25 to 3.90; 742 participants; P value = 0.98) (Radtke, Mayer, et al., 2004) (Appendix 
3.5.3.1 - Analysis 3.1). 
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Hb levels, MCV, other blood indices and iron stores 
Haemoglobin (Hb) 
Hb levels before further donation were reported in one study (Jacobs et al., 1993), in 
which there was no evidence for a difference in Hb levels at follow-up between 
treatment dosage groups (MD 5.00 g/L; 95% CI -0.47 to 10.47; 85 participants; P 
value = 0.07) (Appendix 3.5.3.2 - Analysis 3.2). One study reported Hb levels after 
subsequent donation(s) (Ehn et al., 1968)but results were reported results graphically 
and data extraction could not be undertaken; no significant differences between 
groups were reported in this study. 
Mean corpuscular volume (MCV) 
No studies reported MCV as an outcome. 
Serum ferritin 
Two studies reported serum ferritin levels at follow-up before further donation (Jacobs 
et al., 1993; Radtke, Mayer, et al., 2004). Meta-analysis of these two studies showed 
no evidence for a difference in serum ferritin between dosage groups (MD 2.89 
ng/mL; 95% CI -1.83 to 7.60; 2 studies; 356 participants; P value = 0.23). However, in 
one study which reported serum ferritin level after two (female) or three (male) 
subsequent donations, there was a significant difference in serum ferritin in favour of 
a higher dose (20mg twice daily compared with 10 mg twice daily) of IS (MD 7.96 
ng/mL; 95% CI 1.68 to 14.24; 206 participants; P value = 0.01) (Radtke, Mayer, et al., 
2004) (Appendix 3.5.3.3 - Analysis 3.3). 
Serum or plasma iron 
One study reported serum iron levels after subsequent donations (Lieden et al., 
1975). There was no evidence for a difference in serum iron levels between treatment 
groups in this study (MD 21.00 μg/dL; 95% CI -7.70 to 49.70; 17 participants; P value 
= 0.15) (Appendix 3.5.3.4 - Analysis 3.4). A further study reported results graphically 
and data extraction could not be undertaken; no significant differences between 
groups were reported (Ehn et al., 1968). 
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Total iron binding capacity (TIBC) 
Two studies reported TIBC after subsequent donations (Ehn et al., 1968; Lieden et 
al., 1975), although in the first of these, results were reported graphically and no data 
extraction could be undertaken; this study reported no significant differences between 
treatment groups. In the second study, there was no evidence for a difference in TIBC 
between treatment groups (MD -27.00 μg/dL; 95% CI -78.22 to 24.22; 17 participants; 
P value = 0.30) (Appendix 3.5.3.5 - Analysis 3.5). 
Transferrin saturation (%) 
Transferrin saturation before further donation was reported in one study (Jacobs et 
al., 1993); there was no evidence for a difference in transferrin saturation (MD 5.10%, 
95% CI -0.46 to10.66; 85 participants; P value = 0.07) (Appendix 3.5.3.6 - Analysis 
3.6). No studies reported transferrin saturation after subsequent donation(s). 
Health related quality of life and physical activity 
Physical capacity using a bicycle test was reported in one study (Ehn et al., 1968); 
however, no standard deviations were provided and therefore a formal assessment of 
these results was not possible. No significant differences between treatment groups 
were reported. 
Adverse effects 
Adverse effects were reported descriptively in two studies in which no significant 
differences in the frequency of adverse effects between treatment groups were found 
(Jacobs et al., 1993; Radtke, Mayer, et al., 2004). Specific adverse effects were not 
reported. 
Compliance 
Compliance was measured in all four studies although it was not reported in one 
study (Jacobs et al., 1993) and no study reported compliance separately per 
treatment group. Two studies reported compliance as no more than 10 tablets not 
consumed during the whole period (Ehn et al., 1968; Lieden et al., 1975), which 
occurred in all, and 75% of participants, respectively. In the third study compliance, 
defined as the ingestion of at least 90% of prescribed capsules, was poor in one third 
of male and one quarter of female participants (Radtke, Mayer, et al., 2004). 
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3.6.3.5 Iron supplementation: treatment duration A versus treatment duration B 
One study compared different durations of IS between groups (3108 mg over 28 days 
versus 444 mg over four days) (Bucher et al., 1973). 
Risk ratio of low Hb deferral (primary outcome) 
Low Hb deferral was not reported in this study. 
Hb levels, MCV, other blood indices and iron stores 
Haemoglobin (Hb) 
Post-treatment Hb levels before further donation visits were reported in this study; 
there was no evidence of a difference in Hb levels between treatment arms (MD 1.00 
g/L; 95% CI -0.93 to 2.93; 123 participants; P value = 0.31) (Appendix 3.5.4.1 - 
Analysis 4.1). 
Mean corpuscular volume (MCV) 
MCV was not reported in this study. 
Serum ferritin 
Serum ferritin was not reported in this study. 
Serum or plasma iron 
Significantly higher plasma iron levels before further donation visits were found in 
donors who received IS for the longer treatment duration of 28 days (MD 24.12 μg/dL; 
95% CI 9.36 to 38.88; 123 participants; P value = 0.001) (Appendix 3.5.4.2 - Analysis 
4.2). 
Total iron binding capacity (TIBC) 
TIBC was not reported in this study. 
Transferrin saturation (%) 
A significant difference in transferrin saturation before further donation visits between 
treatment arms was found, in favour of a longer treatment duration of IS (MD 4.81%; 
95% CI 1.93 to 7.69; 123 participants; P value = 0.001) (Appendix 3.5.4.3 - Analysis 
4.3). 
Health related quality of life and physical activity 
No measures of health-related QoL or physical activity were measured in this study. 
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Adverse effects 
Mainly minor side effects were reported in 19 - 29% of donors; this study did not 
provide results separately for each treatment group. 
Compliance 
This study reported treatment compliance only in participants who received treatment 
for the longer period of 28 days; in these participants, tablets were taken on between 
87.7% and 93.4% of total treatment days. 
 
3.6.3.6 Iron supplementation: preparation A versus preparation B 
Twelve studies compared different preparations of IS, which included a comparison of 
ferrous sulphate versus ferrous fumarate (Buzi & Siegenthaler, 1980; Lindholm et al., 
1981), ferrous sulphate versus carbonyl iron (Devasthali et al., 1991; Gordeuk, 
Brittenham, Hughes, Keating, et al., 1987; Gordeuk, Brittenham, Hughes, & Keating, 
1987), ferrous sulphate versus two or three different doses of ferric polymaltose 
(Jacobs et al., 1993; Jacobs et al., 2000), ferrous sulphate versus ferric protein 
succinylate (Landucci & Frontespezi, 1987), two different preparations of ferrous 
sulphate (Busch & Gohrbandt, 1972; Rybo & Sölvell, 1971), and two different 
preparations of ferrous fumarate, heme iron versus non-heme iron (Frykman et al., 
1994) or non-heme iron versus a lower dose of non-heme iron but supplemented with 
heme iron (Borch-Iohnsen et al., 1993). 
Three studies reported Hb levels and other blood indices graphically (Borch-Iohnsen 
et al., 1993; Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, Keating, et al., 
1987). In the first study, data were estimated from the graphs as described in the 
Methods section (Devasthali et al., 1991). However, in the remaining two studies, 
graphs were of insufficient quality to allow reliable data extraction (Borch-Iohnsen et 
al., 1993; Gordeuk, Brittenham, Hughes, Keating, et al., 1987), and in one case 
(Borch-Iohnsen et al., 1993), did not include standard deviations. 
Risk ratio of low Hb deferral (primary outcome) 
One study comparing ferrous sulphate with ferric polymaltose reported low Hb 
deferral rates; however these data were not able to be extracted due to data 
discrepancies in the study report (Jacobs et al., 1993). 
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In the comparison of ferrous sulphate with ferrous fumarate, there was no evidence 
from one study of a difference in the rate of LHD after multiple donation visits (RR 
0.51, 95% CI 0.05 to 5.60; 419 participants; P value = 0.58) (Lindholm et al., 1981) 
(Appendix 3.5.5.1 - Analysis 5.1). 
Hb levels, MCV, other blood indices and iron stores 
Haemoglobin (Hb) 
Two studies comparing ferrous sulphate and ferrous fumarate reported Hb levels 
(Buzi & Siegenthaler, 1980; Lindholm et al., 1981); there was no evidence for a 
difference in Hb levels between iron preparations either before further donation (MD 
2.00; 95% CI -2.85 to 6.85; one study; 61 participants; P value = 0.42) (Buzi & 
Siegenthaler, 1980) or after two subsequent donations (MD 1.00 g/L; 95% CI -0.79 to 
2.79; one study; 346 participants; P value = 0.27) (Lindholm et al., 1981) (Appendix 
3.5.5.2 - Analysis 5.2). 
In the comparison of ferrous sulphate with carbonyl iron, three studies reported Hb 
levels before further donation (Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, 
Keating, et al., 1987; Gordeuk, Brittenham, Hughes, & Keating, 1987), although in 
one study, data was reported graphically and could not be extracted (Gordeuk, 
Brittenham, Hughes, Keating, et al., 1987). Combined evidence from the remaining 
two trials showed no evidence for a difference in Hb levels between treatment arms 
(MD 0.76 g/L; 95% CI -2.98 to 4.49; two studies; 79 participants; P value = 0.69) 
(Appendix 3.5.6.1 - Analysis 6.1). 
Similarly, there was no evidence for a difference in Hb levels before further donation 
from three trials (Jacobs et al., 1993; Jacobs et al., 2000; Landucci & Frontespezi, 
1987) which compared ferrous sulphate with ferric compounds as iron preparations 
(MD 2.36 g/L; 95% CI -0.63 to 5.34; three studies; 261 participants; P value = 0.12) 
(Appendix 3.5.7.1 - Analysis 7.1). 
In the comparison of two preparations of ferrous fumarate (20 mg compared with 16 
mg plus 2 mg heme iron from porcine blood), there was no evidence for a difference 
in mean change from baseline Hb levels (MD -20.0 g/L; 95% CI -80.59 to 40.59; one 
study; 34 participants; P value = 0.52) (Appendix 3.5.9.1 - Analysis 9.1). In another 
study which compared two different preparations of iron fumarate, Hb levels were 
reported as median values and therefore no formal assessment of the effect size 
could be undertaken (Frykman et al., 1994). 
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Mean corpuscular volume (MCV) 
Three studies which compared ferrous sulphate with carbonyl iron reported MCV 
before further donation (Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, 
Keating, et al., 1987; Gordeuk, Brittenham, Hughes, & Keating, 1987), although 
graphical data reporting in one study precluded data extraction (Gordeuk, Brittenham, 
Hughes, Keating, et al., 1987). Combined evidence from the remaining two studies 
showed no difference in MCV after treatment (MD 0.62 fL; 95% CI - 1.49 to 2.74; two 
studies; 79 participants; P value = 0.56) (Appendix 3.5.6.2 - Analysis 6.2). 
There was also no difference in MCV before further donation in a study of ferrous 
sulphate compared with ferric protein succinylate (MD 1.00 fL; 95% CI -1.09 to 3.09; 
40 participants; P value = 0.35) (Landucci & Frontespezi, 1987) (Appendix 3.5.7.2 - 
Analysis 7.2). 
Serum ferritin 
Serum ferritin levels before further donation were reported in three studies 
(Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, Keating, et al., 1987; 
Gordeuk, Brittenham, Hughes, & Keating, 1987) which compared ferrous sulphate 
with carbonyl iron, although data from one two studies could not be extracted 
(Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, Keating, et al., 1987), and one 
study reported geometric mean values (Gordeuk, Brittenham, Hughes, & Keating, 
1987).  
There was also no evidence for a difference in serum ferritin levels before further 
donation from three studies (Jacobs et al., 1993; Jacobs et al., 2000; Landucci & 
Frontespezi, 1987) which compared ferrous sulphate with ferrous compounds (MD 
8.07 ng/mL; 95% CI -1.50 to 17.63; three studies; 261 participants; P value = 0.10) 
(Appendix 3.5.7.3 - Analysis 7.3). 
In the comparison of two preparations of ferrous fumarate (with and without heme 
iron), there was no evidence for a difference in mean change from baseline serum 
ferritin levels (MD -4.00 ng/mL; 95% CI -12.44 to 4.44; one study; 34 participants; P 
value = 0.35) (Appendix 3.5.9.2 - Analysis 9.2). Another study which compared 
different preparations of iron fumarate (Frykman et al., 1994) reported serum ferritin 
as median levels and therefore no formal assessment of the effect size could be 
undertaken (Frykman et al., 1994). 
Chapter 3 – Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or 
anaemia in blood donors 
  
   
134 
 
Serum or plasma iron 
In two studies which compared serum iron levels between ferrous sulphate and 
ferrous fumarate preparations, there was no evidence for a difference in serum iron 
levels between treatment arms either before further donation (MD 7.00 μg/dL; 95% CI 
-7.14 to 21.14; one study; 61 participants; P value = 0.33) (Buzi & Siegenthaler, 
1980), or after subsequent donations (MD 0.00 μg/dL; 95% CI -7.06 to 7.06; one 
study; 346 participants; P value = 1.00) (Lindholm et al., 1981) (Appendix 3.5.5.3 - 
Analysis 5.3). 
Combined evidence from two studies (Devasthali et al., 1991; Gordeuk, Brittenham, 
Hughes, & Keating, 1987) which compared ferrous sulphate and carbonyl iron, also 
showed no difference in serum iron levels before further donation (MD -1.76 μg/dL; 
95% CI -26.49 to 22.97; two studies; 79 participants; P value = 0.89) (Appendix 
3.5.6.3 - Analysis 6.3). In a third study, graphical data were of insufficient quality to 
allow extraction (Gordeuk, Brittenham, Hughes, Keating, et al., 1987). 
Similarly, there was no evidence for a difference in serum iron levels between ferrous 
sulphate and ferric compound iron preparations before further donations (Jacobs et 
al., 2000; Landucci & Frontespezi, 1987) (MD 0.88; 95% CI -3.25 to 5.00; two studies; 
131 participants; P value = 0.68) (Appendix 3.5.7.4 - Analysis 7.4). 
Total iron binding capacity (TIBC) 
There was no evidence for a difference in TIBC either before further donation (MD 
0.00 μg/dL; 95% CI -3.76 to 3.76; one study; 61 participants; P value = 1.00) (Buzi & 
Siegenthaler, 1980), or after subsequent donations (MD 5.59 μg/dL; 95% CI -2.65 to 
13.83; one study; 346 participants; P value = 0.18) (Lindholm et al., 1981) (Appendix 
3.5.5.4 - Analysis 5.4), in studies which compared ferrous sulphate with ferrous 
fumarate. 
There was also no evidence from two studies of a difference in TIBC before further 
donation between ferrous sulphate and carbonyl iron (MD -9.75 μg/dL; 95% CI -52.65 
to 33.16; two studies; 79 participants; P value = 0.66) (Devasthali et al., 1991; 
Gordeuk, Brittenham, Hughes, & Keating, 1987) (Appendix 3.5.6.4 - Analysis 6.4). 
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In the comparison of two preparations of ferrous fumarate (with and without heme 
iron), there was no evidence for a difference in mean change from baseline TIBC 
levels (MD 0.60 μg/dL; 95% CI -2.77 to 3.97; one study; 34 participants; P value = 
0.73) (Appendix 3.5.9.3 - Analysis 9.3). 
Transferrin saturation (%) 
Three studies which compared ferrous sulphate with carbonyl iron reported transferrin 
saturation (Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, Keating, et al., 
1987; Gordeuk, Brittenham, Hughes, & Keating, 1987), although two of these 
reported data graphically and the quality of the graphs in the latter study precluded 
data extraction (Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, Keating, et al., 
1987). Meta-analysis of the remaining two studies showed no evidence for a 
difference in transferrin saturation between treatment arms (MD 2.45%; 95% CI -3.37 
to 8.26; two studies; 79 studies; P value = 0.41) (Appendix 3.5.6.5 - Analysis 6.5). 
However, combined evidence from two studies, which compared ferrous sulphate 
with ferric polymaltose, showed significantly higher levels of transferrin saturation 
before further donation in favour of ferrous sulphate (MD 5.33%; 95% CI 1.61 to 9.05; 
two studies; 221 participants; P value = 0.005), demonstrating a beneficial effect of 
ferrous sulphate over ferric polymaltose (Jacobs et al., 1993; Jacobs et al., 2000) 
(Appendix 3.5.7.5 - Analysis 7.5). 
Health related quality of life and physical activity 
No measures of health-related quality of life or physical activity were measured in 
studies which compared different iron preparations. 
Adverse effects 
In the comparison of ferrous sulphate with ferrous fumarate, one study showed a 
significant increase in overall adverse effects associated with ferrous sulphate (RR 
1.40; 95% CI 1.04 to 1.88; 131 participants; P value = 0.03) (Lindholm et al., 1981)  
(Appendix 3.5.5.5 - Analysis 5.5). However, there were no significant differences 
observed in individual studies (Buzi & Siegenthaler, 1980; Lindholm et al., 1981), or 
from meta-analysis in the frequencies of specific adverse effects, which included 
constipation, diarrhoea, nausea/vomiting and abdominal pain and/or cramps. 
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There was no evidence for a difference in the overall frequency of adverse effects 
between ferrous sulphate and carbonyl iron from a meta-analysis of two studies 
(Devasthali et al., 1991; Gordeuk, Brittenham, Hughes, & Keating, 1987) (RR 0.89; 
95% CI 0.75 to 1.06; two studies; 96 participants; P value = 0.18) (Appendix 3.5.6.6 - 
Analysis 6.6), or in the frequency of specific adverse effects which included 
constipation, diarrhoea, nausea/vomiting, abdominal pain and/or cramps, 
gastric/epigastric pain and headache. However, carbonyl iron was associated with an 
increased risk of taste disturbances compared with ferrous sulphate (RR 0.43; 95% 
CI 0.25 to 0.74; two studies; 96 participants; P value = 0.002) (Appendix 3.5.6.6 - 
Analysis 6.6). 
Adverse effects were not reported in any of the studies which compared ferrous 
sulphate with ferric compound iron preparations. 
In the comparison of heme iron with non-heme iron, one study reported a higher 
frequency of cumulative adverse effects for non-heme iron than heme iron (25% 
versus 14%) (Frykman et al., 1994), although the absence of actual numbers of 
participants prevented a statistical evaluation of this difference. In this study, 
participants who received non-heme iron also experienced a higher rate of gastric 
pain (19% versus 6%), obstipation (35% vs. 14%) and diarrhoea (37% vs. 26%). 
In one study which compared EryferⓇ with an alternative ferrous sulphate preparation 
(Busch & Gohrbandt, 1972), a lower frequency of cumulative adverse effects was 
observed in participants who received EryferⓇ than those who received the alternative 
preparation in both the morning (11.2% versus 4.7%) and the evening (10.0% versus 
2.9%), although actual numbers were not reported and therefore no formal statistical 
assessment of these differences could be undertaken. In this study, adverse effects 
were predominantly gastrointestinal complaints which included loss of appetite, 
indigestion and diarrhoea. In a second study which compared ferrous sulphate with 
an alternative sustained release iron preparation (Rybo & Sölvell, 1971), there were 
no significant differences in the frequency of cumulative adverse effects (RR 1.14; 
95% CI 0.91 to 1.43; 781 participants; P value = 0.26) or specific adverse effects 
including constipation, diarrhoea, nausea/vomiting and epigastric pain (Appendix 
3.5.8.1 - Analysis 8.1). 
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Compliance 
In the comparison of ferrous sulphate with ferrous fumarate, there was no difference 
in the number of participants who were 100% compliant over the treatment period 
(77.5% vs. 82.5% respectively) (Lindholm et al., 1981). 
In a meta-analysis of two studies comparing ferrous sulphate with carbonyl iron 
(Gordeuk, Brittenham, Hughes, Keating, et al., 1987; Gordeuk, Brittenham, Hughes, 
& Keating, 1987), there was no difference in compliance between treatment arms (RR 
0.95; 95% CI 0.84 to 1.09; two studies; 95 participants; P value = 0.48) (Appendix 
3.5.6.7 - Analysis 6.7). A third study reported full compliance in both treatment arms 
(Devasthali et al., 1991). 
Compliance was reported descriptively in two studies (Jacobs et al., 1993; Jacobs et 
al., 2000) which compared ferrous sulphate with ferric compound iron preparations; 
the first of these reported only that some patients stopped treatment due to adverse 
effects (Jacobs et al., 1993). In the second study, tolerance was reported to be "much 
better with the complex exceeding 80% but this was only 60% with the ferrous 
sulphate" (Jacobs et al., 2000). 
The number of study participants who discontinued treatment was similar for ferrous 
sulphate and an alternative sustained release iron preparation (85.1% versus 86.6% 
respectively) (Rybo & Sölvell, 1971). However, in the study of EryferⓇ compared with 
an alternative ferrous sulphate preparation (Busch & Gohrbandt, 1972), compliance 
was significantly higher in participants who received EryferⓇ than in those who 
received the alternative preparation (RR 1.80; 95% CI 1.24 to 2.61; one study; 89 
participants; P value = 0.002) (Appendix 3.5.8.2 - Analysis 8.2). Meta-analysis was 
not carried out due to the differences in alternative iron preparation between the two 
studies. 
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3.7 Discussion 
Iron deficiency is a significant cause of deferral in people wishing to donate blood. 
Donation intervals are set to minimise iron deficiency in repeat blood donors and all 
donors are screened pre-donation at each repeat visit for Hb levels. Deferral of 
donation for a period of six months through failure to pass the Hb threshold is 
associated with failure of donors to return to give blood. Avoiding iron deficiency is 
therefore essential not only to minimise symptoms and morbidity in donors and hence 
increase retention of donors in the long term, but also to maintain the efficiency of a 
donor session where deferral is costly and disruptive. IS for blood donors has been 
considered, and in some settings, has been implemented for certain groups of "at 
risk" donors. Rigorous evidence for the cost and benefits of IS is essential to guide 
policy. 
3.7.1 Summary of main results 
3.7.1.1 The relative and absolute benefits of iron supplementation 
Thirty RCTs met the eligibility criteria, including comparisons of IS with placebo as 
well as different methods of administration, doses, duration and preparations of iron 
supplementation. Meta-analysis of four studies showed a significantly reduced risk of 
deferral due to low Hb in donors who received IS compared with donors who received 
no IS, both at the first donation visit (RR 0.34; 95% CI 0.21 to 0.55; four studies; 1194 
participants; P value < 0.0001) and at subsequent donations (RR 0.25; 95% CI 0.15 
to 0.41; three studies; 793 participants; P value < 0.00001). There is also a clear 
benefit of IS on markers of iron stores but the effect of iron on Hb level, although 
significant, is low. Detailed comparison of the effect of IS on iron stores is hampered 
by different assay methods and lack of standardisation. 
Based on the data from the four studies, the absolute risk of LHD at the first donation 
visit after receiving IS is 3.6% in iron-supplemented donors compared with 10.5% in 
controls. The corresponding absolute risks of deferral after multiple donation visits are 
5.0% and 19.9% respectively, based on the data from three studies.  
Evidence from a single study of parenteral versus oral iron suggests that parenteral 
iron is significantly more effective than oral iron in increasing serum ferritin levels. 
There may also be fewer minor side-effects in donors given parenteral compared with 
oral iron, but widespread use of parenteral iron would not be practical in this 
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population. However, this review has identified four ongoing randomised trials and 
one study awaiting classification which include iron administered intravenously to 
blood donors. Nevertheless, it seems unlikely that parenteral iron would be accepted 
on a mass scale, particularly given recent evidence from a systematic review that use 
of parenteral iron is associated with an increased risk of infection (Litton, Xiao, & Ho, 
2013). 
3.7.1.2 Side effects of iron supplementation  
The benefits of IS with tablets are substantial but the rate of significant side effects is 
high which is likely to limit acceptability and compliance. Adverse effects were 
widespread and were more frequent in donors who received IS than those who did 
not (RR 1.60; 95% CI 1.23 to 2.07; four studies; 1748 participants; P value = 0.0005), 
with a significantly increased risk of gastrointestinal upset and taste disturbances. 
Due to the adverse effects associated with IS, treatment compliance is an issue. The 
absolute risk of adverse effects is 29% in iron supplemented donors compared with 
an absolute risk of 17% in controls. The impact of these side effects on compliance is 
uncertain. Although seven studies identified reasons for non-compliance or 
discontinuation of treatment associated with adverse effects (Blot et al., 1980; Busch 
& Gohrbandt, 1972; Cable et al., 1988; Gordeuk et al., 1990; Gordeuk, Brittenham, 
Hughes, & Keating, 1987; Rybo & Sölvell, 1971; Waldvogel et al., 2012), only two 
trials reported compliance rates separately for both treatment groups (Gordeuk et al., 
1990; Mirrezaie et al., 2008) and taken together, showed no evidence for a difference 
in compliance rates between treatment groups (RR 0.76; 95% CI 0.51 to 1.15; two 
studies; 146 participants; P value = 0.19). Compliance (as measured by ingestion of 
over 90% of tablets) was poorly documented in many of the studies but variable when 
reported (Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004). There are 
unlikely to be significant cost issues associated with iron supplements but compliance 
may be a more important issue if IS is targeted at large numbers of donors in routine 
operational practice. 
The long term effects of IS without measurement of iron stores are unknown and in 
other contexts, iron given indiscriminately has had deleterious consequences in some 
populations (Oppenheimer, 2001; Sazawal et al., 2006). These considerations are 
likely to preclude widespread use of IS by tablets. 
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3.7.2 Overall completeness and applicability of evidence 
There are very few studies of the effects of IS on physical capacity and quality of life 
in blood donors. 
Differences between studies in terms of type of participants, the preparation, dose 
and duration of treatment and the time at which outcomes were measured as well as 
inter-donation interval inevitably limited investigation of the effect of IS on physical 
capacity and quality of life. There is very limited evidence in non-blood donors that IS 
of iron deficient non-anaemic adults improves some aspects of cognitive function 
(Falkingham et al., 2010). Further evidence of the effect of iron stores on cognitive 
function and physical activity or capacity in donors from adequately powered RCTs 
would be crucial to inform future policies.  
It is possible that effects of IS on physical function may take place quickly and be 
found in trials of short term IS. However, immediately after donation these effects are 
confounded by fluctuations in Hb. Furthermore, a reduction in physical or mental 
function may only be seen in those who are iron deficient over a longer period of time. 
While power calculations are difficult without more preliminary data, studies may 
indeed need larger sample sizes and longer follow up periods to see the effects of IS 
on wider measures of physical and mental function.  
One potentially very important question for further study is whether low and/or 
intermittent IS may have a similar effect in reducing anaemia and low Hb deferral to a 
higher dose or continuous IS but with reduced side effects. Only one study directly 
addressed different durations of IS in donors and compared IS of 3108 mg over 28 
days versus 444 mg over four days (Bucher et al., 1973). Unfortunately, deferral due 
to low Hb was not reported and adverse events were not discussed by study group. 
Our review can therefore only search for differences in outcomes among different 
trials of IS where iron was given for different durations.  
The combined evidence from all four studies where deferral rates were reported 
showed a significantly reduced risk of LHD at the first donation visit after treatment in 
donors who received IS (RR 0.34; 95% CI 0.21 to 0.55; four studies; 1194 
participants; P value < 0.0001) and this LHD risk reduction was maintained after 
multiple and/or cumulative donation visits with no evidence of heterogeneity between 
studies (I2 = 0%; 95% CI 0% to 79.3%) (Gordeuk et al., 1990; Maghsudlu et al., 2008; 
Radtke, Mayer, et al., 2004; Radtke, Tegtmeier, et al., 2004). Furthermore, there were 
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no significant differences between male and female donors in LHD rates at first 
donation, after multiple donation visits or over cumulative donation visits (Analysis 
10.1; Analysis 10.2; Analysis 10.3). Looking at the effect of different iron dosing 
schedules on iron stores, meta-analysis of two studies which reported serum ferritin 
levels at follow-up before further donation showed no evidence for a difference in 
serum ferritin between dosage groups (Jacobs et al., 1993; Radtke, Mayer, et al., 
2004). However, in one study which reported serum ferritin levels after two (female) 
or three (male) subsequent donations, there was a significant difference in serum 
ferritin in favour of a higher dose (20 mg twice daily compared with 10 mg twice daily) 
of IS (Radtke, Mayer, et al., 2004)(Analysis 3.3). These differences did not translate 
into significant difference in deferral rates.  
The question of the effect of duration or intensity of IS and outcome has been 
addressed in RCTs of IS in pregnancy and a recent Cochrane systematic review of 
intermittent versus daily IS concluded that there was a reduced incidence of mild to 
moderate anaemia in women taking daily, compared to intermittent, iron supplements 
but no differences in the incidence of adverse outcomes of the pregnancy or in the 
neonate could be ascertained. Nevertheless, there was a significantly reduced 
incidence of side effects in those women receiving intermittent compared to daily IS 
(RR 0.57, 95% CI 0.34 – 0.87) (Peña-Rosas, De-Regil, Dowswell, & Viteri, 2012).  
One physiological explanation for the broadly similar effects of lower versus higher 
doses of iron is that absorption of iron is greater when iron stores are low and the 
proportion of iron absorbed is reduced as iron stores rise, reducing the benefit and 
possibly increasing the side effects as the dose and duration of IS is increased. 
Examining the benefits and adverse events of lower versus higher dose regimes of IS 
would quite clearly be a priority for further work.  
No trials were reported from lower-middle-income or low-income countries. In many 
parts of the world recruitment of donors and blood safety has been the main focus of 
concern and research while low deferral rates in repeat donors have been less of a 
priority. Nevertheless, in many parts of the world iron deficiency is very common (S. 
S. Lim et al., 2012; J. L. Miller, 2013) and high deferral rates in first time donors who 
fail to meet the Hb threshold are certainly observed. Iron replacement in areas where 
malaria and other protozoa or community acquired bacterial infections are prevalent 
may predispose to infection (Drakesmith & Prentice, 2012) and it is likely that the 
question of iron replacement in donors will become an important topic of research in 
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middle-income and low-income countries as the donor base increases and a higher 
proportion of donors are repeat donors. The safety of IS with regard to infection will 
require careful scrutiny in well-designed trials, although it may be more 
straightforward to predict the likelihood of deferral to stratify donation intervals to 
reduce deferral in groups of donors at greater risk of iron deficiency.  
This review highlights the limited amount of data available for IS in the context of 
blood donation. The number of studies is limited for each comparison and they 
usually involve a small number of participants. Small study effects (bias) should be 
considered when interpreting the results. The majority of the data are from studies 
comparing IS versus placebo, but even here, numbers are small. For example, only a 
few events are recorded in each study when looking at the effect of IS on LHD. 
3.7.3 Quality of the evidence 
Thirty RCTs including a total of 4704 participants met the eligibility criteria, including 
19 comparisons of IS and placebo or control, one comparison of oral and parenteral 
IS, four comparisons of different doses of iron supplementation, one comparison of 
different treatment durations of IS, and 12 comparisons of different IS preparations. 
However, the number of studies included in meta-analyses was limited by differences 
in methods of outcome reporting, treatment duration and length of follow-up between 
studies. The reduction in LHD shows a large effect, but due to the risk of bias in the 
included studies the quality of evidence has been downgraded to moderate (see 
Summary of findings of the main characteristics - Table 3.1). 
Heterogeneity confidence intervals for I2 were generally wide due to the low number 
of studies included in each analysis. Visual inspection of forest plots revealed no 
obvious heterogeneity due to date of publication or study size. 
3.7.4 Potential biases in the review process 
The risk of bias was high or unclear in many studies, probably due to poor methods of 
reporting in studies published before 1990 including five that were published before 
1980. Precise definition of the quality of studies is difficult as judgement is based on 
limited evidence but there is no definitive evidence of substantial bias nor of 
systematic error through poor quality studies. 
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3.7.5 Agreements and disagreements with other studies or reviews 
The authors are unaware of any reviews in this area for comparison with the findings 
from other analyses. 
3.8 Author's conclusions 
3.8.1 Implications for practice 
Overall, IS has a substantial effect on reducing the LHD risk but a significant 
proportion of donors taking iron suffer side effects. Blood services seeking a reduction 
in the levels of LHD would wish to consider any reasonable methods to prevent iron 
deficiency, weighing cost against benefits and feasibility. With this in mind, possible 
courses for future action by blood services would be the targeted use of 
supplementation at groups or individuals at greater risk of iron deficiency, stratified or 
personalised donation intervals and/or more effective dietary advice.  
3.8.2 Implications for research 
The effect of dose and preparation of iron on both efficacy and the frequency of side 
effects is unclear from the existing studies. Crucially, the studies do not allow any 
definition of the relationship between dose and duration of IS and benefits or side-
effects. These questions would have to be explored, in large-scale RCTs or pilot 
studies, before widespread use of IS in donors could be considered. Potential 
differences in methods used to assess biomarkers could be important when 
interpreting the absolute change in biomarker values (such as ferritin). There is very 
limited evidence that dietary advice to improve iron store is efficacious and there are 
no trials of dietary advice in donors. Further work in this area should include RCTs of 
a range of interventions to determine efficacy precisely. Finally, there are few existing 
randomised trials of the effects of IS on the physical capacity and quality of life of 
blood donors; future studies should include an assessment of these measures in iron 
supplemented donors. 
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3.13  Differences between protocol and review 
The comparison of Iron Supplementation: schedule A versus schedule B has been 
redefined as a comparison of treatment duration A versus treatment duration B for 
clarity and to avoid any ambiguity in definition. In addition, the comparison of IS 
manufacturer A versus manufacturer B has been renamed as preparation A versus 
iron preparation B to more accurately describe different iron compounds. 
There are some differences in outcomes between the protocol and the review.  
In the protocol for this review, the outcomes "Number of blood donors with a change 
in iron stores" and "Number of donors with a change in Hb levels, mean cell volume 
(MCV) and other blood indices before donations" are vague, since it is unclear how "a 
change" in these measures should be defined. Any level of change in these measures 
may be of clinical interest. Hence, these outcomes have been replaced with a new 
single outcome which now includes iron stores as well as all other measures before 
donation as follows: 
"Mean levels of Hb, MCV, other blood indices and iron stores before further 
donations". 
Also, the outcome "Rate of change in Hb levels, MCV, other blood indices and iron 
stores between donations" included in the protocol for this review does not take into 
account the likely scenario of different numbers of donations at different timepoints 
between studies, and between demographic groups within studies (e.g. males versus 
females). Therefore this outcome has been redefined as measured after subsequent 
donations as follows: 
"Mean levels of Hb, MCV, other blood indices and iron stores after subsequent 
donations". 
The outcome "Total number of successful donations (per donor and per intervention)" 
defined in the protocol has been removed, since this measure is directly correlated 
with the primary outcome "Deferral rates of blood donors (number of prospective 
blood donors who are at least temporarily rejected from blood donation) due to low 
Hb and is therefore deemed uninformative. 
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Finally, treatment compliance is an important issue in oral IS and this has been added 
as a new outcome. 
It had been intended to analyse continuous outcomes as mean change from baseline; 
however, few studies reported continuous outcomes as mean change from baseline 
values and therefore endpoint (follow-up) values have been compared for all 
comparisons. 
Additionally, it was intended to contact study authors in order to obtain information 
that was missing or unclear in the published report; however, this was not done due 
to the time that had elapsed since publication of the majority of studies. 
Sensitivity analyses based on allocation concealment were not performed due to the 
high number of studies deemed to have a high risk of bias associated with allocation 
concealment. It was also the intention to carry out subgroup analyses by donation 
history, menopausal status, Hb threshold for donation and trial setting, but this was 
not possible due to a paucity of studies reporting these factors. These will be 
addressed in future updates of this review if sufficient data become available.
Chapter 4 – Dissemination and impact analysis 
   
147 
 
 
 
Chapter 4 – Dissemination and impact analysis 
 
Chapters 2 and 3 described the two related systematic reviews regarding factors 
leading to blood donors falling below low Hb thresholds and how blood collection 
organisations around the world have attempted to improve donor health and the 
numbers of successful donation attempts by providing iron supplements.  
This chapter describes the dissemination strategy and impact assessment.  
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4.1 Introduction to assessment of dissemination and impact 
4.1.1    Dissemination 
Dissemination (from Latin disseminare “scattering seeds“) is a key step in the 
transition from research to practice (knowledge translation) (P. Wilson, Petticrew, 
Calnan, & Nazareth, 2010a).  If the primary purpose of research is to build a 
knowledge base, confirm or refute theories, test the effectiveness of practical 
approaches, and ultimately benefit patients, then the dissemination of findings is an 
integral component of the research process. In research, we need to be concerned 
with conveying our findings to other researchers, to practitioners, policymakers, and 
to the public. Knowledge in isolation is futile, especially in respect to evidence-based 
practice. 
In a recent survey of principal investigators (P. Wilson, Petticrew, Calnan, & 
Nazareth, 2010b) it was found that, although researchers recognised the importance 
of dissemination (93% rating it as important or very important), only 9% actively 
planned their strategy for dissemination (although three quarters said they would wish 
to). 
The Becker model (Sarli, Dubinsky, & Holmes, 2010) offers a number of strategies for 
improving the impact of one's research, and that of Pardoe (2012) offers a guide for 
dissemination . Practically, it may well be most prudent to devise the dissemination 
strategy with respect to the criteria against which it will be evaluated, such as that of 
the Research Councils UK (Research Councils UK, n.d.)  
However, dissemination is not without its pitfalls. Song et al (2010) concluded that the 
process is likely to be biased, even for systematic reviews such as these (Song et al., 
2010). Studies that report positive effects were more likely to be published and so 
more likely to be included in a systematic review. These biases can be minimised by 
systematically searching for, and including, difficult to obtain studies such as grey 
literature (informally published material) for which traditional search methods prove 
ineffective) and foreign language articles, or performing statistical sensitivity analyses. 
Indeed, one of the reviewers of the Iron Supplementation Cochrane review 
specifically asked whether foreign language papers had been included. Of the 
included studies, seven papers from six separate studies first required translation. 
Additionally, several papers were not included after a translation had been reviewed. 
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4.1.1.1 Models for Knowledge Translation 
There are a number of frameworks for transferring knowledge, such as the Becker 
Model previously mentioned and that of Grimshaw, Eccles, Lavis, Hill, and Squires 
(2012). The latter suggest five questions: 
1. "What should be transferred?" 
Current systematic reviews of good quality are needed to provide evidence to 
decision-makers so they produce clinical guidelines, policy briefs, patient decision 
aids and effective summaries. They should include not only what works and for 
whom, but why and at what cost. 
2. "To whom should research knowledge be transferred?" 
It should reach as many different target audiences to whom that knowledge may be 
relevant. 
3. "By whom should research knowledge be transferred?" 
Different messengers may be needed dependent on the nature of the message and 
the target audience. 
4. "How should research knowledge be transferred?" 
Grimshaw et al. (2012) state that little evidence exists as to the efficacy of different 
dissemination strategies. It is suggested that the message is more likely to be 
effectively transferred if there is an assessment made of the possible problems and 
promoters for any particular route. 
5. "With what effect should research knowledge be transferred?" 
How to measure the efficacy of a dissemination strategy remains subject to 
considerable debate. The outcome should determined by the intended audience. It 
should be read, find its way into policy documents and guidelines and so change 
practise. Knowledge is of little benefit even if published in an esteemed journal with a 
high impact factor if the policy makers for which it is intended do not read it and utilise 
its information.  
This last question is concerned with the impact of the research and is discussed in 
the next section. 
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4.1.2 Impact assessment of output 
Impact is defined by the Research Councils UK (RCUK) as "the demonstrable 
contribution that excellent research makes to society and the economy" (Research 
Councils UK, n.d.). This is not a simple task; the impacts from research can take 
many forms, become apparent at different times within, and even after, the research 
cycle and be promoted through different means. RCUK asks the central questions of 
who will benefit from the research, and how. 
4.1.2.1 Research Output 
With the ever growing body of scientific information the amount of information is so 
large that its physical storage is no longer possible. Additionally, financial constraints 
limit the amount resource that can be dedicated to the purchase of journals.  
Individuals and Institutions look to measures such as the Impact Factor (IF) to help 
decide which journals have sufficient merit to warrant purchase (Dong, Loh, & 
Mondry, 2005). The effects of a study - its impact - can be immediate and short-term 
as well broader and longer-term, either positive or negative, expected or unforeseen. 
What is important when assessing impact is the value to the recipients of the 
information contained. There are formal methods to define impact (see below), but 
less formal feedback can be gained from the stakeholders. 
Citation Index 
Citation indices, such as the Web of Science, Scopus and Google Scholar, are useful 
to see who is citing your work and in what way. They depend on the links between 
similar research items leading to matching or related scientific literature. In this way, 
an article's importance can be determined by cross-reference to all the articles citing 
it. Originally citation indices were used to retrieve related articles but increasingly they 
are employed in bibliometrics - a method to quantitate academic literature for 
research evaluation. 
Journal Impact Factor (JIF) 
As previously mentioned, it is difficult to objectively measure the quality of a journal 
and the accessibility of the JIF has contributed to its popularity. However, it must be 
borne in mind the JIF is prone to bias from a number of directions. These include the 
language of both the database and the articles it contains, how the citations are 
collected, the algorithm used to calculate the JIF, on-line availability of the articles, 
publication delay from acceptance, etc. (Royle, Kandala, Barnard, & Waugh, 2013).  
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4.1.3.2 Other indicators of impact 
There are other performance indicators of the quality of research outputs beyond 
publication metrics. Some of these (adapted from the Becker Model) are listed below:  
Clinical Implementation - when research findings are adopted into clinical practice 
within the community, possibly through the implementation of guidelines (see below). 
Community benefit - where an improvement in the health or well-being of the 
community results from the research. 
Legislation and policy - when the research output forms the basis for new laws, 
guidelines, standards or policy. 
Economic benefit - cost improvements are derived from the research.  
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4.2 Planning the dissemination strategy and impact evaluation 
One needs to consider the intended impact of the research when adopting a 
dissemination strategy so that the evidence can be used by the stakeholders to effect 
change. For the Iron and Blood donors review programme there were a number of 
different stakeholders. In the first instance, there were the policy makers in the Donor 
Services Directorate of NHSBT, whose interest was the factors that might predispose 
donors to defer and whether treating them with iron supplements would be a safe and 
effective means to prevent deferral. Researchers who will, or are likely to, design and 
implement RCTs investigating different donation rates in blood donors will know of 
what contributing factors to be aware when analysing their findings, or which 
formulation of iron and what dosing regimen might be most beneficial when providing 
IS to blood donors to prevent low LHD. 
Additionally, the information generated would be of use to Blood Services of other 
countries who may be looking at similar issues. The findings could also improve the 
treatment of the chronically anaemic patient. 
Finally, and more importantly, the blood donors themselves should be able to access 
the information that contributes to their health and wellbeing. By providing them with 
the data in an accessible format they can make informed decisions as to what they 
might do to improve their chance of donation (e.g. dietary changes), what personal 
factors may have contributed to a failed donation attempt and why they have been 
offered assistance to remedy their health should they have failed to meet the lower 
Hb thresholds. 
However, remaining with the five questions from the Grimshaw Model: 
 
1. "What should be transferred?"  
The principal intention for the systematic reviews was to provide good quality 
evidence to inform the design of large-scale RCTs. However, progress reports need 
to be supplied to the commissioners of the research (National Institute for Health 
Research) and fellow researchers. Generalisable findings should be passed on to the 
public. 
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2. "To whom should research knowledge be transferred?" 
Not only should it reach those researchers involved in the RCTs but also the NIHR. 
Colleagues in other Blood Services should be made aware of the findings, not only to 
help inform their decision-making but to avoid unnecessary duplication of effort. It 
should also go to the public in general and the donors in particular so they may 
understand the reasoning behind the trials in which they are being asked to 
participate and why the results of those trials may alter the way in which they are 
being asked to donate.  
3. "By whom should research knowledge be transferred?" 
Researcher to researcher. Principal Investigators have the duty to pass on the 
information to the commissioners, but they are reliant on the findings being handed to 
them by their researchers. It may be that someone of a higher academic standing can 
provide the necessary gravitas to approach policy makers to enable change in policy. 
4. "How should research knowledge be transferred?" 
A problem inherent with all forms of knowledge translation is ‘will the information 
reach the target audience - will they attend, read, listen to the messages you are 
trying to convey’?. 
5. "With what effect should research knowledge be transferred?", i.e. assessing 
the impact 
Were the reviews published? 
Did they reach their target audience?  
Were they in an appropriate format and of sufficient clarity for the target audience? 
Were they well received? 
Will they change practice for the better? 
These will be presented in the next section and discussed. 
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Table 4.1 Comparison of dissemination methods 
Method Target 
audience 
Why? Possible problems Promoters 
Discussion Policy makers   
Fellow experts 
Ensure correct information and 
requirements before start of project. 
 
Is the information relevant and 
recorded. 
Attendees from appropriate 
disciplines. Extensive minutes. 
Reports Commissioners As above, and ensure the political 
will to convert into guidance. 
Has sufficient progress been 
made. 
Extensive experience in progress 
reports. 
Posters Researchers Inform researchers gap in evidence 
Inform researchers about possible 
subgroups  
Can sufficient detail be 
imparted. 
Pre-presentation abstracts. 
Presentation 
 
Policy makers  
Researchers  
As above. 
 
Inexperience with public 
speaking. 
Pre-presentation abstracts 
Presentation skills training. 
Conferences 
 
Policy makers   
Researchers  
As above 
 
Attendance by presenter/ 
international audience. 
Pre-presentation abstracts. 
Papers Researchers Inform researchers of the quality of 
available evidence. 
Will the research be published. 
Is the journal too specialised. 
Work with experts in SR. Target 
publication to audience. 
Web-based Blood donors 
General public 
Improve awareness by public 
Encourage new donors. 
Public may not have access to 
internet. Lack of web-based 
media experience. 
Work with Web experts to maximise 
uptake. 
Donor 
publication 
Blood donors Improve health of the donor 
Improve donation success. 
Will it be of sufficient 
comprehensibility. 
Work with publishers skilled in plain 
English. 
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4.3 Evaluation of dissemination and impact 
Table 4.2: Timeline of dissemination. 
Date Title Scope Location Participants 
20 October 
2008 
Donor Iron 
Project 
Discussion. Support donor health in 
general and problems of anaemia and 
iron deficiency in particular. 
Filton, Bristol NHSBT Blood Donor Management 
8 October 
2010 
First meeting of 
Systematic 
Review (SR) 
team 
Discussion. Define the scope of the 
SR and propose project plan. Discuss 
search strategies. 
NHSBT, Oxford Graham Smith 
Dave Roberts 
Sheila Fisher 
Susan Brunskill 
Carolyn Doree 
23 November 
2010 
Iron Workshop Presentation. “Aim 1: Iron and Blood 
Donors” as part of “Erythropoiesis in 
Health and Disease” Programme.  
Association of Anaesthetists, 
London 
NHSBT Blood 
Donor 
Management 
Dave Roberts 
 
NHSBT R&D 
Institute of Public 
Health 
Neurologist 
27 July 2011 Iron and Blood 
Donors Workshop 
Presentation. Feed initial findings into 
proposed RCT and influence its design 
(INTERVAL study). 
NHSBT, Oxford Graham Smith 
Dave Roberts 
NHSBT R&D, 
Cambridge 
Sheila Fisher 
Dept of Public 
Health 
 
19-20 
September 
2011 
NHSBT Annual 
R&D conference 
Poster. Sharing progress of different 
NHSBT R&D strands. Presented poster 
on low Hb SR. 
Robinson College, Cambridge Graham Smith 
Dave Roberts 
NHSBT R&D 
 
12 April 2012 Programme D 
Review Meeting  
Presentation. Presented oral update of 
low Hb SR. 
Lady Margaret Hall, Oxford Graham Smith 
Dave Roberts 
 
Sheila Fisher 
NHSBT R&D 
21 December 
2012 
Transfusion Paper. Rejection of low Hb SR due to 
fact that it presented no new work. 
 Graham Smith 
Dave Roberts 
 
Sheila Fisher 
Carolyn Doree 
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Date Title Scope Location Participants 
10 January 
2013 
Programme D 
Review Meeting 
Presentation. Presented oral update of 
low Hb SR and progress with iron 
supplementation SR. 
St Catherine’s College, Oxford Graham Smith 
Dave Roberts 
 
Sheila Fisher 
NHSBT R&D 
2 July 2013 Programme D 
Review Meeting 
Presentation. Presented oral update of 
iron supplementation SR. 
SS Great Britain, Bristol Graham Smith 
Dave Roberts 
 
Sheila Fisher 
NHSBT R&D 
5 July 2013 
 
October 2013 
Transfusion 
Medicine 
Paper. Low Hb SR accepted on 23 
April 2013. 
 
e-Published 
 
Vol. 23 (5)  
pp 309 – 320  
Graham Smith 
Dave Roberts 
 
Sheila Fisher 
Carolyn Doree 
5 December 
2013 
Cochrane 
Collaboration 
Paper. Iron supplementation SR 
submitted. 
 Graham Smith 
Dave Roberts 
Sheila Fisher  
 
Carolyn Doree 
Emanuele Di 
Angelantonio 
28 January 
2014 
Cochrane 
Collaboration 
Web-based. Volunteered to collaborate 
with Cochrane Wikipaedian in 
Residence. 
 Graham Smith 
 
 
3 July 2014 Cochrane 
Collaboration 
Paper. Iron supplementation SR 
published. 
DOI: 
10.1002/14651858.CD009532.pub2 
Graham Smith 
Dave Roberts 
Sheila Fisher  
 
Carolyn Doree 
Emanuele Di 
Angelantonio 
24-26 
September 
2014 
British Blood 
Transfusion 
Society 
Conference. 24.09.14 All day meeting 
on iron therapy. 
Harrogate, Yorkshire Graham Smith 
Dave Roberts 
 
 
Table 4.2: Timeline of dissemination (continued) 
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4.3.1 Posters - See Appendix 4.1 
4.3.1.1  NHSBT Annual R&D conference   
19-20 September 2011. Robinson College, Cambridge.  
 
4.3.2  Presentations - See Appendix 4.2 
4.3.2.1  Programme D Review Meeting 
12 April 2012. Lady Margaret Hall, Oxford - Appendix 4.2.1 
 
4.3.2  Programme D Review Meeting 
2 July 2013. SS Great Britain, Bristol - Appendix 4.2.2 
 
4.3.3 Conferences 
19-20 September 2011, NHSBT Annual R&D conference, Robinson College, Cambridge. 
Presented poster on low Hb SR.  
24 -26 September 2014, British Blood Transfusion Society Annual Conference, Harrogate 
International Conference Centre. Iron Therapy Symposium. 
 
4.3.4 Papers 
Two publications were produced during this study: 
1. Smith, G. A., Fisher, S. A., Dorée, C., & Roberts, D. J. (2013). A systematic review of 
factors associated with the deferral of donors failing to meet low haemoglobin 
thresholds. Transfus Med, 23(5), 309-320. 
 
2. Smith, G. A., Fisher, S. A., Doree, C., Di Angelantonio, E., & Roberts, D. J. (2014). Oral 
or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in 
blood donors. Cochrane Database of Systematic Reviews, (7). Retrieved from 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009532.pub2/abstract. 
doi:10.1002/14651858.CD009532.pub2 
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4.3.4.1 Impact Factors  
ISI Web of Knowledge provides an index of impact factors (as well as other journal metrics) 
for the journals who rejected or accepted my papers (Table 4.3). 
Table 4.3: Impact Factors for journals, as at 31 July 2014. 
Journal Current Impact 
Factor (IF) 
Five year 
average IF 
Transfusion 3.526 3.180 
Transfusion Medicine 1.259 1.599 
Cochrane Review 5.785 Not available 
 
4.3.4.2 Citations 
Google Scholar Citations is a relatively simple way for me to keep track of citations to my 
two publications. By adding the references to this citation database I can follow who is citing 
my work. Indeed I can even map the number of citations with time. I made my profile public 
so it appears in Google Scholar results should people search on my name, but is available at 
http://scholar.google.com/citations?user=QOknVnIAAAAJ 
 Likewise, ResearchGate, an on-line research networking forum, provides a means to track 
those publications which have cited the papers you have added to your profile. It can be 
accessed at https://www.researchgate.net/home 
Web of Science provides another way of monitoring citations of your work, at 
http://apps.webofknowledge.com/UA_GeneralSearch_input.do?SID=Y1dIfJtXK9QHxBppjvM
&product=UA&search_mode=GeneralSearch&errorQid=1  
Table 4.4: Google scholar/ResearchGate citations as at 15 September, 2014 
 
 
4.3.5 Web-based 
At the time of submission, no specific web-based material had been disseminated. 
Additionally, the possibility of recording a four minute podcast was discussed with the 
Cochrane Collaboration but was discounted for the reasons in 4.3.6, below. 
Paper Google 
scholar 
Research 
Gate 
Web of 
Science 
(Smith, Fisher, Dorée, & Roberts, 2013) 2 0 2 
(Smith, Fisher, Doree, Di Angelantonio, & Roberts, 
2014) 
0 0 0 
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4.3.6 Press Release 
The Cochrane Press Office were very keen to have a release at the same time as the 
intended time of publication (mid-June, 2014). It was thought, within NHSBT Corporate 
Communications, not to be a good idea because they did not want  the review to clash with 
World Blood Donor day (June 14) and deflect from the message that was being promoted. 
Also, as blood donation was likely to be high in the public awareness, there were concerns 
of a possible backlash from donors (phone calls to the donor centres/ helplines asking  "why 
am I not on iron", "am I going to get ill if I donate too much", etc.). The outcome was an 
agreement to delay the publication of the review for two weeks and to have a press release 
in waiting but only to issue if necessary in response to any queries.  
 
4.3.7 The Becker List of Impact Indicators 
See Appendix 4.3. 
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4.4 Discussion 
It is difficult to assess the efficacy of the work I have carried out and of the routes I have 
employed to disseminate the information. Although the dissemination model of Grimshaw et 
al. (2012) was employed I cannot lay claim to have adopted a theoretically-informed 
approach to my dissemination strategy, such as advocated by Wilson et al (P. Wilson et al., 
2010a). What I have tried to do is, first and foremost, get the findings to those I would 
consider my "Commissioners" - NHSBT - who might be supposed to have the greatest use 
for them. Secondly, I have tried to employ a multimodal communication approach, to use as 
many routes as possible (as laid out in Appendices 4.1 - 4.5). Finally, the journals in which 
these systematic reviews were published may not, as measured by numerical citation 
indices or impact factors, have had the greatest impact but would be seen by those who 
would employ the results to good effect.  
Unsurprisingly, Table 4.4 shows very few citations (as of 15 September 2014) and, not 
unexpectedly, those solely of the paper published first (unless there was an extremely rapid 
publication, two and a half months between publication and its citation is unlikely). The 
various citation indices returned different citation rates; ResearchGate found none (but only 
returns those citations stored within its database by its network members) whereas Google 
Scholar and Web of Science each returned two citations. Interestingly, they described three 
different publications, highlighting the possibility that no one measure would accurately 
describe publication success. 
Most non-published routes of dissemination were targeted towards researchers designing 
trials so that they may influence the design of those trials. This was done ahead of 
publication as a series of "update" sessions in order for those trials to proceed as rapidly as 
possible. Those trials have appeared, or will appear, in International Registries of Trials so 
would be available for researchers in other countries to use as a guide for their own 
research. 
The first study, that of the risk factors for low Hb in blood donors, was published in a journal 
which, although not of the highest JIF, does have a history of publishing such articles and so 
would be read by an international audience with an interest in that particular area of study. It 
has been successful insofar as it has been acknowledged by NHSBT researchers for the 
design of the "Interval Study" (see 4.5.1- Future/Ongoing Work, below). 
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The Iron Supplementation SR was a study into an intervention that will lead to an evaluation 
as a potential treatment for reduction of iron-deficient anaemia in blood donors in England.  It 
was released through the Cochrane Collaboration, an organisation with an international 
reputation for high quality systematic reviews, a greater than average JIF and a valued 
resource for researchers interested in a systematic review under their guidelines. Cochrane 
Reviews are also "Open Access" (OA), at least in the UK, the aim of which is to make the 
results of academic research freely and easily accessible to all. OA is not without its critics. 
In a recent on-line debate (chaired by Claire Shaw for Guardian Professional on 25th 
October 2013, 12.00-14.00 BST) OA was accused of promoting poor quality research by 
allowing less rigorous peer-review. Interestingly, one participant ("Curtrice") mooted the 
possibility of a Wikipedia model for scientific publication (http://curt-
rice.com/2012/06/07/wikipedia-as-a-model-for-scientific-publishing/). Something akin to this 
is being investigated by Cochrane in partnership with Wikipedia via the Wiki Project Med 
Foundation.  I have volunteered to collaborate with the Wikipaedian-in-Residence, a new 
position created by the Cochrane Collaboration in February 2014 to promote the use of 
independent, high-quality evidence in Wikipedia articles (Appendix 4.5). The aim is for 
Cochrane to utilise Wikipedia’s global resources to reach new audiences. 
 
4.5 Future/ongoing work 
4.5.1  Interval Study (Appendix 4.6) 
INTERVAL Study: To Determine Whether the Interval Between Blood Donations in England 
Can be Safely and Acceptably Decreased  
(ClinicalTrials.gov Identifier:NCT01610635). 
This study began in 2012 after the initial findings of the systematic review were presented at 
a joint meeting with the trials organisers on 27th July 2011. The contribution of the Low Hb 
SR was acknowledged in the update briefings presented at the Program Review meetings 
(Appendix 4.6). As of June, 2014, over 50,000 blood donors had been recruited to the trial (I 
being one of them from January 2013) and recruitment was halted due to the recruitment 
target being reached . The donors will be followed for two years, the last enrolees until June 
2016. 
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4.5.2  Iron Supplementation RCT 
The next phase of the NHSBT's plans to improve donor health is to use the 50,000 donors 
recruited for the Interval study as basis for investigating the effects of iron supplementation 
in an RCT (recruiting more, if required). The findings of the Iron Supplementation SR will 
determine whether the trial looks at type, duration and/or dose of Iron Supplementation, 
which haematological indices will best determine its efficacy and what adverse effects (AE) 
need to be observed. Indeed, these AE have been incorporated into quality of life 
questionnaires sent to participants in the Interval Study (4.5.1, above). 
 
4.6 Impact for donors and donation 
I have discussed the impact of the work from a scientific viewpoint. But what of other 
measures of impact (section 4.1.3.2), especially for the stakeholders, i.e. the donors and 
NHSBT? How have these studies helped with the original aims of the research programme 
described in Chapter One, that of determining the factors that contribute to donors failing the 
low Hb threshold required for a successful donation and describing the effects of iron 
supplementation in donors when used to prevent iron deficiency? 
The Interval Study described in 4.5.1, although primarily designed to investigate the effect of 
inter-donation duration, will take into account the risk factors highlighted from the low Hb SR. 
Indeed, the study itself will provide new estimates of the relative risk factors which can be 
incorporated into new guidelines, such as the algorithms in preventative medicine developed 
during the Framingham Heart Study (D'Agostino et al., 2008). Studies have already 
assessed multiple risk factors to give a likelihood of failing pre-donation screening (Baart et 
al., 2014; Baart et al., 2012; Baart et al., 2011; Hillgrove et al., 2011; Rigas et al., 2014). By 
using those risk factors the donor can be assigned to a donation frequency tailored to their 
own particular risk characteristics and in order to minimise the likelihood of a failed donation 
attempt, with its associated effect on donor morale and its cost to NHSBT. For example, a 
hypothetical table of the cumulative relative risks could be created (Table 4.5a) and donation 
intervals set according to a donor's characteristics (Table 4.5b). Although neither the Low Hb 
deferral SR, nor the Cochrane review, found studies regarding dietary effects in blood 
donors, there is a body of evidence that diet can effect anaemia rates in the general 
population (International Nutritional Anemia Consultative Group (INACG), 1998). 
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A young, white, omnivorous, male donor of higher BMI (cumulative risk - CR - of 5.0) would 
be assigned to the most frequent donation group (e.g. every eight weeks), whereas a much 
older, smaller, Asian vegetarian (CR = 8.1), would donate every 12 weeks (as would a white, 
omnivorous, woman - CR = 8.1 - whose BMI was greater than 30). A slight, black, 
vegetarian female (CR = 10.4) could be assigned to the lowest frequency donor group.  
This would necessitate a donor database being created that would incorporate these 
algorithms using the risk factors data, and this information being applied so as to invite 
donors according to their ideal donation interval. In this way the management of the donor 
can be customised to their individual characteristics (Spencer, 2014). Ideally the database 
would be incorporate an artificial neural network, capable of machine learning and pattern 
recognition, so that it might improve its ability to optimise donation rates and donor health 
without the need for constant human re-evaluation of its algorithms.  
 
 
 
 
 
 
 
 
Table 4.5a: Theoretical donor risk factors for low Hb deferral.  
 
 
 
 
 
Table 4.5b: Donation frequency determined by cumulative risk for low Hb deferral.  
 
 
Risk Factor Relative Risk 
Gender 
Male 
1.0 
Female 
4.0 
Ethnicity 
White 
1.0 
Black 
1.1 
Asian 
1.2 
Other 
1.3 
White 
1.1 
Black 
1.8 
Hispanic 
1.0 
Other 
1.5 
BMI 
<30 
1.6 
>30 
1.0 
<30 
1.8 
>30 
1.0 
Age 
18-45 
1.0 
46-55 
1.6 
56-75 
2.8 
Any 
1.0 
Diet 
Non-vegetarian 
1.0 
Vegetarian 
1.5 
Non-
vegetarian 
1.0 
Vegetarian 
1.8 
Cumulative 
Risk 
Donation 
frequency (wks) 
5-6 8 
6.1 - 8.0 10 
8.1 - 9.0 12 
9.1 -10.0 14 
>10 16 
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The possibility exists that blood services would use this information to target potential donors 
according to those characteristics. Would concerted recruitment drives be aimed towards 
those individuals most likely to successfully donate? Would the ideal prospective donor be a 
young, white, omnivorous male graduate who, although exhibits the "bad" traits of being 
overweight and a smoker (wherein lies a contradiction; donors are traditionally chosen on  
the basis of good health), would donate regular (preferably at a mobile donation site) after 
appealing to their nepotistic tendencies. 
Donors are already targeted; male donors are chosen in preference to females, and not 
because of their likelihood to donate successfully (NBC News, 2007). Blood products that 
contain a large proportion of plasma (FFP, platelets) are sourced from male donors to 
decrease the risk of Transfusion-related Acute Lung Injury (TRALI) as women are more 
likely to form the causative antibodies (Eder & Benjamin, 2009; Toy et al., 2012). This 
directed donation strategy is taken further when obtaining FFP for neonates, as it is only 
taken from non-UK sourced (from countries with low vCJD prevalence) male donors to 
lessen the risk of vCJD as well as reduce the risk of TRALI (British Committee for Standards 
in Haematology et al., 2004). It may be only a small step further to choose to concentrate 
resources on recruiting those potential donors who give a high return on investment. Taken 
to an extreme, potential donors who score above a theoretical threshold for cumulative risk 
might even be considered too cost-ineffective to attempt to bleed. 
Beutler and Waalen (2006) suggested setting low Hb thresholds according to gender and 
ethnicity. Should thresholds be set according to other risk factors? Practically, this would be 
hard to achieve using the CuSO4 screening method currently used within the UK Blood 
Services. Already there are two different vials containing CuSO4 of different specific gravity 
(SG) for screening males and females, each used a limited number of times before being 
replaced. There would be considerable difficulty in expanding that to having a range of vials 
of different SG, recording how many times each had been used and then which one should 
be used for each donor, taking into account their gender, weight, age, ethnicity, etc. Clearly, 
a change to the screening procedure is required. The HemaCue® colorimetric POCT 
machines are already interfaced with Laboratory Information Management Systems (LIMS) 
within hospitals so should be able to be interfaced with donor databases to manage the 
appropriate threshold for a particular donor. Already laptops containing donor information are 
taken to mobile donor sessions within England. Ideally the screening method itself should be 
non-invasive, but those methods available at present are not sufficiently accurate. 
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A question is raised as to what level should those threshold be set? Even when different, 
lower, thresholds are used every study observed in the low Hb SR recorded greater LHD for 
women. Should those thresholds be set to defer the same percentage of donors within that 
category? What should that percentage be - one, two, five, ten per cent?  The WHO defines 
anaemia as Hb being below 130 g/L for males and 120 g/L for females, based on two 
standard deviations below the mean (Vitamin and Mineral Nutrition Information System, 
2011). At these levels it would be expected that 2.5% of donors would fail. Some studies are 
showing as high as 47% LHD (Agnihotri, 2010) for women at a threshold level (120 g/L) only 
marginally higher than that defined as clinically anaemic by WHO (Agnihotri, 2010). I would 
suggest that normal ranges need to be set for the population they serve, and then related to 
the clinical effects of those ranges. 
Currently, with respect to their iron status, donors are only prevented from giving blood when 
their iron levels have fallen sufficiently to reduce Hb to a level where they fail the CuSO4 
screening test. It would be far better to detect falling iron levels before the donor develops 
frank anaemia, so avoiding rejection and potential failure to return, and the administrative 
costs associated with that. There is no POCT screening test that provides a real-time 
evaluation of iron deficiency immediately prior to donation so we are left with retrospective 
testing, post-donation.  
Those with iron-deficiency could be notified and given dietary advice and, possibly, informed 
of the risks of iron supplementation, should the donor wish to pursue that route. In this way a 
blood service might avoid the difficulties in having to prescribe IS, except in the most 
extreme of cases. In these instances it should only offer IS with the lowest incidence of side 
effects (despite the likelihood of them being more expensive). Of course, there would need 
to be a support structure to offer advice to donors (NHSBT already has its Donor Helpline - 
0300 123 23 23 - but this would need to be reconfigured to deal with any increase in 
enquiries).  
The findings of the IS systematic review show that serum ferritin levels are significantly 
associated with response to IS and that treatment of donors with iron is effective in 
preventing donors failing the Hb screening test by raising their serum ferritin levels, and thus 
the Hb level, although at a cost of a 60% increase in associated adverse effects. The 
proposed iron supplementation RCT will determine what is to be the best dosing regimen 
and the extent of the adverse events.  
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A cost-benefit analysis would need to be performed to see if the decreased administrative 
costs and increase in donor retention off-sets the cost of serum ferritin testing and cost of the 
iron supplementation itself. With respect to the side effects of the intervention (both negative 
and positive) it is also important to evaluate the quality of life indicators for the donor 
themselves. 
By judicious tailoring of donation intervals according to the epidemiological profile of the 
donor and use of iron supplementation for those donors who fail, or are in danger of failing, 
the Hb test an holistic approach to improving donor health should be achieved.  In this way, 
other impact indicators, such as improvements to clinical practice and donor health, new 
guidelines for donor testing and decreased costs from improved donor retention, will be 
evidenced. 
My concern is that, with adverse publicity, this could be considered a form of blood farming. 
NHSBT produces a magazine for donors ("The Donor") in which it highlights areas it 
believes to be of interest to the donor population, whether it be articles of human interest 
from patients whom have received blood products, biopics of various NHSBT departments 
involved in the production of blood products or testing of donors and items related to the 
health of donors. Future articles would publicise the research findings from the two RCT and 
so encourage those donors with lower risk ratings to donate, perhaps to alter their diet to 
help prevent deferral and explain why additional post-donation testing has been introduced 
for the supply of iron supplementation to improve donor health and well-being. My 
collaboration with the Wikipaedian-in-Residence should further help the health promotion 
aspects of this work by reaching a wider public audience allowing them to be more aware of  
blood donation and the importance of donor health. 
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Chapter 5 – Personal and professional development 
 
The previous Chapters have introduced the context behind the systematic reviews, 
how I carried out those reviews and by what means I have tried to pass on their 
information to achieve an effective dissemination. This chapter discusses how I came 
to the professional doctorate, how it affected me as an individual, both on a personal 
and a professional level. 
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5.1  The journey begins? 
"Sometimes it's the journey that teaches you a lot about your destination".- Drake 
(born Aubrey Drake Graham). 
Looking back, I believe I first began on the path to the Professional Doctorate course 
in 1981, when I graduated from a four-year sandwich degree course. I realised at that 
time I wanted to progress further on the academic route;  in hindsight I was more 
concerned with what Maslow described as fulfilling "lower" esteem needs, the need 
for the respect of others (i.e. the need for status) (Maslow, 1943).  
 
Figure 5-1 Maslow's Hierarchy of Needs. Reproduced from   
http://hansengeorge.blogspot.co.uk/2011/09/maslows-hierarchy-of-needs.html 
 
My degree specialisation was general Animal Physiology, (Medical) Entomology in 
particular, and my sandwich placements had all been in the area of field trials work. I 
applied for a number of MSc courses (Entomology, Parasitology) but funding was 
difficult to obtain for anyone holding less than a 2:1 Honours degree (mine was a 2:2). 
The employment situation was not dissimilar to that currently (2014), with few 
opportunities available.  
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5.2 From there to here 
"Our deeds still travel with us from afar, and what we have been makes us what we 
are." - George Eliot. 
I entered BioMedical Science (BMSc) after three months unemployment (a seemingly 
long period to a 22 year old) when I accepted a position as a Junior "B" Medical 
Laboratory Scientific Officer (MLSO) which would now be a Trainee BioMedical 
Scientist (BMS) within a hospital Haematology Laboratory. Although not my preferred 
career path (laboratory-based, rather than field work. Fewer insects!) it was related 
through its medical content. 
Graduate entry into BMSc was rare in the early 1980s, and non-existent within this 
particular Laboratory. There was no formalised academic course for "State" 
Registration with the Council for Professions Supplementary to Medicine (now 
Registration with the Health and Care Professions Council) for a graduate; completion 
of twelve month’s work experience had to be followed by successful passing of an 
oral exam. Existing trainees had completed the two-year HNC course in Haematology 
and Blood Transfusion Science and some believed I was being preferentially fast-
tracked to State Registration. On my part, there was an underlying belief that  I was 
deserving of something better than a routine laboratory job, something more suited to 
an enquiring mind . A certain degree of friction resulted and I sought an alternative 
position although I was now convinced I wanted to remain in a clinically-based career.  
Having successfully completed my training and obtained my registration as an MLSO 
in Haematology and Blood Transfusion I started a position in the Research and 
Development (R&D) Department of Southampton Blood Transfusion Centre as a 
Scientific Officer (later termed Clinical Scientist [CS]). Here I felt I might have more 
scope to develop any talents I might have gained from University in a clinical science 
(CSc) research environment as a CS than the more routine diagnostic setting of the 
BMS (as well as receiving more pay and annual leave!).  Circumstance has since 
shown I did not have, nor still have in some areas, many of the skills needed for a 
successful BMS or CS. 
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I include this brief CV to highlight the confused nature of my career. I came to BMSc 
as a graduate, a route more typical for a CS, but Registered as a BMS before 
practising as a CS. In 2003 the HCPC made the titles of BMS and CS legally 
protected, so I had to decide which I wanted. I made a case for, and was successful 
in, "grandparenting", i.e. switching from registration with the BMS board of the HCPC 
to the CS board without having to meet the usual entry requirements. This is not 
without its problems, as there is no Transfusion Science modality within CSc. The 
confusion is further compounded as I have undertaken this Profession Doctorate (PD) 
which, originally was to lead to a Doctorate in BMSc (if successful) rather than CSc. 
Furthermore, since April 2010, I have held two Blood Transfusion service manager 
positions for which an essential person specification requirement was to be a BMS. In 
July 2014 I applied to transfer to the Professional Doctorate in Health Science, as it is 
a more flexible title more in keeping with my role. 
Whilst working within R&D in Southampton I passed the Blood Group Serology and 
Transfusion Science course leading towards Fellowship of the Institute of Biomedical 
Sciences at what is now the University of Portsmouth (UoP). This was (and the MSc 
which replaced it) the highest discipline-specific qualification achievable. After 
supporting my line manager in the completion of his PhD it was time to progress my 
own aspirations. I registered with UoP for a MPhil/PhD in 1996; unfortunately the 
same year as NHSBT underwent extensive re-organisation of their R&D. This 
resulted in a change of job to a more service-orientated laboratory, albeit one with 
extensive ties to R&D and a promise to study for a PhD after 2 - 3 years, “when I had 
the lab running smoothly”.  
Seven years later I had still not begun my PhD. Why? In part, there was never a 
period where I, or the laboratory, was not subject to some external change and partly 
because I found none of the potential PhD projects particularly stimulating. During an 
appraisal my line manager suggested that perhaps I lacked sufficient motivation to 
complete a PhD. I was stung into action, not least because I began to question 
whether he was correct.  
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I had to decide the direction of my career development. Although my role at the time 
was essentially managerial I still felt myself to be a scientist. Furthermore, study 
towards an MBA would not have been supported by my, then, line manager who was 
a Principal Investigator for NHSBT. Wanting to achieve the highest level of Maslow's 
Hierarchy of Needs, that of self-actualisation (being the best you can be) then within 
my chosen field this meant trying for Consultant level of expertise. Within the NHS 
Agenda for Change career framework a doctorate is seen as a required academic 
qualification for Advanced Practitioner or Consultant grade posts (University of 
Portsmouth). In the field of Pathology, outside of Medicine, not only is a doctorate 
required but also successful completion of the Membership of the Royal College of 
Pathology Part 1 and 2 examinations in a specific Pathology discipline. Obtaining a 
Consultant grade in Blood Transfusion is not, currently, available through 
examination; only through scientific publication (requiring at least  30 papers; 10 as 
first author (Royal College of Pathologists, n.d.))  
So why did I choose the PD course, rather than the more culturally acceptable (within 
NHSBT, at least) PhD route? The recommendation of an existing PD student and 
having the approval of a new line manager meant I investigated the PD course. I had 
existing ties to Portsmouth University through study for the FIBMS, lecturing and 
research collaborations. The course itself appealed, as it appeared more relevant to 
my role as the head of a clinical laboratory whereas the PhD is more research 
oriented. Additionally, the taught element meant I, and the organisation, had to make 
a commitment – once the fees had been paid there was less chance organisational 
influence would prevent me from at least completing that element. 
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5.3 Where we are now 
"Always do your best. What you plant now, you will harvest later". - Og Mandino. 
I feel that I benefitted enormously from my fellow students on the PD course. After an 
absence of over 20 years I found it difficult to begin formal study. When faced with the 
assignments I experienced panic and inertia, but found it of great help to find that my 
colleagues felt the same and together we would discuss ways to proceed, forming 
what de Haan would call a peer consultation group (de Haan, 2005). Although my 
primary peer group consisted of BMS from disciplines outside Haematology or Blood 
Transfusion, the unique insights gained from working with other healthcare 
professionals was invaluable, both during the PD course and, subsequently, in my 
professional life when dealing with diverse staff groups. Likewise, of the taught 
element of the PD I particularly enjoyed the qualitative research module, something I 
had not encountered previously and, although achieved only poor results from the 
assignment, am more receptive to their use and value in healthcare research. 
The course as a whole, and the Research Resource assignment in particular, proved 
useful when mentoring others, not only for second degrees such as the MSc (three 
students) but also for those beginning their formal qualifications in BMSc with the  
Foundation Degree (one student). 
A major challenge lay ahead in the choice of the project. My line manager and would- 
be supervisor's main interest at the time was the molecular biology behind platelet 
immunology. Although I had an interest in the field it failed to stimulate me sufficiently 
to want to make it my PD project. My supervisor was concerned that I would have to 
delay commencement until I had completed the taught element of the PD so passed 
the reins to others (although I did eventually work on, and help publish, the research 
(Jennings et al., 2007; Stafford et al., 2008).  
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In 2006, having successfully applied for an Accredited Prior Experiential Learning 
exemption from the Publication and Dissemination module, I was ready to begin a 
project that was of much greater interest to me. I was to investigate the molecular and 
serological nature of a rare platelet disorder, with a view to setting up a national 
reference service and external quality assessment scheme.  I began the necessary 
paperwork for ethical approval, designed consent forms and information leaflets and, 
more importantly, gained a new line manager who was much more supportive of the 
research (due to a re-organisation within NHSBT). Unfortunately their strategy was to 
close my laboratory, which resulted in the gradual loss of staff necessary to back-fill 
me for the project and my eventual redundancy in 2007.  
All the proposed PD projects had been lab-based. With no job the possibility of such 
research was minimal, and no better when I was finally employed as a locum in 2008 
for two years managing a stem cell laboratory (for NHSBT). This period emphasised 
to me the lack of development opportunities available to locums, which has led me to 
offer as much support as possible to any in my employ. 
In 2010 there was discussion within the PD course as to whether those who could not 
complete the project element but had been successful for the taught element should 
be awarded a Masters in Research. Having deferred for nearly five years, and with no 
apparent possibility of my even beginning any project, I thought this would be the only 
way in which I could gain a further qualification. However, Dr Sally Kilburn, my current 
supervisor, suggested I might consider the possibility of systematic review to form the 
project. She explained that the academic endeavour, and intellectual activities 
involved in carrying out systematic reviews, especially if involving different 
approaches would be more than sufficient for a professional doctorate. Sally believed 
the University might be prepared to accept two such reviews, properly researched 
and prepared, as being of sufficient academic merit to pass the project element of the 
PD. 
I eagerly adopted the idea of being able to take control of the next phase of the PD 
without being reliant on others (or so I thought at the time) or the need for laboratory 
equipment and consumables (and associated costs as I was, in effect, self-funded). 
Fortunately, I was working nearby to the NHSBT Systematic Review (SR) team who 
were receptive to the collaboration. I contacted numerous NHSBT Principle 
Investigators (PI) for a "sponsor", who would have a research question which they 
thought would benefit from SR.  
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Initially, a number of reviews in the general area of my past platelet experience were 
discussed but finally the PI whom had previously agreed to be my work-based 
supervisor offered the present topics that would feed into his NIHR research 
programme on donor health. In July 2011 my project proposal was accepted by the 
University Examination Board. 
The SRs themselves I approached with a degree of trepidation. I had no formal 
training in the area of SR and no expertise in the field of donor deferral and iron 
supplementation. However, the Advanced Research Techniques unit of the PD 
contained sections on systematic searching and critical appraisal, which would prove 
invaluable in this endeavour. To an extent, I thought it was hardly research at all, just 
regurgitation of the work of others (a sentiment echoed by some clinical scientists 
who do not understand the difference between a systematic review and a review 
article). What I found was the process was much harder than I had thought and in my 
opinion requiring a different, but no less expert, skill set than that required for 
laboratory-based research. I think I can honestly say I have not put in the same 
degree of work into my other papers and would alert anyone whom might be 
contemplating a similar route that it is not an easy option. Were it not for the support 
of the SRI team I am not sure I would have completed the SRs and I am sure they 
would not have been of the same high standard. However, I found the experience 
particularly rewarding and would hope this project might help or even inspire other 
health professionals who cannot do workplace-based projects to consider other less 
obvious avenues for their doctorate projects. 
The work has already resulted in a change in other's (and my own) perception of my 
area of expertise. I have been a reviewer for the journal Transfusion Medicine for a 
number of years, solely regarding articles within the field of platelet immunology, 
where I have 25 years of experience. Indeed, six years after leaving that field I was 
still being asked to review such papers. However, whilst I was writing up this thesis I 
was asked to review a paper on a study of low Hb deferral in German donors. Not 
only had this body of work left me much better equipped to review such an article 
effectively and to offer (hopefully) useful advice to the authors on how to re-write it in 
a manner that would enable it to be published, but it provided a welcome change in 
emphasis. It may also indicate that this project has enabled me to gain a small level 
of expertise beyond that which I had when I began the PD course. 
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Since 2010, I have been working with routine blood transfusion laboratories where 
involvement with R&D has been minimal. That does not mean that it has to be non-
existent. Thinking "outside the box", as Sally did for this project, means I, too, have 
looked for potentially useful information for publication and dissemination in areas 
other than traditional research projects. I realise we in the NHS sit upon a wealth of 
information which we either do not realise its true value or lack the time to evaluate. I 
have written two papers in 2013/14 (other than those comprising this thesis). The first 
examined the reasoning behind the existing practise for neonatal transfusion within 
two hospitals in one Trust and offering evidence-based alternatives to reduce 
neonatal blood wastage and increase clinical safety. A second looked at a number of 
ways to reduce blood wastage in adults, and evaluated their efficacy.  
Additionally, when I took over as Lead for the blood transfusion laboratories of three 
Trusts within a Pathology Network, I was able to use the analytical techniques I had 
gained from the PD course to benchmark staffing levels, workloads etcetera; not only 
between the three Trusts currently within my remit, but also to those two hospitals for 
which I was previously responsible. This benchmarking exercise has been distributed 
to the blood transfusion laboratories of London and the South East, so they might 
adopt it when negotiating safe staffing levels for their workload. I believe this, and the 
two previous exercises, benefited from the skills I gained from the PD course. 
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5.4 The future 
"The only thing we know about the future is that it will be different." - 
Peter Drucker. 
 
I hope to reach  the level of Consultant Transfusion Scientist through publication. If 
the two papers above are accepted then I will have 36 publications in the field of 
Blood Transfusion, nine as first author. Although this does not strictly meet the current 
requirements of the Royal College of Pathology (they require a total of 30 
publications, 10 as first author) I will make a preliminary application to see if they 
might accept the greater than minimum publications as an alternative. If successful, I 
would be only the second, to my knowledge, outside the NHSBT to gain Consultant 
status as a Transfusion Scientist. 
In order to apply my knowledge and experience within the field of Blood Transfusion I 
have applied for Membership as the Blood Service Manager representative of the 
Advisory Committee on the Safety on Blood, Tissues and Organs (SaBTO). This 
committee gives impartial expert scientific advice to the Government on the risks 
associated with the supply and use of blood and blood products for transfusion 
purposes (similarly for those tissues, organs, etc. used in transplantation). I feel my 
background in R&D, my experience in both routine primary, secondary and tertiary 
referral laboratories in a variety of clinical specialisations and the knowledge and 
skills acquired from the PD, would prove useful in this setting. Unfortunately the 
closing date is not until September 2014 so the outcome may not be known by the 
time of submission. 
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5.5 Epilogue 
"What we call the beginning is often the end. And to make an end is to make a 
beginning. The end is where we start from." - T. S. Eliot.  
As I come towards what I hope will be the completion of the PD, I believe my reasons 
for needing to be successful have moved from the "lower" to the "higher" version of 
Maslow's esteem needs. If I am fortunate enough to obtain my doctorate it would not 
immediately help me in my current position (although I am certain it would help me 
with any future career aspirations). However, it will help me in terms of self-respect. I 
already feel more self-confident through achieving a degree of mastery, and were I to 
achieve the doctorate I would also gain professional independence and freedom. I do 
not know whether I will have reached the top-most level that of self-actualisation, 
being the best that I could be. I think I may have achieved the best I could be under 
the circumstances that I encountered. During the 10 years from commencement of 
the PD to submission I have had four jobs (being made redundant from three), the 
latter three being very different from the field in which I had spent 25 years. I have 
had four research projects, two of which I disliked, one which I would dearly have 
wished  to complete, and the one I did which I started viewing only as a means to an 
end. My personal circumstances have changed dramatically too, with all three of my 
children being born during the active phase of this project. I believe, at least in my 
own mind, that I have laid to rest any doubts that I might have had regarding my 
commitment to obtaining a doctorate. 
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